[{"Element":"<div class=\"WordSection1\"> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX I<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg tablets.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each tablet contains 75 mg of\r irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 15.37 mg of lactose monohydrate per tablet.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2771 engraved\r on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled with\r 150 mg once daily, the dose of Karvea can be increased to 300 mg, or\r other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).\r In particular, the addition of a diuretic such as hydrochlorothiazide has been\r shown to have an additive effect with Karvea (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for theolder people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">T<\/span><\/u><span lang=\"EN-GB\">here is\r evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia: <\/span><\/u><span lang=\"EN-GB\">Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the renin-angiotensin\r system. Therefore, the use of Karvea is not recommended.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p> <p class=\"EMEABodyText\"><a name=\"_Hlk37089325\"><span lang=\"FR\">Karvea 75 mg\r tablet contains lactose. <\/span><\/a><span lang=\"EN-GB\">Patients with rare\r hereditary problems of galactose intolerance, total lactase deficiency or\r glucose-galactose malabsorption should not take this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 75 mg tablet contains sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers, long-acting\r calcium channel blockers, and thiazide diuretics. Prior treatment with high\r dose diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the renin-angiotensin\r system, concomitant use of potassium-sparing diuretics, potassium supplements,\r salt substitutes containing potassium or other medicinal products that may\r increase serum potassium levels (e.g. heparin) may lead to increases in\r serum potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported with\r irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: w<span style=\"color:black\">hen angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and\r lactation<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\">It is unknown whether irbesartan or its metabolites are\r excreted in human milk. <\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\">Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3).<\/span> <\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the ability to drive and use machine. When\r driving vehicles or operating machines, it should be taken into account that\r dizziness or weariness may occur during treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients\r (i.e., uncommon) but in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p> <p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in\r some cases associated with increased plasma creatine kinase              levels),\r muscle cramps<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive\r system and breast disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"EN-GB\">Uncommon:      sexual\r dysfunction<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ATC code:\r C09C A04.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine\r and placebo. In 1,715 hypertensive patients with type 2 diabetes,\r proteinuria \u2265 900 mg\/day and serum creatinine ranging from\r 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the placebo\r group (21%).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials (ONTARGET\r (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint\r Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have\r examined the use of the combination of an ACE-inhibitor with an angiotensin II\r receptor blocker. ONTARGET was a study conducted in patients with a history of\r cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus\r accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in\r patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity \/ non-linearity<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157\u2011176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of\r irbesartan is 11-15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan\r were observed in female hypertensive patients. However, there was no difference\r in the half-life and accumulation of irbesartan. No dosage adjustment is\r necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span>\r values were also somewhat greater in oldersubjects (\u2265 65 years)\r than those of young subjects (18-40 years). However the terminal half-life\r was not significantly altered. No dosage adjustment is necessary in older\r people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically relevant\r doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Microcrystalline\r cellulose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Magnesium stearate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Colloidal hydrated silica<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pregelatinised maize starch<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Poloxamer 188<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not store\r above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"NO-BOK\">EU\/1\/97\/049\/001-003<br\/>\r EU\/1\/97\/049\/010<br\/>\r EU\/1\/97\/049\/013<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu<\/span><\/p> <p class=\"MsoNormal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg tablets.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each tablet contains 150 mg of\r irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 30.75 mg of lactose monohydrate per tablet.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2772 engraved\r on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS<\/span><\/u><span lang=\"EN-GB\">): <u>t<\/u>here\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia: <\/span><\/u><span lang=\"EN-GB\">Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme inhibitors\r or angiotensin-II receptor antagonists that affect this system has been\r associated with acute hypotension, azotaemia, oliguria, or rarely acute renal\r failure (see section 4.5). As with any antihypertensive agent, excessive blood\r pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 150 mg tablet contains lactose.\r <\/span><span lang=\"EN-GB\">Patients with rare hereditary problems of galactose\r intolerance, total lactase deficiency or glucose-galactose malabsorption should\r not take this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 150 mg tablet contains sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely administered\r with other antihypertensive agents, such as beta-blockers, long-acting calcium\r channel blockers, and thiazide diuretics. Prior treatment with high dose\r diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing productsand\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">:.clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and potassium-sparing\r diuretics<\/span><\/u><span lang=\"EN-GB\">:based on experience with the use\r of other medicinal products that affect the renin-angiotensin system,\r concomitant use of potassium-sparing diuretics, potassium supplements, salt\r substitutes containing potassium or other medicinal products that may increase\r serum potassium levels (e.g. heparin) may lead to increases in serum\r potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: w<span style=\"color:black\">hen angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by\r glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions\r were observed when irbesartan was coadministered with warfarin, a medicinal\r product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and\r lactation<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative antihypertensive\r treatments which have an established safety profile for use in pregnancy. When\r pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm\r infant.<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\">It is unknown whether irbesartan or its metabolites are\r excreted in human milk. <\/p> <p class=\"EMEABodyText\">Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3).<\/span> <\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the ability to drive and use machnes. When driving\r vehicles or operating machines, it should be taken into account that dizziness\r or weariness may occur during treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients\r (i.e., uncommon) but in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p> <p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive\r system and breast disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"EN-GB\">Uncommon:      sexual\r dysfunction<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ATC code:\r C09C A04.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active, selective\r angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is expected to\r block all actions of angiotensin-II mediated by the AT<sub>1<\/sub> receptor,\r regardless of the source or route of synthesis of angiotensin-II. The selective\r antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing on\r the same total dose.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo\r (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of\r overt proteinuria, demonstrating a 70% relative risk reduction versus placebo\r (p = 0.0004) for the higher dose. An accompanying improvement in the\r glomerular filtration rate (GFR) was not observed during the first three months\r of treatment. The slowing in the progression to clinical proteinuria was\r evident as early as three months and continued over the 2 year period.\r Regression to normoalbuminuria (&lt; 30 mg\/day) was more frequent in\r the Karvea 300 mg group (34%) than in the placebo group (21%).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity\/ non-linearity<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157-176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of irbesartan\r is 11-15 hours. Steady-state plasma concentrations are attained within\r 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in oldersubjects\r (\u2265 65 years) than those of young subjects (18-40 years).\r However the terminal half-life was not significantly altered. No dosage\r adjustment is necessary in older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Microcrystalline\r cellulose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Magnesium stearate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Colloidal hydrated silica<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pregelatinised maize starch<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Poloxamer 188<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"NO-BOK\">EU\/1\/97\/049\/004-006<br\/>\r EU\/1\/97\/049\/011<br\/>\r EU\/1\/97\/049\/014<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p> <p class=\"MsoNormal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg tablets.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each tablet contains 300 mg of\r irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 61.50 mg of lactose monohydrate per tablet.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2773 engraved\r on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):<\/span><\/u><span lang=\"EN-GB\"> there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><span lang=\"EN-GB\">: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis, obstructive\r hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with other\r vasodilators, special caution is indicated in patients suffering from aortic or\r mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the renin-angiotensin\r system. Therefore, the use of Karvea is not recommended.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 300 mg tablet contains lactose.\r <\/span><span lang=\"EN-GB\">Patients with rare hereditary problems of galactose\r intolerance, total lactase deficiency or glucose-galactose malabsorption should\r not take this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 300 mg tablet contains sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see\r section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: w<span style=\"color:black\">hen angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and lactation<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in risk\r cannot be excluded. Whilst there is no controlled epidemiological data on the\r risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may\r exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3 and 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available regarding\r the use of Karvea during breast-feeding, Karvea is not recommended and\r alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm\r infant.<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\">It is unknown whether irbesartan or its metabolites are\r excreted in human milk. <\/p> <p class=\"EMEABodyText\">Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3).<\/span> <\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the abilityto drive and use machine. When\r driving vehicles or operating machines, it should be taken into account that\r dizziness or weariness may occur during treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon)\r but in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive\r system and breast disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"EN-GB\">Uncommon:      sexual\r dysfunction<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ATC code:\r C09C A04.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the\r placebo group (21%).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials (ONTARGET\r (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint\r Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have\r examined the use of the combination of an ACE-inhibitor with an angiotensin II\r receptor blocker. ONTARGET was a study conducted in patients with a history of\r cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus\r accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in\r patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity \/ non-linearity<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157-176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of\r irbesartan is 11-15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan\r were observed in female hypertensive patients. However, there was no difference\r in the half-life and accumulation of irbesartan. No dosage adjustment is\r necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span>\r values were also somewhat greater in oldersubjects (\u2265 65 years)\r than those of young subjects (18-40 years). However the terminal half-life\r was not significantly altered. No dosage adjustment is necessary in older\r people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Microcrystalline\r cellulose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Magnesium stearate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Colloidal hydrated silica<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pregelatinised maize starch<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Poloxamer 188<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"NO-BOK\">EU\/1\/97\/049\/007-009<br\/>\r EU\/1\/97\/049\/012<br\/>\r EU\/1\/97\/049\/015<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p> <p class=\"MsoNormal\"><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated\r tablets.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each film-coated tablet contains 75 mg\r of irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 25.50 mg of lactose monohydrate per film-coated tablet.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Film-coated\r tablet.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2871 engraved\r on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be\r made.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):<\/span><\/u><span lang=\"EN-GB\"> there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia: <\/span><\/u><span lang=\"EN-GB\">Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently\r less effective in lowering blood pressure in black people than in non-blacks,\r possibly because of higher prevalence of low-renin states in the black\r hypertensive population (see section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is\r associated with a higher frequency of adverse events such as hypotension, hyperkalaemia\r and decreased renal function (including acute renal failure) compared to the\r use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective\r COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.\r No significant pharmacokinetic or pharmacodynamic interactions were observed\r when irbesartan was coadministered with warfarin, a medicinal product\r metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the\r pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of\r digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and lactation<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of\r pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred from\r the second trimester of pregnancy, ultrasound check of renal function and skull\r is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available regarding\r the use of Karvea during breast-feeding, Karvea is not recommended and\r alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether irbesartan or its\r metabolites are excreted in human milk. <\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\">Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). <\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Based on\r its pharmacodynamic properties, irbesartan is unlikely to affect the ability to\r drive and use machines. When driving vehicles or operating machines, it should\r be taken into account that dizziness or weariness may occur during treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for\r irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).\r The incidence of adverse events was not related to dose (in the recommended\r dose range), gender, age, race, or duration of treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with microalbuminuria\r and normal renal function, orthostatic dizziness and orthostatic hypotension\r were reported in 0.5% of the patients (i.e., uncommon) but in excess of\r placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear\r and labyrinth disorder<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      sexual dysfunction<\/span><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p> <p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">I<\/span><span lang=\"EN-GB\">n a randomised\r trial of 318 hypertensive children and adolescents aged 6 to\r 16 years, the following adverse reactions occurred in the 3-week\r double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),\r cough (0.9%). In the 26-week open-label period of this trial the most frequent\r laboratory abnormalities observed were creatinine increases (6.5%) and elevated\r CK values in 2% of child recipients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be\r hypotension and tachycardia; bradycardia might also occur from overdose. No\r specific information is available on the treatment of overdose with Karvea. The\r patient should be closely monitored, and the treatment should be symptomatic\r and supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan\r is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ATC code: C09C A04.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with\r minimal change in heart rate. The decrease in blood pressure is dose-related\r for once a day doses with a tendency towards plateau at doses above\r 300 mg. Doses of 150-300 mg once daily lower supine or seated blood\r pressures at trough (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood\r pressure gradually returns toward baseline. Rebound hypertension has not been\r observed.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk\r (diabetic, family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean\r reduction from baseline in the primary efficacy variable, trough seated\r systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg\r (medium dose), 13.2 mmHg (high dose). No significant difference was\r apparent between these doses. Adjusted mean change of trough seated diastolic\r blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg\r (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period\r where patients were re-randomized to either active medicinal product or\r placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP\r and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on\r all doses of irbesartan (see section 4.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the\r placebo group (21%).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group that in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity\/non-linearity<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are\r not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. <\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in patients\r with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet\r core:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Microcrystalline cellulose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Silicon dioxide<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Magnesium stearate.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Film-coating:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Titanium dioxide<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Macrogol 3000<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Carnauba wax.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 30<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 90<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"SL\">EU\/1\/97\/049\/016-020<br\/>\r EU\/1\/97\/049\/031<br\/>\r EU\/1\/97\/049\/034<br\/>\r EU\/1\/97\/049\/037<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated\r tablets.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each film-coated tablet contains 150 mg\r of irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 51.00 mg of lactose monohydrate per film-coated tablet.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Film-coated\r tablet.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2872 engraved\r on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary forolder people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): t<\/span><\/u><span lang=\"EN-GB\">here\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><span lang=\"EN-GB\">: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme inhibitors\r or angiotensin-II receptor antagonists that affect this system has been\r associated with acute hypotension, azotaemia, oliguria, or rarely acute renal\r failure (see section 4.5). As with any antihypertensive agent, excessive blood\r pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 150 mg fil -coated tablet contains\r sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium\r (23 mg) per tablet, that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers, long-acting\r calcium channel blockers, and thiazide diuretics. Prior treatment with high\r dose diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure) compared\r to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the renin-angiotensin\r system, concomitant use of potassium-sparing diuretics, potassium supplements,\r salt substitutes containing potassium or other medicinal products that may\r increase serum potassium levels (e.g. heparin) may lead to increases in\r serum potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE inhibitors,\r concomitant use of angiotensin II antagonists and NSAIDs may lead to an\r increased risk of worsening of renal function, including possible acute renal\r failure, and an increase in serum potassium, especially in patients with poor\r pre-existing renal function. The combination should be administered with\r caution, especially in the elderly. Patients should be adequately hydrated and\r consideration should be given to monitoring renal function after initiation of\r concomitant therapy, and periodically thereafter.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and lactation<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether irbesartan or its\r metabolites are excreted in human milk. <\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\">Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). <\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Based on its\r pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive\r and use machines. When driving vehicles or operating machines, it should be\r taken into account that dizziness or weariness may occur during treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for\r irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).\r The incidence of adverse events was not related to dose (in the recommended\r dose range), gender, age, race, or duration of treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and orthostatic\r hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess\r of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:       impaired renal function including cases\r of renal failure in patients at risk (see section 4.4)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      sexual dysfunction<\/span><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p> <p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">I<\/span><span lang=\"EN-GB\">n a randomised\r trial of 318 hypertensive children and adolescents aged 6 to\r 16 years, the following adverse reactions occurred in the 3-week\r double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),\r cough (0.9%). In the 26-week open-label period of this trial the most frequent\r laboratory abnormalities observed were creatinine increases (6.5%) and elevated\r CK values in 2% of child recipients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be\r hypotension and tachycardia; bradycardia might also occur from overdose. No\r specific information is available on the treatment of overdose with Karvea. The\r patient should be closely monitored, and the treatment should be symptomatic\r and supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan\r is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ATC code: C09C A04.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of 8-13\/5-8 mm Hg\r (systolic\/diastolic) greater than those associated with placebo.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide\r (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood\r pressure reduction at trough of 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk\r (diabetic, family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean reduction\r from baseline in the primary efficacy variable, trough seated systolic blood\r pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose),\r 13.2 mmHg (high dose). No significant difference was apparent between\r these doses. Adjusted mean change of trough seated diastolic blood pressure\r (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose),\r 5.6 mmHg (high dose). Over a subsequent two week period where patients\r were re-randomized to either active medicinal product or placebo, patients on\r placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to\r +0.1 and -0.3 mmHg changes respectively in those on all doses of\r irbesartan (see section 4.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes,\r proteinuria \u2265 900 mg\/day and serum creatinine ranging from\r 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately\r 33% of patients in the irbesartan group reached the primary renal composite\r endpoint compared to 39% and 41% in the placebo and amlodipine groups [20%\r relative risk reduction versus placebo (p = 0.024) and 23% relative\r risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the placebo\r group (21%).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity \/ non-linearity<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are eliminated\r by both biliary and renal pathways. After either oral or IV administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C irbesartan, about 20% of\r the radioactivity is recovered in the urine, and the remainder in the faeces.\r Less than 2% of the dose is excreted in the urine as unchanged irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. <\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet\r core:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Microcrystalline cellulose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Silicon dioxide<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Magnesium stearate.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Film-coating:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Titanium dioxide<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Macrogol 3000<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Carnauba wax.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 30<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 90<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"SL\">EU\/1\/97\/049\/021-025<br\/>\r EU\/1\/97\/049\/032<br\/>\r EU\/1\/97\/049\/035<br\/>\r EU\/1\/97\/049\/038<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated\r tablets.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each film-coated tablet contains 300 mg\r of irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 102.00 mg of lactose monohydrate per film-coated tablet.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Film-coated\r tablet.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2873 engraved\r on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary forolder people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with angiotensin-II\r receptor antagonists.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the administration\r of Karvea in patients with a recent kidney transplantation.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS<\/span><\/u><span lang=\"EN-GB\">): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the renin-angiotensin-aldosterone\r system, hyperkalaemia may occur during the treatment with Karvea, especially in\r the presence of renal impairment, overt proteinuria due to diabetic renal\r disease, and\/or heart failure. Close monitoring of serum potassium in patients\r at risk is recommended (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><span lang=\"EN-GB\">: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from aortic\r or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see\r section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin converting\r enzyme inhibitors. Similar effects have been very rarely reported with\r irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE inhibitors,\r concomitant use of angiotensin II antagonists and NSAIDs may lead to an\r increased risk of worsening of renal function, including possible acute renal\r failure, and an increase in serum potassium, especially in patients with poor\r pre-existing renal function. The combination should be administered with\r caution, especially in the elderly. Patients should be adequately hydrated and\r consideration should be given to monitoring renal function after initiation of\r concomitant therapy, and periodically thereafter.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.\r No significant pharmacokinetic or pharmacodynamic interactions were observed when\r irbesartan was coadministered with warfarin, a medicinal product metabolised by\r CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the\r pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of\r digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and\r lactation<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy\r (see sections 4.3 and 4.4).<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in risk\r cannot be excluded. Whilst there is no controlled epidemiological data on the\r risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may\r exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3 and 4.4).<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether irbesartan or its\r metabolites are excreted in human milk. <\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\">Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). <\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Based on\r its pharmacodynamic properties, irbesartan is unlikely to affect the ability to\r drive and use machines. When driving vehicles or operating machines, it should\r be taken into account that dizziness or weariness may occur during treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for irbesartan-treated\r patients (3.3%) than for placebo-treated patients (4.5%). The incidence of\r adverse events was not related to dose (in the recommended dose range), gender,\r age, race, or duration of treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon)\r but in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria\r and in excess of placebo.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are derived\r from spontaneous reports.<\/span><\/p> <p class=\"EMEABodyText\"><b><\/b><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear\r and labyrinth disorder<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders <\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      sexual dysfunction<\/span><\/p> <p class=\"EMEABodyText\" style=\"text-align:justify\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p> <p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">I<\/span><span lang=\"EN-GB\">n a randomised\r trial of 318 hypertensive children and adolescents aged 6 to 16 years,\r the following adverse reactions occurred in the 3-week double-blind phase:\r headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the\r 26-week open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be hypotension\r and tachycardia; bradycardia might also occur from overdose. No specific\r information is available on the treatment of overdose with Karvea. The patient\r should be closely monitored, and the treatment should be symptomatic and\r supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose.\r Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ATC code: C09C A04.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with\r minimal change in heart rate. The decrease in blood pressure is dose-related\r for once a day doses with a tendency towards plateau at doses above\r 300 mg. Doses of 150-300 mg once daily lower supine or seated blood\r pressures at trough (i.e. 24 hours after dosing) by an average of 8-13\/5-8 mm Hg\r (systolic\/diastolic) greater than those associated with placebo.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks\r after start of therapy. The antihypertensive effects are maintained during long\r term therapy. After withdrawal of therapy, blood pressure gradually returns toward\r baseline. Rebound hypertension has not been observed.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide\r (12.5 mg) to irbesartan once daily results in a further placebo-adjusted\r blood pressure reduction at trough of 7-10\/3-6 mm Hg\r (systolic\/diastolic).<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less response\r to irbesartan monotherapy. When irbesartan is administered concomitantly with a\r low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive\r response in black patients approaches that of white patients.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic,\r family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean\r reduction from baseline in the primary efficacy variable, trough seated systolic\r blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium\r dose), 13.2 mmHg (high dose). No significant difference was apparent\r between these doses. Adjusted mean change of trough seated diastolic blood\r pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium\r dose), 5.6 mmHg (high dose). Over a subsequent two week period where\r patients were re-randomized to either active medicinal product or placebo,\r patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP\r compared to +0.1 and -0.3 mmHg changes respectively in those on all doses\r of irbesartan (see section 4.2).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined. Patients\r were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine\r calcium blockers) were added as needed to help achieve the blood pressure goal.\r While similar blood pressure was achieved in all treatment groups, fewer\r subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%)\r or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt\r proteinuria, demonstrating a 70% relative risk reduction versus placebo\r (p = 0.0004) for the higher dose. An accompanying improvement in the\r glomerular filtration rate (GFR) was not observed during the first three months\r of treatment. The slowing in the progression to clinical proteinuria was\r evident as early as three months and continued over the 2 year period.\r Regression to normoalbuminuria (&lt; 30 mg\/day) was more frequent in\r the Karvea 300 mg group (34%) than in the placebo group (21%).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and angiotensin\r II receptor blockers.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. <\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linarity \/ non-linearity<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. <\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at \u2265 90 mg\/kg\/day,\r in macaques at \u2265 10 mg\/kg\/day). All of these changes were\r considered to be caused by the pharmacological action of irbesartan. For\r therapeutic doses of irbesartan in humans, the hyperplasia\/ hypertrophy of the\r renal juxtaglomerular cells does not appear to have any relevance.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet\r core:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Microcrystalline cellulose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Silicon dioxide<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Magnesium stearate.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Film-coating:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Titanium dioxide<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Macrogol 3000<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Carnauba wax.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">3 years.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 30<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 90<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p> <p class=\"EMEAHeading2\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"SL\">EU\/1\/97\/049\/026-030<br\/>\r EU\/1\/97\/049\/033<br\/>\r EU\/1\/97\/049\/036<br\/>\r EU\/1\/97\/049\/039<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><\/p> <p class=\"EMEATitle\"><\/p> <p class=\"EMEATitle\"><\/p> <p class=\"EMEATitle\"><\/p> <p class=\"EMEATitle\"><\/p> <p class=\"EMEATitle\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX II<\/span><\/p> <p class=\"EMEATitle\"><\/p> <p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.0pt;text-align:left;\r text-indent:-35.3pt\"><span lang=\"EN-GB\">A.        MANUFACTURERS RESPONSIBLE FOR\r BATCH RELEASE<\/span><\/p> <p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.0pt;text-align:left;\r text-indent:-35.3pt\"><\/p> <p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.0pt;text-align:left;\r text-indent:-35.3pt\"><span lang=\"EN-GB\">B.        CONDITIONS OR RESTRICTIONS\r REGARDING SUPPLY AND USE<\/span><\/p> <p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.0pt;text-align:left;\r text-indent:-35.3pt\"><\/p> <p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.0pt;text-align:left;\r text-indent:-35.3pt\"><span lang=\"EN-GB\">C.        OTHER CONDITIONS AND\r REQUIREMENTS OF THE MARKETING AUTHORISATION<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p align=\"left\" class=\"EMEATitle\" style=\"margin-left:85.0pt;text-align:left;\r text-indent:-35.3pt\"><span lang=\"EN-GB\">D.        CONDITIONS OR RESTRICTIONS WITH\r REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">A.      MANUFACTURERS RESPONSIBLE FOR\r BATCH RELEASE<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Name and address of the manufacturers\r responsible for batch release<\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">Sanofi Winthrop Industrie<br\/>\r 1 rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex<br\/>\r France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">Sanofi Winthrop Industrie<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2<br\/>\r France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">Chinoin Private Co. Ltd.<br\/>\r L\u00e9vai u.5.<br\/>\r 2112 Veresegyhaz<br\/>\r Hungary<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">SANOFI-AVENTIS, S.A.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Ctra. C-35 (La Batlloria-Hostalric), km.\r 63.09<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">17404 Riells i Viabrea (Girona) - Spain<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The printed package leaflet of the\r medicinal product must state the name and address of the manufacturer\r responsible for the release of the concerned batch.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">B.      CONDITIONS OR RESTRICTIONS\r REGARDING SUPPLY AND USE<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Medicinal product subject to medical\r prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><b><span lang=\"EN-GB\">C.      OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING\r AUTHORISATION<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:.25in;text-indent:-.25in\"><\/p> <p class=\"EMEABodyText\" style=\"margin-left:64.35pt;text-indent:-64.35pt;\r page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Symbol;color:black\">\u00b7<\/span><b><span lang=\"EN-GB\">Periodic Safety Update Reports (PSURs)<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><a name=\"_Hlk37090071\"><span style='font-family:\"TimesNewRomanPSMT\",serif;\r color:black'>The requirements for submission o<\/span><\/a><span style='font-family:\"TimesNewRomanPSMT\",serif'>f PSURs<\/span><span lang=\"EN-GB\">\r for this medicinal product are set out in the list of Union reference dates\r (EURD list) provided for under Article 107c(7) of Directive 2001\/83<\/span><span lang=\"EN-GB\">\/EC<\/span><span lang=\"EN-GB\"> and any subsequent updates published on\r the European medicines web-portal.<\/span><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><b><span lang=\"EN-GB\">D.      CONDITIONS OR\r RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT<\/span><\/b><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:64.35pt;text-indent:-64.35pt\"><a name=\"_BPDC_LN_INS_1002\"><\/a><span lang=\"EN-GB\" style=\"font-family:Symbol;\r color:black\">\u00b7<\/span><b><span lang=\"EN-GB\">Risk Management Plan (RMP)<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX III<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">LABELLING AND PACKAGE LEAFLET<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">A. LABELLING<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\r PACKAGING <\/span><\/p> <p class=\"EMEATitlePAC\"><\/p> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea 75 mg\r tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each\r tablet contains: irbesartan 75 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Excipients:\r also contains lactose monohydrate. See leaflet for further information.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND\r CONTENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">28 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Oral use.\r Read the package leaflet before use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED\r OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep out\r of the sight and reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION\r NUMBER(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/010\r - 14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/001 -\r 28 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/002 -\r 56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/013 -\r 56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/003\r - 98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR\r SUPPLY<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.     Information in Braille<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"EMEATitlePAC\" style=\"border:none\"><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">PC: <\/span><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">SN:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">NN:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON\r BLISTERS OR STRIPS<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       NAME OF THE MARKETING\r AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">sanofi-aventis groupe<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"FR\">3.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"FR\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       Other<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">14 - 28 - 56 - 98 tablets:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mon<br\/>\r Tue<br\/>\r Wed<br\/>\r Thu<br\/>\r Fri<br\/>\r Sat<br\/>\r Sun<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">56 x 1 tablets:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\r PACKAGING <\/span><\/p> <p class=\"EMEATitlePAC\"><\/p> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea 150 mg\r tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE\r SUBSTANCE(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each\r tablet contains: irbesartan 150 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Excipients:\r also contains lactose monohydrate. See leaflet for further information.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND\r CONTENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">28 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Oral use.\r Read the package leaflet before use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED\r OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep out\r of the sight and reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION\r NUMBER(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/011\r - 14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/004 -\r 28 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/005 -\r 56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/014 -\r 56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/006\r - 98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR\r SUPPLY<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.     Information in Braille<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"EMEATitlePAC\" style=\"border:none\"><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">PC: <\/span><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">SN:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">NN:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON BLISTERS\r OR STRIPS<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       NAME OF THE MARKETING\r AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">sanofi-aventis groupe<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"FR\">3.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"FR\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       Other<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">14 - 28 - 56 - 98 tablets:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mon<br\/>\r Tue<br\/>\r Wed<br\/>\r Thu<br\/>\r Fri<br\/>\r Sat<br\/>\r Sun<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">56 x 1 tablets:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\r PACKAGING <\/span><\/p> <p class=\"EMEATitlePAC\"><\/p> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea 300 mg\r tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE\r SUBSTANCE(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each\r tablet contains: irbesartan 300 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Excipients:\r also contains lactose monohydrate. See leaflet for further information.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND\r CONTENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">28 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Oral use.\r Read the package leaflet before use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED\r OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep out\r of the sight and reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE MARKETING\r AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION\r NUMBER(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/012\r - 14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/007 -\r 28 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/008 -\r 56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/015 -\r 56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/009\r - 98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR\r SUPPLY<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.     Information in Braille<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"EMEATitlePAC\" style=\"border:none\"><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">PC: <\/span><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">SN:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">NN:<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON\r BLISTERS OR STRIPS<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       NAME OF THE MARKETING AUTHORISATION\r HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">sanofi-aventis groupe<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"FR\">3.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"FR\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       Other<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"background:silver\">14 - 28 - 56 - 98 tablets:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mon<br\/>\r Tue<br\/>\r Wed<br\/>\r Thu<br\/>\r Fri<br\/>\r Sat<br\/>\r Sun<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">56 x 1 tablets:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER PACKAGING\r <\/span><\/p> <p class=\"EMEATitlePAC\"><\/p> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE\r SUBSTANCE(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each\r tablet contains: irbesartan 75 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Excipients:\r also contains lactose monohydrate. See leaflet for further information.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND\r CONTENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">14 tablets<br\/>\r 28 tablets<br\/>\r 30 tablets<br\/>\r 56 tablets<br\/>\r 56 x 1 tablets<br\/>\r 84 tablets<br\/>\r 90 tablets<br\/>\r 98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oral use. Read the package leaflet\r before use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED\r OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep out\r of the sight and reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not store\r above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION\r NUMBER(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/016\r - 14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/017 -\r 28 tablets<br\/>\r EU\/1\/97\/049\/034 - 30 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/018 -\r 56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/019 -\r 56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"SL\" style=\"background:silver\">EU\/1\/97\/049\/031 -\r 84<\/span><span lang=\"FR\" style=\"background:silver\"> tablets<br\/>\r EU\/1\/97\/049\/037 - 90 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span style=\"background:silver\">EU\/1\/97\/049\/020 - 98<\/span><span lang=\"EN-GB\" style=\"background:silver\"> tablets<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR\r SUPPLY<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.     information in braille<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"EMEATitlePAC\" style=\"border:none\"><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">PC: <\/span><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">SN:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">NN:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON\r BLISTERS OR STRIPS<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       NAME OF THE MARKETING\r AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">sanofi-aventis groupe<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"FR\">3.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"FR\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       OTher<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span style=\"background:\r silver\">14 - 28 - 56 - 84 - 98 <\/span><span lang=\"LT\" style=\"background:silver\">tablets:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mon<br\/>\r Tue<br\/>\r Wed<br\/>\r Thu<br\/>\r Fri<br\/>\r Sat<br\/>\r Sun<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">30 - 56 x 1 - 90 tablets:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\r PACKAGING <\/span><\/p> <p class=\"EMEATitlePAC\"><\/p> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated\r tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE\r SUBSTANCE(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each\r tablet contains: irbesartan 150 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Excipients:\r also contains lactose monohydrate. See leaflet for further information.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND\r CONTENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">14 tablets<br\/>\r 28 tablets<br\/>\r 30 tablets<br\/>\r 56 tablets<br\/>\r 56 x 1 tablets<br\/>\r 84 tablets<br\/>\r 90 tablets<br\/>\r 98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oral use. Read the package leaflet\r before use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED\r OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep out\r of the sight and reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION NUMBER(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/021\r - 14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/022 -\r 28 tablets<br\/>\r EU\/1\/97\/049\/035 - 30 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/023 -\r 56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/024 -\r 56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"SL\" style=\"background:silver\">EU\/1\/97\/049\/032 -\r 84<\/span><span lang=\"FR\" style=\"background:silver\"> tablets<br\/>\r EU\/1\/97\/049\/038 - 90 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span style=\"background:silver\">EU\/1\/97\/049\/025 - 98<\/span><span lang=\"EN-GB\" style=\"background:silver\"> tablets<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR\r SUPPLY<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.     information in braille<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"EMEATitlePAC\" style=\"border:none\"><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">PC: <\/span><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">SN:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">NN:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON\r BLISTERS OR STRIPS<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       NAME OF THE MARKETING\r AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">sanofi-aventis groupe<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"FR\">3.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"FR\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       OTher<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span style=\"background:\r silver\">14 - 28 - 56 - 84 - 98 <\/span><span lang=\"LT\" style=\"background:silver\">tablets:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mon<br\/>\r Tue<br\/>\r Wed<br\/>\r Thu<br\/>\r Fri<br\/>\r Sat<br\/>\r Sun<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">30 - 56 x 1 - 90 tablets:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">PARTICULARS TO APPEAR ON THE OUTER\r PACKAGING <\/span><\/p> <p class=\"EMEATitlePAC\"><\/p> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">OUTER CARTON<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated\r tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       STATEMENT OF ACTIVE SUBSTANCE(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Each\r tablet contains: irbesartan 300 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">3.       LIST OF EXCIPIENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Excipients:\r also contains lactose monohydrate. See leaflet for further information.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       PHARMACEUTICAL FORM AND CONTENTS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">14 tablets<br\/>\r 28 tablets<br\/>\r 30 tablets<br\/>\r 56 tablets<br\/>\r 56 x 1 tablets<br\/>\r 84 tablets<br\/>\r 90 tablets<br\/>\r 98 tablets<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       METHOD AND ROUTE(S) OF\r ADMINISTRATION<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Oral use. Read the package leaflet\r before use.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">6.       SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED\r OUT OF THE SIGHT AND REACH OF CHILDREN<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Keep out\r of the sight and reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">7.       OTHER SPECIAL WARNING(S), IF\r NECESSARY<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">8.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">9.       SPECIAL STORAGE CONDITIONS<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\" style=\"margin-left:30.0pt;text-indent:-30.0pt\"><span lang=\"EN-GB\">10.     SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL\r PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF\r APPROPRIATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">11.     NAME AND ADDRESS OF THE\r MARKETING AUTHORISATION HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">12.     MARKETING AUTHORISATION\r NUMBER(S)<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">EU\/1\/97\/049\/026\r - 14 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/027 -\r 28 tablets<br\/>\r EU\/1\/97\/049\/036 - 30 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/028 -\r 56 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\" style=\"background:silver\">EU\/1\/97\/049\/029 -\r 56 x 1 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"SL\" style=\"background:silver\">EU\/1\/97\/049\/033 -\r 84<\/span><span lang=\"FR\" style=\"background:silver\"> tablets<br\/>\r EU\/1\/97\/049\/039 - 90 tablets<\/span><\/p> <p class=\"EMEABodyText\"><span style=\"background:silver\">EU\/1\/97\/049\/030 - 98<\/span><span lang=\"EN-GB\" style=\"background:silver\"> tablets<\/span><\/p> <p class=\"EMEABodyText\"> <\/p> <p class=\"EMEABodyText\"> <\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">13.     BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">14.     GENERAL CLASSIFICATION FOR\r SUPPLY<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Medicinal\r product subject to medical prescription.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">15.     INSTRUCTIONS ON USE<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">16.     information in braille<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">17.     UNIQUE\r IDENTIFIER \u2013 2D BARCODE<\/span><\/b><\/p> <\/div> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">2D barcode carrying the unique identifier\r included.<\/span><\/p> <p class=\"MsoNormal\"><\/p> <p class=\"MsoNormal\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 0in 4.0pt\"> <p class=\"MsoNormal\" style=\"border:none;padding:0in\"><b><span lang=\"EN-GB\">18.     UNIQUE\r IDENTIFIER - HUMAN READABLE DATA<\/span><\/b><\/p> <\/div> <p class=\"EMEATitlePAC\" style=\"border:none\"><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">PC: <\/span><\/p> <p class=\"EMEATitlePAC\" style=\"border:none\"><span lang=\"EN-GB\" style=\"font-weight:\r normal\">SN:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">NN:<\/span><\/p> <b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">MINIMUM PARTICULARS TO APPEAR ON\r BLISTERS OR STRIPS<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg tablets<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">2.       NAME OF THE MARKETING AUTHORISATION\r HOLDER<\/span><\/p> <\/div> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"FR\">sanofi-aventis groupe<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"FR\">3.       EXPIRY DATE<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"FR\">EXP<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">4.       BATCH NUMBER<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Lot<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEATitlePAC\"><span lang=\"EN-GB\">5.       OTher<\/span><\/p> <\/div> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span style=\"background:\r silver\">14 - 28 - 56 - 84 - 98 <\/span><span lang=\"LT\" style=\"background:silver\">tablets:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Mon<br\/>\r Tue<br\/>\r Wed<br\/>\r Thu<br\/>\r Fri<br\/>\r Sat<br\/>\r Sun<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"background:silver\">30 - 56 x 1 - 90 tablets:<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">B. PACKAGE LEAFLET<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">Karvea 75 mg tablets<\/span><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\" style=\"font-weight:normal\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Read all of this leaflet carefully before\r you start taking this medicine because it contains important information for\r you.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to\r others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><u><span lang=\"EN-GB\">What is in this leaflet<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.       What Karvea is and what it is used for<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.       What you need to know before you take Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.       How to take Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.       How to store Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">1.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What\r Karvea is and what it is used for<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea belongs to a group of medicines\r known as angiotensin-II receptor antagonists. Angiotensin-II is a substance\r produced in the body which binds to receptors in blood vessels causing them to\r tighten. This results in an increase in blood pressure. Karvea prevents the\r binding of angiotensin-II to these receptors, causing the blood vessels to\r relax and the blood pressure to lower. Karvea slows the decrease of kidney\r function in patients with high blood pressure and type 2 diabetes.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is used in adult patients<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to treat high blood pressure (<i>essential hypertension<\/i>)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to protect the kidney in patients with high blood pressure,\r type 2 diabetes and laboratory evidence of impaired kidney function.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">2.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What\r you need to know before you take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Do not take Karvea<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>allergic<\/b> to irbesartan or any other ingredients of\r this medicine (listed in section 6)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>more than 3 months pregnant<\/b>. (It is also better to\r avoid Karvea in early pregnancy \u2013 see pregnancy section)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">if you have diabetes or impaired kidney function <\/span><\/b><span lang=\"EN-GB\">and you are treated with a blood pressure lowering medicine\r containing aliskiren. <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Warning and precautions<\/span><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\" style=\"font-weight:normal\">Talk to your\r doctor before taking Karvea and<\/span><span lang=\"EN-GB\"> if any of the following\r apply to you:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you get <b>excessive vomiting or diarrhoea<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>kidney problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>heart problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you receive Karvea for <b>diabetic kidney disease<\/b>. In this\r case your doctor may perform regular blood tests, especially for measuring blood\r potassium levels in case of poor kidney function<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you develop <b>low blood sugar levels<\/b> (symptoms may include\r sweating, weakness, hunger, dizziness, trembling, headache, flushing or\r paleness, numbness, having a fast, pounding heart beat), particularly if you\r are being treated for diabetes.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>going to have an operation<\/b> (surgery) or <b>be\r given anaesthetics<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><span lang=\"EN-GB\">if you are taking any of the following medicines\r used to treat high blood pressure:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">an ACE-inhibitor (for example enalapril, lisinopril,\r ramipril), in particular if you have diabetes-related kidney problems.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">aliskiren<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may check your kidney\r function, blood pressure, and the amount of electrolytes (e.g. potassium) in\r your blood at regular intervals.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">See also information under the heading\r \u201cDo not take Karvea\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Karvea is not recommended in early\r pregnancy, and must not be taken if you are more than 3 months pregnant,\r as it may cause serious harm to your baby if used at that stage (see pregnancy\r section).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Children and adolescents<\/span><\/p> <p class=\"EMEABodyText\">This medicinal product should not be used in children and\r adolescents because the safety and efficacy have not yet been fully\r established.<\/p> <p class=\"EMEAHeading3\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Other medicines and Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you are\r taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may need to change your dose\r and\/or to take other precautions:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> If you are taking an ACE-inhibitor or aliskiren\r (see also information under the headings \u201cDo not take Karvea\u201d and \u201cWarnings and\r precautions\u201d).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">You may need to have blood checks if\r you take:<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium supplements<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">salt substitutes containing potassium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium-sparing medicines (such as certain diuretics)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">medicines containing lithium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">repaglinide (medication used for lowering blood sugar levels)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you take certain painkillers, called\r non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Karvea with food and drink<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea can be taken with or without\r food.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Pregnancy<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Your doctor will normally advise you\r to stop taking Karvea before you become pregnant or as soon as you know you are\r pregnant and will advise you to take another medicine instead of Karvea. Karvea\r is not recommended in early pregnancy, and must not be taken when more than\r 3 months pregnant, as it may cause serious harm to your baby if used after\r the third month of pregnancy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Breast-feeding<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor if you are\r breast-feeding or about to start breast-feeding. Karvea is not recommended for\r mothers who are breast-feeding, and your doctor may choose another treatment\r for you if you wish to breast-feed, especially if your baby is newborn, or was\r born prematurely.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Driving and using machines<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is unlikely to affect your\r ability to drive or use machines. However, occasionally dizziness or weariness\r may occur during treatment of high blood pressure. If you experience these,\r talk to your doctor before attempting to drive or use machines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains lactose<\/span><\/b><span lang=\"EN-GB\">. If you have been told by your doctor that you have an intolerance\r to some sugars (e.g. lactose), contact your doctor before taking this medicinal\r product.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains sodium. <\/span><\/b><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet,\r that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">3.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>How\r to take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Always take this medicine exactly as\r your doctor has told you. Check with your doctor or pharmacist if you are not\r sure.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Method of administration<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is for <b>oral use<\/b>. Swallow the\r tablets with a sufficient amount of fluid (e.g. one glass of water). You can\r take Karvea with or without food. Try to take your daily dose at about the same\r time each day. It is important that you continue to take Karvea until your\r doctor tells you otherwise.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The usual\r dose is 150 mg once a day (two tablets a day). The dose may later be\r increased to 300 mg (four tablets a day) once daily depending on blood\r pressure response.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure and type 2 diabetes with kidney\r disease<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">In patients\r with high blood pressure and type 2 diabetes, 300 mg (four tablets a\r day) once daily is the preferred maintenance dose for the treatment of\r associated kidney disease.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The doctor may advise a lower dose,\r especially when starting treatment in certain patients such as those on <b>haemodialysis<\/b>,\r or those <b>over the age of 75 years.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The maximal blood pressure lowering\r effect should be reached 4-6 weeks after beginning treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea should not be given to children\r under 18 years of age. If a child swallows some tablets, contact your\r doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you take more Karvea than you should<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally take too many\r tablets, contact your doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you forget to take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally miss a daily dose,\r just take the next dose as normal. Do not take a double dose to make up for a\r forgotten dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions on the\r use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">4.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>Possible\r side effects<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\r cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some of these effects may be serious and\r may require medical attention.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with similar medicines, rare cases of\r allergic skin reactions (rash, urticaria), as well as localised swelling of the\r face, lips and\/or tongue have been reported in patients taking irbesartan. If\r you get any of these symptoms or get short of breath, <b>stop taking Karvea and\r contact your doctor immediately.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of the side effects listed\r below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Very common: <\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common: may affect up to 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon: may affect up to 1 in 100\r people<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Side\r effects reported in clinical studies for patients treated with Karvea were:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Very common (<\/span><span lang=\"EN-GB\">may affect\r more than 1 in 10 people)<\/span><span lang=\"EN-GB\">: if you suffer from high\r blood pressure and type 2 diabetes with kidney disease, blood tests may\r show an increased level of potassium.<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyTextIndent\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Common (<\/span><span lang=\"EN-GB\">may affect up to\r 1 10 people)<\/span><span lang=\"EN-GB\">: dizziness, feeling sick\/vomiting, fatigue\r and blood tests may show raised levels of an enzyme that measures the muscle\r and heart function (creatine kinase enzyme). In patients with high blood\r pressure and type 2 diabetes with kidney disease, dizziness when getting up\r from a lying or sitting position, low blood pressure when getting up from a\r lying or sitting position, pain in joints or muscles and decreased levels of a\r protein in the red blood cells (haemoglobin) were also reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Uncommon (<\/span><span lang=\"EN-GB\">may affect up to 1 in 100 people)<\/span><span lang=\"EN-GB\">: heart rate increased, flushing, cough, diarrhoea,\r indigestion\/heartburn, sexual dysfunction (problems with sexual performance),\r chest pain.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some undesirable effects have been\r reported since marketing of Karvea. Undesirable effects where the frequency is\r not known are: feeling of spinning, headache, taste disturbance, ringing in the\r ears, <\/span><span lang=\"EN-GB\">muscle cramps, <\/span><span lang=\"EN-GB\">pain in\r joints and muscles, <\/span><span lang=\"EN-GB\">decreased number of red blood cells\r (anaemia \u2013 symptoms may include tiredness, headaches, being short of breath\r when exercising, dizziness and looking pale),<\/span><span lang=\"EN-GB\"> reduced\r number of platelets, abnormal liver function, increased blood potassium levels,\r impaired kidney function, inflammation of small blood vessels<\/span><span lang=\"EN-GB\">mainly affecting the skin<\/span><span lang=\"EN-GB\"> (a condition known as leukocytoclastic vasculitis),<\/span><span lang=\"EN-GB\"> severe allergic reactions (anaphylactic shock)<\/span><span lang=\"EN-GB\"> and <\/span><span lang=\"EN-GB\">low blood sugar levels. Uncommon cases of\r jaundice (yellowing of the skin and\/or whites of the eyes) have also been\r reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of side effects<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\r your doctor or pharmacist. This includes any possible side effects not listed\r in this leaflet. You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in <\/span><\/span><span class=\"MsoHyperlink\"><span lang=\"ES-TRAD\" style=\"background:silver;text-decoration:\r none\">Appendix V<\/span><\/span><span lang=\"EN-GB\">. By reporting side effects you\r can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">5.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>How\r to store Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\r reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the expiry\r date which is stated on the carton and on the blister after EXP. The expiry\r date refers to the last day of that month.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. Ask your pharmacist how to throw away of\r medicines you no longer use. These measures will help protect the environment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>Contents\r of the pack and other information<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea contains<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The active substance is irbesartan. Each tablet of Karvea 75 mg\r contains 75 mg irbesartan.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The other ingredients are microcrystalline cellulose, croscarmellose\r sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,\r pregelatinised maize starch, and poloxamer 188. Please see section 2 \u201cKarvea\r contains lactose\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea looks like and contents of\r the pack<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg tablets are white\r to off-white, biconvex, and oval-shaped with a heart debossed on one side and\r the number 2771 engraved on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg tablets are\r supplied in blister packs of 14, 28, 56 or 98 tablets. Unidose blister\r packs of 56 x 1 tablet for delivery in hospitals are also\r available.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Marketing Authorisation Holder:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Manufacturer:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">SANOFI WINTHROP INDUSTRIE<br\/>\r 1, rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"EN-GB\">SANOFI WINTHROP INDUSTRIE<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2 - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For any information about this medicinal\r product, please contact the local representative of the Marketing Authorisation\r Holder.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Belgi\u00eb\/<\/span><\/b><b><span lang=\"CS\">Belgique<\/span><\/b><b><span lang=\"MT\">\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: <span style=\"layout-grid-mode:\r   line\">+32 (0)2 710 54 00<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">UAB sanofi-aventis Lietuva<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +370 5 2755224<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Bulgaria EOOD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b<\/span><span lang=\"IT\">.<\/span><span lang=\"BG\">: +<\/span><span lang=\"IT\">359 (0)2<\/span><span lang=\"IT\"> 970 53 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR-LU\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-LU\">T\u00e9l\/Tel: <\/span><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">+32 (0)2 710 54 00 (<\/span><span lang=\"FR-BE\">Belgique\/Belgien)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis, s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 233 086 111<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">SANOFI-AVENTIS Zrt.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel.: +36 1 <\/span><span lang=\"HU\">505 0050<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +45 45 16 70 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +39 02 39394275<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi-Aventis Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 0800 52 52 010<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel. aus dem Ausland: +49 69 305 21 131<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Genzyme Europe B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +31 20 245 4000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Estonia O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +372 627 34 88<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Norge AS<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +47 67 10 71 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis AEBE<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"CS\">: +30\r   210 900 16 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">sanofi-aventis GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 1 80 185 \u2013 0<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">sanofi-aventis, S.A.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Tel: +34 93 485 94 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel.: +48 22 280 00 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">sanofi-aventis France<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">T\u00e9l: 0 800 222 555<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Appel depuis l\u2019\u00e9tranger : +33 1 57 63 23 23<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Sanofi - Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +351 21 35 89 400<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +385 1 600 34 00<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Romania SRL<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +40 <\/span><span lang=\"IT\">(0) 21 317 31\r   36<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Ireland Ltd. T\/A SANOFI<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +353 (0) 1 403 56 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +386 1 560 48 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"CS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SK\">sanofi-<\/span><span lang=\"CS\">aventis Slovakia\r   <\/span><span lang=\"SK\">s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +<\/span><span lang=\"SK\">421 2 <\/span><span lang=\"EN-GB\">33 100 100<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel<\/span><span lang=\"CS\">: 800 536389<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Oy<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Puh\/Tel: +358 (0) 201 200 300<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Cyprus Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +<\/span><span lang=\"FR\">357\r   22 871600<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi AB<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 (0)8 634 50 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Latvia SIA<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 67 33 24 51<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +44 (0) 845 372 7101<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu\/<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">Karvea 150 mg tablets<\/span><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\" style=\"font-weight:normal\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Read all of this leaflet carefully\r before you start taking this medicine because it contains important information\r for you.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to\r others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><u><span lang=\"EN-GB\">What is in this leaflet<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.       What Karvea is and what it is used for<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.       What you need to know before you take Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.       How to take Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.       How to store Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">1.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What\r Karvea is and what it is used for<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea belongs to a group of medicines\r known as angiotensin-II receptor antagonists. Angiotensin-II is a substance\r produced in the body which binds to receptors in blood vessels causing them to\r tighten. This results in an increase in blood pressure. Karvea prevents the\r binding of angiotensin-II to these receptors, causing the blood vessels to\r relax and the blood pressure to lower. Karvea slows the decrease of kidney\r function in patients with high blood pressure and type 2 diabetes.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is used in adult patients<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to treat high blood pressure (<i>essential hypertension<\/i>)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to protect the kidney in patients with high blood pressure,\r type 2 diabetes and laboratory evidence of impaired kidney function.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">2.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What\r you need to know before you take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Do not take Karvea<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>allergic<\/b> to irbesartan or any other ingredients of\r this medicine (listed in section 6)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>more than 3 months pregnant<\/b>. (It is also better to\r avoid Karvea in early pregnancy \u2013 see pregnancy section)<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><b><span lang=\"EN-GB\">if you have diabetes or impaired kidney\r function <\/span><\/b><span lang=\"EN-GB\">and you are treated with a blood pressure\r lowering medicine containing aliskiren. <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Warning and precautions<\/span><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\" style=\"font-weight:normal\">Talk to your\r doctor before taking Karvea and<\/span><span lang=\"EN-GB\"> if any of the following\r apply to you:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you get <b>excessive vomiting or diarrhoea<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>kidney problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>heart problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you receive Karvea for <b>diabetic kidney disease<\/b>. In this\r case your doctor may perform regular blood tests, especially for measuring\r blood potassium levels in case of poor kidney function<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you develop <b>low blood sugar levels<\/b> (symptoms may include\r sweating, weakness, hunger, dizziness, trembling, headache, flushing or\r paleness, numbness, having a fast, pounding heart beat), particularly if you\r are being treated for diabetes.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>going to have an operation<\/b> (surgery) or <b>be\r given anaesthetics<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><span lang=\"EN-GB\">if you are taking any of the following medicines\r used to treat high blood pressure:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">an ACE-inhibitor (for example enalapril,\r lisinopril, ramipril), in particular if you have diabetes-related kidney\r problems.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">aliskiren<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may check your kidney\r function, blood pressure, and the amount of electrolytes (e.g. potassium) in\r your blood at regular intervals.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">See also information under the heading\r \u201cDo not take Karvea\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Karvea is not recommended in early\r pregnancy, and must not be taken if you are more than 3 months pregnant,\r as it may cause serious harm to your baby if used at that stage (see pregnancy\r section).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Children and adolescents<\/span><\/p> <p class=\"EMEABodyText\">This medicinal product should not be used in children and\r adolescents because the safety and efficacy have not yet been fully\r established.<\/p> <p class=\"EMEAHeading3\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Other medicines and Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you\r are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may need to change your dose\r and\/or to take other precautions:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> If you are taking an ACE-inhibitor or\r aliskiren (see also information under the headings \u201cDo not take Karvea\u201d and\r \u201cWarnings and precautions\u201d).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">You may need to have blood checks if\r you take:<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium supplements<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">salt substitutes containing potassium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium-sparing medicines (such as certain diuretics)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">medicines containing lithium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">repaglinide (medication used for lowering blood sugar levels)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you take certain painkillers, called\r non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Karvea with food and drink<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea can be taken with or without\r food.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Pregnancy<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Your doctor will normally advise you\r to stop taking Karvea before you become pregnant or as soon as you know you are\r pregnant and will advise you to take another medicine instead of Karvea. Karvea\r is not recommended in early pregnancy, and must not be taken when more than\r 3 months pregnant, as it may cause serious harm to your baby if used after\r the third month of pregnancy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Breast-feeding<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor if you are\r breast-feeding or about to start breast-feeding. Karvea is not recommended for\r mothers who are breast-feeding, and your doctor may choose another treatment\r for you if you wish to breast-feed, especially if your baby is newborn, or was\r born prematurely.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Driving and using machines<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is unlikely to affect your\r ability to drive or use machines. However, occasionally dizziness or weariness\r may occur during treatment of high blood pressure. If you experience these,\r talk to your doctor before attempting to drive or use machines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains lactose<\/span><\/b><span lang=\"EN-GB\">. If you have been told by your doctor that you have an intolerance\r to some sugars (e.g. lactose), contact your doctor before taking this medicinal\r product.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains sodium. <\/span><\/b><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet,\r that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">3.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>How\r to take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Always take this medicine exactly as\r your doctor has told you. Check with your doctor or pharmacist if you are not\r sure.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Method of administration<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is for <b>oral use<\/b>. Swallow\r the tablets with a sufficient amount of fluid (e.g. one glass of water). You\r can take Karvea with or without food. Try to take your daily dose at about the\r same time each day. It is important that you continue to take Karvea until your\r doctor tells you otherwise.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The usual\r dose is 150 mg once a day. The dose may later be increased to 300 mg\r (two tablets a day) once daily depending on blood pressure response.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure and type 2 diabetes with\r kidney disease<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">In patients\r with high blood pressure and type 2 diabetes, 300 mg (two tablets a\r day) once daily is the preferred maintenance dose for the treatment of\r associated kidney disease.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The doctor may advise a lower dose,\r especially when starting treatment in certain patients such as those on <b>haemodialysis<\/b>,\r or those <b>over the age of 75 years.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The maximal blood pressure lowering\r effect should be reached 4-6 weeks after beginning treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea should not be given to children\r under 18 years of age. If a child swallows some tablets, contact your\r doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you take more Karvea than you should<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally take too many\r tablets, contact your doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you forget to take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally miss a daily dose,\r just take the next dose as normal. Do not take a double dose to make up for a\r forgotten dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions on the\r use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">4.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>Possible\r side effects<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\r cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some of these effects may be serious and\r may require medical attention.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with similar medicines, rare cases of\r allergic skin reactions (rash, urticaria), as well as localised swelling of the\r face, lips and\/or tongue have been reported in patients taking irbesartan. If\r you get any of these symptoms or get short of breath, <b>stop taking Karvea and\r contact your doctor immediately.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of the side effects listed\r below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Very common: <\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common: may affect up to 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon: may affect up to 1 in 100\r people<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Side\r effects reported in clinical studies for patients treated with Karvea were:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Very common (<\/span><span lang=\"EN-GB\">may affect\r more than 1 in 10 people)<\/span><span lang=\"EN-GB\">: if you suffer from high\r blood pressure and type 2 diabetes with kidney disease, blood tests may\r show an increased level of potassium.<\/span><\/p> <p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p> <p class=\"EMEABodyTextIndent\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Common (<\/span><span lang=\"EN-GB\">may affect up to\r 1 10 people)<\/span><span lang=\"EN-GB\">: dizziness, feeling sick\/vomiting, fatigue\r and blood tests may show raised levels of an enzyme that measures the muscle\r and heart function (creatine kinase enzyme). In patients with high blood\r pressure and type 2 diabetes with kidney disease, dizziness when getting\r up from a lying or sitting position, low blood pressure when getting up from a\r lying or sitting position, pain in joints or muscles and decreased levels of a\r protein in the red blood cells (haemoglobin) were also reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Uncommon (<\/span><span lang=\"EN-GB\">may affect up to 1 in 100 people)<\/span><span lang=\"EN-GB\">: heart rate increased, flushing, cough, diarrhoea,\r indigestion\/heartburn, sexual dysfunction (problems with sexual performance),\r chest pain.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Some undesirable effects have been reported\r since marketing of Karvea. Undesirable effects where the frequency is not known\r are: feeling of spinning, headache, taste disturbance, ringing in the ears, <\/span><span lang=\"EN-GB\">muscle cramps, <\/span><span lang=\"EN-GB\">pain in joints and muscles, <\/span><span lang=\"EN-GB\">decreased number of red blood cells (anaemia \u2013 symptoms may include\r tiredness, headaches, being short of breath when exercising, dizziness and\r looking pale), <\/span><span lang=\"EN-GB\">reduced number of platelets, abnormal\r liver function, increased blood potassium levels, impaired kidney function,\r inflammation of small blood vessels<\/span><span lang=\"EN-GB\">mainly affecting the skin<\/span><span lang=\"EN-GB\"> (a condition known\r as leukocytoclastic vasculitis),<\/span>severe allergic\r reactions (anaphylactic shock) <span lang=\"EN-GB\">and <\/span><span lang=\"EN-GB\">low\r blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and\/or\r whites of the eyes) have also been reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of side effects<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\r your doctor or pharmacist. This includes any possible side effects not listed\r in this leaflet. You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in <\/span><\/span><span class=\"MsoHyperlink\"><span lang=\"ES-TRAD\" style=\"background:silver;text-decoration:\r none\">Appendix V<\/span><\/span><span lang=\"EN-GB\">. By reporting side effects you\r can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">5.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>How\r to store Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\r reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\r expiry date which is stated on the carton and on the blister after EXP. The\r expiry date refers to the last day of that month.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. Ask your pharmacist how to throw away of\r medicines you no longer use. These measures will help protect the environment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>Contents\r of the pack and other information<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea contains<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The active substance is irbesartan. Each tablet of Karvea 150 mg\r contains 150 mg irbesartan.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The other ingredients are microcrystalline cellulose, croscarmellose\r sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,\r pregelatinised maize starch, and poloxamer 188. <\/span>Please see section\r 2 \u201cKarvea contains lactose\u201d.<\/p> <p class=\"EMEABodyTextIndent\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea looks like and contents of\r the pack<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg tablets are\r white to off-white, biconvex, and oval-shaped with a heart debossed on one side\r and the number 2772 engraved on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg tablets are\r supplied in blister packs of 14, 28, 56 or 98 tablets. Unidose blister\r packs of 56 x 1 tablet for delivery in hospitals are also\r available.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Marketing Authorisation Holder:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Manufacturer:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">SANOFI WINTHROP INDUSTRIE<br\/>\r 1, rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">SANOFI WINTHROP INDUSTRIE<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2 - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">CHINOIN PRIVATE CO. LTD.<br\/>\r L\u00e9vai u.5.<br\/>\r 2112 Veresegyh\u00e1z - Hungary<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For any information about this medicinal\r product, please contact the local representative of the Marketing Authorisation\r Holder.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Belgi\u00eb\/<\/span><\/b><b><span lang=\"CS\">Belgique<\/span><\/b><b><span lang=\"MT\">\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi Belgium<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: <span style=\"layout-grid-mode:\r   line\">+32 (0)2 710 54 00<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">UAB sanofi-aventis Lietuva<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +370 5 2755224<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Bulgaria EOOD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b<\/span><span lang=\"IT\">.<\/span><span lang=\"BG\">: +<\/span><span lang=\"IT\">359 (0)2<\/span><span lang=\"IT\"> 970 53 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR-LU\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-LU\">T\u00e9l\/Tel: <\/span><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">+32 (0)2 710 54 00 (<\/span><span lang=\"FR-BE\">Belgique\/Belgien)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis, s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 233 086 111<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">SANOFI-AVENTIS Zrt.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel.: +36 1 <\/span><span lang=\"HU\">505 0050<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +45 45 16 70 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +39 02 39394275<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi-Aventis Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 0800 52 52 010<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel. aus dem Ausland: +49 69 305 21 131<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Genzyme Europe B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +31 20 245 4000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Estonia O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +372 627 34 88<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Norge AS<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +47 67 10 71 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis AEBE<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"CS\">: +30\r   210 900 16 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">sanofi-aventis GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 1 80 185 \u2013 0<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">sanofi-aventis, S.A.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Tel: +34 93 485 94 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel.: +48 22 280 00 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">sanofi-aventis France<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">T\u00e9l: 0 800 222 555<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Appel depuis l\u2019\u00e9tranger : +33 1 57 63 23 23<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Sanofi - Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +351 21 35 89 400<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +385 1 600 34 00<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Romania SRL<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +40 <\/span><span lang=\"IT\">(0) 21 317 31\r   36<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Ireland Ltd. T\/A SANOFI<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +353 (0) 1 403 56 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +386 1 560 48 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"CS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SK\">sanofi-<\/span><span lang=\"CS\">aventis Slovakia\r   <\/span><span lang=\"SK\">s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +<\/span><span lang=\"SK\">421 2 <\/span><span lang=\"EN-GB\">33 100 100<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel<\/span><span lang=\"CS\">: 800 536389<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Oy<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Puh\/Tel: +358 (0) 201 200 300<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Cyprus Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +<\/span><span lang=\"FR\">357\r   22 871600<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi AB<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 (0)8 634 50 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Latvia SIA<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 67 33 24 51<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +44 (0) 845 372 7101<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu\/<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\">Karvea 300 mg tablets<\/span><\/p> <p class=\"EMEATitle\"><span lang=\"EN-GB\" style=\"font-weight:normal\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Read all of this leaflet carefully\r before you start taking this medicine because it contains important information\r for you.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to\r others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><u><span lang=\"EN-GB\">What is in this leaflet<\/span><\/u><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">1.       What Karvea is and what it is used for<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">2.       What you need to know before you take Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">3.       How to take Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">5.       How to store Karvea<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt;text-indent:-28.35pt\"><span lang=\"EN-GB\">6.       Contents of the pack and other information<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">1.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What\r Karvea is and what it is used for<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea belongs to a group of medicines\r known as angiotensin-II receptor antagonists. Angiotensin-II is a substance\r produced in the body which binds to receptors in blood vessels causing them to\r tighten. This results in an increase in blood pressure. Karvea prevents the\r binding of angiotensin-II to these receptors, causing the blood vessels to\r relax and the blood pressure to lower. Karvea slows the decrease of kidney\r function in patients with high blood pressure and type 2 diabetes.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is used in adult patients<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to treat high blood pressure (<i>essential hypertension<\/i>)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to protect the kidney in patients with high blood pressure,\r type 2 diabetes and laboratory evidence of impaired kidney function.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">2.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What\r you need to know before you take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Do not take Karvea<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>allergic<\/b> to irbesartan or any other ingredients of\r this medicine (listed in section 6)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>more than 3 months pregnant<\/b>. (It is also better to\r avoid Karvea in early pregnancy \u2013 see pregnancy section)<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><b><span lang=\"EN-GB\">if you have diabetes or impaired kidney <\/span><\/b><span lang=\"EN-GB\">function and you are treated with a blood pressure lowering medicine\r containing aliskiren.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Warning and precautions<\/span><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\" style=\"font-weight:normal\">Talk to your\r doctor before taking Karvea and<\/span><span lang=\"EN-GB\"> if any of the following\r apply to you:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you get <b>excessive vomiting or diarrhoea<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>kidney problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>heart problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you receive Karvea for <b>diabetic kidney disease<\/b>. In this\r case your doctor may perform regular blood tests, especially for measuring\r blood potassium levels in case of poor kidney function<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you develop <b>low blood sugar levels<\/b> (symptoms may include\r sweating, weakness, hunger, dizziness, trembling, headache, flushing or\r paleness, numbness, having a fast, pounding heart beat), particularly if you\r are being treated for diabetes.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>going to have an operation<\/b> (surgery) or <b>be\r given anaesthetics<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><span lang=\"EN-GB\">if you are taking any of the following medicines\r used to treat high blood pressure:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">an ACE-inhibitor (for example enalapril,\r lisinopril, ramipril), in particular if you have diabetes-related kidney\r problems.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">aliskiren<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may check your kidney\r function, blood pressure, and the amount of electrolytes (e.g. potassium) in\r your blood at regular intervals.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">See also information under the heading\r \u201cDo not take Karvea\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Karvea is not recommended in early\r pregnancy, and must not be taken if you are more than 3 months pregnant,\r as it may cause serious harm to your baby if used at that stage (see pregnancy\r section).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Children and adolescents<\/span><\/p> <p class=\"EMEABodyText\">This medicinal product should not be used in children and\r adolescents because the safety and efficacy have not yet been fully\r established.<\/p> <p class=\"EMEAHeading3\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Other medicines and Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you\r are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may need to change your dose\r and\/or to take other precautions:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> If you are taking an ACE-inhibitor or\r aliskiren (see also information under the headings \u201cDo not take Karvea\u201d and\r \u201cWarnings and precautions\u201d).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">You may need to have blood checks if\r you take:<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium supplements<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">salt substitutes containing potassium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium-sparing medicines (such as certain diuretics)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">medicines containing lithium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">repaglinide (medication used for lowering blood sugar levels)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you take certain painkillers, called\r non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Karvea with food and drink<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea can be taken with or without\r food.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Pregnancy<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Your doctor will normally advise you\r to stop taking Karvea before you become pregnant or as soon as you know you are\r pregnant and will advise you to take another medicine instead of Karvea. Karvea\r is not recommended in early pregnancy, and must not be taken when more than\r 3 months pregnant, as it may cause serious harm to your baby if used after\r the third month of pregnancy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Breast-feeding<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor if you are\r breast-feeding or about to start breast-feeding. Karvea is not recommended for\r mothers who are breast-feeding, and your doctor may choose another treatment\r for you if you wish to breast-feed, especially if your baby is newborn, or was\r born prematurely.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Driving and using machines<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is unlikely to affect your\r ability to drive or use machines. However, occasionally dizziness or weariness\r may occur during treatment of high blood pressure. If you experience these,\r talk to your doctor before attempting to drive or use machines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains lactose<\/span><\/b><span lang=\"EN-GB\">. If you have been told by your doctor that you have an intolerance\r to some sugars (e.g. lactose), contact your doctor before taking this medicinal\r product.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains sodium. <\/span><\/b><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet,\r that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">3.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>How\r to take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Always take this medicine exactly as\r your doctor has told you. Check with your doctor or pharmacist if you are not\r sure.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Method of administration<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is for <b>oral use<\/b>. Swallow\r the tablets with a sufficient amount of fluid (e.g. one glass of water). You\r can take Karvea with or without food. Try to take your daily dose at about the\r same time each day. It is important that you continue to take Karvea until your\r doctor tells you otherwise.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The usual\r dose is 150 mg once a day. The dose may later be increased to 300 mg\r once daily depending on blood pressure response.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure and type 2 diabetes with\r kidney disease<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">In patients\r with high blood pressure and type 2 diabetes, 300 mg once daily is\r the preferred maintenance dose for the treatment of associated kidney disease.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The doctor may advise a lower dose,\r especially when starting treatment in certain patients such as those on <b>haemodialysis<\/b>,\r or those <b>over the age of 75 years.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The maximal blood pressure lowering\r effect should be reached 4-6 weeks after beginning treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea should not be given to children\r under 18 years of age. If a child swallows some tablets, contact your\r doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you take more Karvea than you should<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally take too many\r tablets, contact your doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you forget to take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally miss a daily dose,\r just take the next dose as normal. Do not take a double dose to make up for a\r forgotten dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions on the\r use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">4.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>Possible\r side effects<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\r cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some of these effects may be serious and\r may require medical attention.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with similar medicines, rare cases of\r allergic skin reactions (rash, urticaria), as well as localised swelling of the\r face, lips and\/or tongue have been reported in patients taking irbesartan. If\r you get any of these symptoms or get short of breath, <b>stop taking Karvea and\r contact your doctor immediately.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of the side effects listed\r below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Very common: <\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common: may affect up to 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon: may affect up to 1 in 100\r people<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Side effects reported in clinical\r studies for patients treated with Karvea were:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Very common (<\/span><span lang=\"EN-GB\">may affect more than 1 in 10\r people)<\/span><span lang=\"EN-GB\">: if you suffer from high blood pressure and\r type 2 diabetes with kidney disease, blood tests may show an increased\r level of potassium.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Common (<\/span><span lang=\"EN-GB\">may affect up to 1 10 people)<\/span><span lang=\"EN-GB\">: dizziness, feeling sick\/vomiting, fatigue and blood tests may show\r raised levels of an enzyme that measures the muscle and heart function\r (creatine kinase enzyme). In patients with high blood pressure and type 2\r diabetes with kidney disease, dizziness when getting up from a lying or sitting\r position, low blood pressure when getting up from a lying or sitting position,\r pain in joints or muscles and decreased levels of a protein in the red blood\r cells (haemoglobin) were also reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Uncommon (<\/span><span lang=\"EN-GB\">may affect up to 1 in 100 people)<\/span><span lang=\"EN-GB\">: heart rate increased, flushing, cough, diarrhoea, indigestion\/heartburn,\r sexual dysfunction (problems with sexual performance), chest pain.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Some undesirable effects have been reported\r since marketing of Karvea. Undesirable effects where the frequency is not known\r are: feeling of spinning, headache, taste disturbance, ringing in the ears, <\/span><span lang=\"EN-GB\">muscle cramps, <\/span><span lang=\"EN-GB\">pain in joints and muscles, <\/span><span lang=\"EN-GB\">decreased number of red blood cells (anaemia \u2013 symptoms may include\r tiredness, headaches, being short of breath when exercising, dizziness and\r looking pale), <\/span><span lang=\"EN-GB\">reduced number of platelets, abnormal liver\r function, increased blood potassium levels, impaired kidney function, inflammation\r of small blood vessels<\/span><span lang=\"EN-GB\">mainly\r affecting the skin<\/span><span lang=\"EN-GB\"> (a condition known as\r leukocytoclastic vasculitis),<\/span>severe allergic\r reactions (anaphylactic shock) <span lang=\"EN-GB\">and <\/span><span lang=\"EN-GB\">low\r blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and\/or\r whites of the eyes) have also been reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of side effects<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\r your doctor or pharmacist. This includes any possible side effects not listed\r in this leaflet. You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in <\/span><\/span><span class=\"MsoHyperlink\"><span lang=\"ES-TRAD\" style=\"background:silver;text-decoration:\r none\">Appendix V<\/span><\/span><span lang=\"EN-GB\">. By reporting side effects you\r can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">5.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>How\r to store Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\r reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\r expiry date which is stated on the carton and on the blister after EXP. The expiry\r date refers to the last day of that month.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. Ask your pharmacist how to throw away of\r medicines you no longer use. These measures will help protect the environment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>Contents\r of the pack and other information<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea contains<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The active substance is irbesartan. Each tablet of Karvea 300 mg\r contains 300 mg irbesartan.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The other ingredients are microcrystalline cellulose, croscarmellose\r sodium, lactose monohydrate, magnesium stearate, colloidal hydrated silica,\r pregelatinised maize starch, and poloxamer 188. <\/span>Please see section\r 2 \u201cKarvea contains lactose\u201d.<\/p> <p class=\"EMEABodyTextIndent\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea looks like and contents of\r the pack<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg tablets are\r white to off-white, biconvex, and oval-shaped with a heart debossed on one side\r and the number 2773 engraved on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg tablets are\r supplied in blister packs of 14, 28, 56 or 98 tablets. Unidose blister\r packs of 56 x 1 tablet for delivery in hospitals are also\r available.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Marketing Authorisation Holder:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris<\/span><span lang=\"FR-BE\">- France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Manufacturer:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">SANOFI WINTHROP INDUSTRIE<br\/>\r 1, rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">SANOFI WINTHROP INDUSTRIE<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2 - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">CHINOIN PRIVATE CO. LTD.<br\/>\r L\u00e9vai u.5.<br\/>\r 2112 Veresegyh\u00e1z - Hungary<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For any information about this medicinal\r product, please contact the local representative of the Marketing Authorisation\r Holder.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Belgi\u00eb\/<\/span><\/b><b><span lang=\"CS\">Belgique<\/span><\/b><b><span lang=\"MT\">\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi Belgium<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: <span style=\"layout-grid-mode:\r   line\">+32 (0)2 710 54 00<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">UAB sanofi-aventis Lietuva<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +370 5 2755224<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Bulgaria EOOD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b<\/span><span lang=\"IT\">.<\/span><span lang=\"BG\">: +<\/span><span lang=\"IT\">359 (0)2<\/span><span lang=\"IT\"> 970 53 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR-LU\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-LU\">T\u00e9l\/Tel: <\/span><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">+32 (0)2 710 54 00 (<\/span><span lang=\"FR-BE\">Belgique\/Belgien)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis, s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 233 086 111<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">SANOFI-AVENTIS Zrt.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel.: +36 1 <\/span><span lang=\"HU\">505 0050<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +45 45 16 70 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +39 02 39394275<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi-Aventis Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 0800 52 52 010<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel. aus dem Ausland: +49 69 305 21 131<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Genzyme Europe B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +31 20 245 4000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Estonia O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +372 627 34 88<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Norge AS<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +47 67 10 71 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis AEBE<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"CS\">: +30\r   210 900 16 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">sanofi-aventis GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 1 80 185 \u2013 0<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">sanofi-aventis, S.A.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Tel: +34 93 485 94 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel.: +48 22 280 00 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">sanofi-aventis France<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">T\u00e9l: 0 800 222 555<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Appel depuis l\u2019\u00e9tranger : +33 1 57 63 23 23<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Sanofi - Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +351 21 35 89 400<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +385 1 600 34 00<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Romania SRL<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +40 <\/span><span lang=\"IT\">(0) 21 317 31\r   36<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Ireland Ltd. T\/A SANOFI<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +353 (0) 1 403 56 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +386 1 560 48 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"CS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SK\">sanofi-<\/span><span lang=\"CS\">aventis Slovakia\r   <\/span><span lang=\"SK\">s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +<\/span><span lang=\"SK\">421 2 <\/span><span lang=\"EN-GB\">33 100 100<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: <\/span><span lang=\"CS\">800 536389<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Oy<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Puh\/Tel: +358 (0) 201 200 300<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Cyprus Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +<\/span><span lang=\"FR\">357\r   22 871600<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi AB<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 (0)8 634 50 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Latvia SIA<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 67 33 24 51<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +44 (0) 845 372 7101<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu\/<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Karvea<\/span><\/b><span lang=\"EN-GB\"> <b>75<\/b> <b>mg\r film-coated tablets<\/b><\/span><\/p> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Read all of this leaflet carefully\r before you start taking this medicine because it contains important information\r for you.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to\r others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><u><span lang=\"EN-GB\">What is in this leaflet<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">1.       What Karvea is and what it is\r used for<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">2.       What you need to know before\r you take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">3.       How to take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">5.       How to store Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">6.       Contents of the pack and other\r information<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>1.       What Karvea is and what it is used for<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea belongs to a group of medicines\r known as angiotensin-II receptor antagonists. Angiotensin-II is a substance\r produced in the body which binds to receptors in blood vessels causing them to\r tighten. This results in an increase in blood pressure. Karvea prevents the\r binding of angiotensin-II to these receptors, causing the blood vessels to\r relax and the blood pressure to lower. Karvea slows the decrease of kidney\r function in patients with high blood pressure and type 2 diabetes.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is used in adult patients<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to treat high blood pressure (<i>essential hypertension<\/i>)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to protect the kidney in patients with high blood pressure,\r type 2 diabetes and laboratory evidence of impaired kidney function.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What you\r need to know before you take<\/span><span lang=\"EN-GB\" style=\"text-transform:none\">Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Do not take Karvea<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>allergic<\/b> to irbesartan or any other ingredients of\r this medicine (listed in section 6)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>more than 3 months pregnant<\/b>. (It is also\r better to avoid Karvea in early pregnancy \u2013 see pregnancy section)<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><b><span lang=\"EN-GB\">if you have diabetes or impaired kidney\r function <\/span><\/b><span lang=\"EN-GB\">and you are treated with a blood pressure\r lowering medicine containing aliskiren. <\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Warnings and precautions<\/span><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\" style=\"font-weight:normal\">Talk to your\r doctor before taking Karvea<\/span><span lang=\"EN-GB\" style=\"font-weight:normal\">and <\/span><span lang=\"EN-GB\">if any of the following\r apply to you:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you get <b>excessive vomiting or diarrhoea<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>kidney problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>heart problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you receive Karvea for <b>diabetic kidney disease<\/b>. In this\r case your doctor may perform regular blood tests, especially for measuring\r blood potassium levels in case of poor kidney function<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you develop <b>low blood sugar levels<\/b> (symptoms may include\r sweating, weakness, hunger, dizziness, trembling, headache, flushing or\r paleness, numbness, having a fast, pounding heart beat), particularly if you\r are being treated for diabetes.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>going to have an operation<\/b> (surgery) or <b>be\r given anaesthetics<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><span lang=\"EN-GB\">if you are taking any of the following medicines\r used to treat high blood pressure:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">an ACE-inhibitor (for example enalapril,\r lisinopril, ramipril), in particular if you have diabetes-related kidney\r problems.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">aliskiren<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may check your kidney\r function, blood pressure, and the amount of electrolytes (e.g. potassium) in\r your blood at regular intervals.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">See also information under the heading\r \u201cDo not take Karvea\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Karvea is not recommended in early\r pregnancy, and must not be taken if you are more than 3 months pregnant,\r as it may cause serious harm to your baby if used at that stage (see pregnancy\r section).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Children and adolescents<\/span><\/p> <p class=\"EMEABodyText\">This medicinal product should not be used in children and\r adolescents because the safety and efficacy have not yet been fully\r established.<\/p> <p class=\"EMEAHeading3\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Other medicines and Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you\r are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may need to change your dose\r and\/or to take other precautions:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> If you are taking an ACE-inhibitor or\r aliskiren (see also information under the headings \u201cDo not take Karvea\u201d and\r \u201cWarnings and precautions\u201d).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">You may need to have blood checks if\r you take:<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium supplements<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">salt substitutes containing potassium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium-sparing medicines (such as certain diuretics)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">medicines containing lithium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">repaglinide (medication used for lowering blood sugar levels)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you take certain painkillers, called\r non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Karvea with food and drink<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea can be taken with or without\r food.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Pregnancy<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Your doctor will normally advise you\r to stop taking Karvea before you become pregnant or as soon as you know you are\r pregnant and will advise you to take another medicine instead of Karvea. Karvea\r is not recommended in early pregnancy, and must not be taken when more than\r 3 months pregnant, as it may cause serious harm to your baby if used after\r the third month of pregnancy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Breast-feeding<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor if you are\r breast-feeding or about to start breast-feeding. Karvea is not recommended for\r mothers who are breast-feeding, and your doctor may choose another treatment\r for you if you wish to breast-feed, especially if your baby is newborn, or was\r born prematurely.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Driving and using machines<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is unlikely to affect your\r ability to drive or use machines. However, occasionally dizziness or weariness\r may occur during treatment of high blood pressure. If you experience these,\r talk to your doctor before attempting to drive or use machines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains lactose<\/span><\/b><span lang=\"EN-GB\">. If you have been told by your doctor that you have an intolerance\r to some sugars (e.g. lactose), contact your doctor before taking this medicinal\r product.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains sodium. <\/span><\/b><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet,\r that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>3.       How to take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Always take this medicine exactly as\r your doctor has told you. Check with your doctor or pharmacist if you are not\r sure.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Method of administration<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is for <b>oral use<\/b>. Swallow\r the tablets with a sufficient amount of fluid (e.g. one glass of water). You\r can take Karvea with or without food. Try to take your daily dose at about the\r same time each day. It is important that you continue to take Karvea until your\r doctor tells you otherwise.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The usual\r dose is 150 mg once a day (two tablets a day). The dose may later be\r increased to 300 mg (four tablets a day) once daily depending on blood pressure\r response.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure and type 2 diabetes with kidney\r disease<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">In patients\r with high blood pressure and type 2 diabetes, 300 mg (four tablets a\r day) once daily is the preferred maintenance dose for the treatment of\r associated kidney disease.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The doctor may advise a lower dose,\r especially when starting treatment in certain patients such as those on <b>haemodialysis<\/b>,\r or those <b>over the age of 75 years.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The maximal blood pressure lowering\r effect should be reached 4-6 weeks after beginning treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea should not be given to children\r under 18 years of age. If a child swallows some tablets, contact your\r doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you take more Karvea than you should:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally take too many tablets,\r contact your doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you forget to take Karvea:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally miss a daily dose,\r just take the next dose as normal. Do not take a double dose to make up for a\r forgotten dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions on the\r use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>4.       Possible side effects<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\r cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some of these effects may be serious and\r may require medical attention.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with similar medicines, rare cases of\r allergic skin reactions (rash, urticaria), as well as localised swelling of the\r face, lips and\/or tongue have been reported in patients taking irbesartan. If\r you get any of these symptoms or get short of breath, <b>stop taking Karvea and\r contact your doctor immediately.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of the side effects listed\r below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Very common: <\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common: may affect up to 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon: may affect up to 1 in 100\r people<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Side effects reported in clinical\r studies for patients treated with Karvea were:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Very common (<\/span><span lang=\"EN-GB\">may affect more than 1 in 10\r people)<\/span><span lang=\"EN-GB\">: if you suffer from high blood pressure and\r type 2 diabetes with kidney disease, blood tests may show an increased\r level of potassium.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Common (<\/span><span lang=\"EN-GB\">may affect up to 1 10 people)<\/span><span lang=\"EN-GB\">: dizziness, feeling sick\/vomiting, fatigue and blood tests may show\r raised levels of an enzyme that measures the muscle and heart function\r (creatine kinase enzyme). In patients with high blood pressure and type 2\r diabetes with kidney disease, dizziness when getting up from a lying or sitting\r position, low blood pressure when getting up from a lying or sitting position,\r pain in joints or muscles and decreased levels of a protein in the red blood\r cells (haemoglobin) were also reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Uncommon (<\/span><span lang=\"EN-GB\">may affect up to 1 in 100 people)<\/span><span lang=\"EN-GB\">: heart rate increased, flushing, cough, diarrhoea,\r indigestion\/heartburn, sexual dysfunction (problems with sexual performance),\r chest pain.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Some undesirable effects have been reported\r since marketing of Karvea. Undesirable effects where the frequency is not known\r are: feeling of spinning, headache, taste disturbance, ringing in the ears, <\/span><span lang=\"EN-GB\">muscle cramps, <\/span><span lang=\"EN-GB\">pain in joints and muscles, <\/span><span lang=\"EN-GB\">decreased number of red blood cells (anaemia \u2013 symptoms may include\r tiredness, headaches, being short of breath when exercising, dizziness and\r looking pale), <\/span><span lang=\"EN-GB\">reduced number of platelets, abnormal\r liver function, increased blood potassium levels, impaired kidney function,\r inflammation of small blood vessels<\/span><span lang=\"EN-GB\">mainly affecting the skin<\/span><span lang=\"EN-GB\"> (a condition known\r as leukocytoclastic vasculitis),<\/span>severe allergic\r reactions (anaphylactic shock) <span lang=\"EN-GB\">and <\/span><span lang=\"EN-GB\">low\r blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and\/or\r whites of the eyes) have also been reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of side effects<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\r your doctor or pharmacist. This includes any possible side effects not listed\r in this leaflet. You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in <\/span><\/span><span class=\"MsoHyperlink\"><span lang=\"ES-TRAD\" style=\"background:silver;text-decoration:\r none\">Appendix V<\/span><\/span><span lang=\"EN-GB\">. By reporting side effects you\r can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>5.       How to store Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\r reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\r expiry date which is stated on the carton and on the blister after EXP. The\r expiry date refers to the last day of that month.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. Ask your pharmacist how to throw away medicines\r you no longer use. These measures will help protect the environment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>6.       Contents of the pack and other information<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea contains<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The active substance is irbesartan. Each tablet of Karvea 75 mg\r contains 75 mg irbesartan.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The other ingredients are lactose monohydrate, microcrystalline\r cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium\r stearate, titanium dioxide, macrogol 3000, carnauba wax. <\/span>Please see\r section 2 \u201cKarvea contains lactose\u201d.<\/p> <p class=\"EMEABodyTextIndent\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea looks like and contents of\r the pack<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated\r tablets are white to off-white, biconvex, and oval-shaped with a heart debossed\r on one side and the number 2871 engraved on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated\r tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or\r 98 film-coated tablets. Unidose blister packs of\r 56 x 1 film-coated tablet for delivery in hospitals are also\r available.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Marketing Authorisation Holder:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris<\/span><span lang=\"FR-BE\">- France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Manufacturer:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">SANOFI WINTHROP INDUSTRIE<br\/>\r 1, rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"EN-GB\">SANOFI WINTHROP INDUSTRIE<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2 - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For any information about this medicinal\r product, please contact the local representative of the Marketing Authorisation\r Holder.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Belgi\u00eb\/<\/span><\/b><b><span lang=\"CS\">Belgique<\/span><\/b><b><span lang=\"MT\">\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: <span style=\"layout-grid-mode:\r   line\">+32 (0)2 710 54 00<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">UAB sanofi-aventis Lietuva<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +370 5 2755224<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Bulgaria EOOD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b<\/span><span lang=\"IT\">.<\/span><span lang=\"BG\">: +<\/span><span lang=\"IT\">359 (0)2<\/span><span lang=\"IT\"> 970 53 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR-LU\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi Belgium\r   <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-LU\">T\u00e9l\/Tel: <\/span><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">+32 (0)2 710 54 00 (<\/span><span lang=\"FR-BE\">Belgique\/Belgien)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis, s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 233 086 111<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">SANOFI-AVENTIS Zrt.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel.: +36 1 <\/span><span lang=\"HU\">505 0050<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +45 45 16 70 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +39 02 39394275<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi-Aventis Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 0800 52 52 010<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel. aus dem Ausland: +49 69 305 21 131<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Genzyme Europe B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +31 20 245 4000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Estonia O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +372 627 34 88<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Norge AS<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +47 67 10 71 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis AEBE<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"CS\">: +30\r   210 900 16 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">sanofi-aventis GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 1 80 185 \u2013 0<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">sanofi-aventis, S.A.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Tel: +34 93 485 94 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel.: +48 22 280 00 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">sanofi-aventis France<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">T\u00e9l: 0 800 222 555<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Appel depuis l\u2019\u00e9tranger : +33 1 57 63 23 23<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Sanofi - Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +351 21 35 89 400<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +385 1 600 34 00<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia        <\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Romania SRL<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +40 <\/span><span lang=\"IT\">(0) 21 317 31\r   36<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Ireland Ltd. T\/A SANOFI<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +353 (0) 1 403 56 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +386 1 560 48 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"CS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SK\">sanofi-<\/span><span lang=\"CS\">aventis Slovakia\r   <\/span><span lang=\"SK\">s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +<\/span><span lang=\"SK\">421 2 <\/span><span lang=\"EN-GB\">33 100 100<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: 800 536389<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Oy<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Puh\/Tel: +358 (0) 201 200 300<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Cyprus Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +<\/span><span lang=\"FR\">357\r   22 871600<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi AB<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 (0)8 634 50 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Latvia SIA<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 67 33 24 51<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +44 (0) 845 372 7101<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu\/<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Karvea<\/span><\/b><span lang=\"EN-GB\"> <b>150<\/b> <b>mg\r film-coated tablets<\/b><\/span><\/p> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Read all of this leaflet carefully\r before you start taking this medicine because it contains important information\r for you.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to\r others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><u><span lang=\"EN-GB\">What is in this leaflet<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">1.       What Karvea is and what it is\r used for<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">2.       What you need to know before\r you take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">3.       How to take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">5.       How to store Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">6.       Contents of the pack and other\r information<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>1.       What Karvea is and what it is used for<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea belongs to a group of medicines\r known as angiotensin-II receptor antagonists. Angiotensin-II is a substance\r produced in the body which binds to receptors in blood vessels causing them to\r tighten. This results in an increase in blood pressure. Karvea prevents the\r binding of angiotensin-II to these receptors, causing the blood vessels to\r relax and the blood pressure to lower. Karvea slows the decrease of kidney\r function in patients with high blood pressure and type 2 diabetes.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is used in adult patients<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to treat high blood pressure (<i>essential hypertension<\/i>)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to protect the kidney in patients with high blood pressure,\r type 2 diabetes and laboratory evidence of impaired kidney function.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">2.       <span style=\"text-transform:\r uppercase\">What you need to know before you take Karvea<\/span>Do not take\r Karvea<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>allergic<\/b>to irbesartan or any other ingredients of this\r medicine (listed in section 6)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>more than 3 months pregnant<\/b>. (It is also\r better to avoid Karvea in early pregnancy \u2013 see pregnancy section)<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><b><span lang=\"EN-GB\">if you have diabetes or impaired kidney\r function<\/span><\/b><span lang=\"EN-GB\"> and you are treated with a blood pressure\r lowering medicine containing aliskiren.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Warnings and precautions<\/span><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\" style=\"font-weight:normal\">Talk to your\r doctor before taking Karvea<\/span><span lang=\"EN-GB\" style=\"font-weight:normal\">and <\/span><span lang=\"EN-GB\">if any of the following\r apply to you:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you get <b>excessive vomiting or diarrhoea<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>kidney problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>heart problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you receive Karvea for <b>diabetic kidney disease<\/b>. In this\r case your doctor may perform regular blood tests, especially for measuring\r blood potassium levels in case of poor kidney function<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you develop <b>low blood sugar levels<\/b> (symptoms may include\r sweating, weakness, hunger, dizziness, trembling, headache, flushing or\r paleness, numbness, having a fast, pounding heart beat), particularly if you\r are being treated for diabetes.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>going to have an operation<\/b> (surgery) or <b>be\r given anaesthetics<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><span lang=\"EN-GB\">if you are taking any of the following medicines\r used to treat high blood pressure:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">an ACE-inhibitor (for example enalapril,\r lisinopril, ramipril), in particular if you have diabetes-related kidney\r problems.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">aliskiren<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may check your kidney\r function, blood pressure, and the amount of electrolytes (e.g. potassium) in\r your blood at regular intervals.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">See also information under the heading\r \u201cDo not take Karvea\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Karvea is not recommended in early\r pregnancy, and must not be taken if you are more than 3 months pregnant,\r as it may cause serious harm to your baby if used at that stage (see pregnancy\r section).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Children and adolescents<\/span><\/p> <p class=\"EMEABodyText\">This medicinal product should not be used in children and\r adolescents because the safety and efficacy have not yet been fully\r established.<\/p> <p class=\"EMEAHeading3\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Other medicines and Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you\r are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may need to change your dose\r and\/or to take other precautions:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> If you are taking an ACE-inhibitor or aliskiren\r (see also information under the headings \u201cDo not take Karvea\u201d and \u201cWarnings and\r precautions\u201d).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">You may need to have blood checks if\r you take:<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium supplements<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">salt substitutes containing potassium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium-sparing medicines (such as certain diuretics)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">medicines containing lithium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">repaglinide (medication used for lowering blood sugar levels)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you take certain painkillers, called\r non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Karvea with food and drink<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea can be taken with or without\r food.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Pregnancy<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Your doctor will normally advise you\r to stop taking Karvea before you become pregnant or as soon as you know you are\r pregnant and will advise you to take another medicine instead of Karvea. Karvea\r is not recommended in early pregnancy, and must not be taken when more than\r 3 months pregnant, as it may cause serious harm to your baby if used after\r the third month of pregnancy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Breast-feeding<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor if you are\r breast-feeding or about to start breast-feeding. Karvea is not recommended for\r mothers who are breast-feeding, and your doctor may choose another treatment\r for you if you wish to breast-feed, especially if your baby is newborn, or was\r born prematurely.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Driving and using machines<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is unlikely to affect your\r ability to drive or use machines. However, occasionally dizziness or weariness\r may occur during treatment of high blood pressure. If you experience these,\r talk to your doctor before attempting to drive or use machines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains lactose<\/span><\/b><span lang=\"EN-GB\">. If you have been told by your doctor that you have an intolerance\r to some sugars (e.g. lactose), contact your doctor before taking this medicinal\r product.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains sodium. <\/span><\/b><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet,\r that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>3.       How to take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Always take this medicine exactly as\r your doctor has told you. Check with your doctor or pharmacist if you are not\r sure.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Method of administration<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is for <b>oral use<\/b>. Swallow\r the tablets with a sufficient amount of fluid (e.g. one glass of water). You\r can take Karvea with or without food. Try to take your daily dose at about the\r same time each day. It is important that you continue to take Karvea until your\r doctor tells you otherwise.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The usual\r dose is 150 mg once a day. The dose may later be increased to 300 mg\r (two tablets a day) once daily depending on blood pressure response.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure and type 2 diabetes with\r kidney disease<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">In patients\r with high blood pressure and type 2 diabetes, 300 mg (two tablets a\r day) once daily is the preferred maintenance dose for the treatment of\r associated kidney disease.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The doctor may advise a lower dose,\r especially when starting treatment in certain patients such as those on <b>haemodialysis<\/b>,\r or those <b>over the age of 75 years.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The maximal blood pressure lowering\r effect should be reached 4-6 weeks after beginning treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea should not be given to children\r under 18 years of age. If a child swallows some tablets, contact your\r doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you take more Karvea than you should:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally take too many\r tablets, contact your doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you forget to take Karvea:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally miss a daily dose,\r just take the next dose as normal. Do not take a double dose to make up for a\r forgotten dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions on the\r use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>4.       Possible side effects<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\r cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some of these effects may be serious and\r may require medical attention.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with similar medicines, rare cases of\r allergic skin reactions (rash, urticaria), as well as localised swelling of the\r face, lips and\/or tongue have been reported in patients taking irbesartan. If\r you get any of these symptoms or get short of breath, <b>stop taking Karvea and\r contact your doctor immediately.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of the side effects listed\r below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Very common: <\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common: may affect up to 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon: may affect up to 1 in 100\r people<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Side effects reported in clinical\r studies for patients treated with Karvea were:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Very common (<\/span><span lang=\"EN-GB\">may affect more than 1 in 10\r people)<\/span><span lang=\"EN-GB\">: if you suffer from high blood pressure and\r type 2 diabetes with kidney disease, blood tests may show an increased\r level of potassium.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Common (<\/span><span lang=\"EN-GB\">may affect up to 1 10 people)<\/span><span lang=\"EN-GB\">: dizziness, feeling sick\/vomiting, fatigue and blood tests may show\r raised levels of an enzyme that measures the muscle and heart function\r (creatine kinase enzyme). In patients with high blood pressure and type 2\r diabetes with kidney disease, dizziness when getting up from a lying or sitting\r position, low blood pressure when getting up from a lying or sitting position,\r pain in joints or muscles and decreased levels of a protein in the red blood\r cells (haemoglobin) were also reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Uncommon (<\/span><span lang=\"EN-GB\">may affect up to 1 in 100 people)<\/span><span lang=\"EN-GB\">: heart rate increased, flushing, cough, diarrhoea,\r indigestion\/heartburn, sexual dysfunction (problems with sexual performance),\r chest pain.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Some undesirable effects have been reported\r since marketing of Karvea. Undesirable effects where the frequency is not known\r are: feeling of spinning, headache, taste disturbance, ringing in the ears, <\/span><span lang=\"EN-GB\">muscle cramps, <\/span><span lang=\"EN-GB\">pain in joints and muscles, <\/span><span lang=\"EN-GB\">decreased number of red blood cells (anaemia \u2013 symptoms may include\r tiredness, headaches, being short of breath when exercising, dizziness and\r looking pale), <\/span><span lang=\"EN-GB\">reduced number of platelets, abnormal\r liver function, increased blood potassium levels, impaired kidney function,\r inflammation of small blood vessels<\/span><span lang=\"EN-GB\">mainly affecting the skin<\/span><span lang=\"EN-GB\"> (a condition known\r as leukocytoclastic vasculitis),<\/span>severe allergic\r reactions (anaphylactic shock) <span lang=\"EN-GB\">and <\/span><span lang=\"EN-GB\">low\r blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and\/or\r whites of the eyes) have also been reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of side effects<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\r your doctor or pharmacist. This includes any possible side effects not listed\r in this leaflet. You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in <\/span><\/span><span class=\"MsoHyperlink\"><span lang=\"ES-TRAD\" style=\"background:silver;text-decoration:\r none\">Appendix V<\/span><\/span><span lang=\"EN-GB\">. By reporting side effects you\r can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>5.       How to store Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\r reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\r expiry date which is stated on the carton and on the blister after EXP. The\r expiry date refers to the last day of that month.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. Ask your pharmacist how to throw away medicines\r you no longer use. These measures will help protect the environment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>6.       Contents of the pack and other information<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea contains<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The active substance is irbesartan. Each tablet of Karvea 150 mg\r contains 150 mg irbesartan.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The other ingredients are lactose monohydrate, microcrystalline\r cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium\r stearate, titanium dioxide, macrogol 3000, carnauba wax. <\/span>Please see\r section 2 \u201cKarvea contains lactose\u201d.<\/p> <p class=\"EMEABodyTextIndent\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea looks like and contents of\r the pack<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated\r tablets are white to off-white, biconvex, and oval-shaped with a heart debossed\r on one side and the number 2872 engraved on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated\r tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or\r 98 film-coated tablets. Unidose blister packs of\r 56 x 1 film-coated tablet for delivery in hospitals are also\r available.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Marketing Authorisation Holder:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris<\/span><span lang=\"FR-BE\">- France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Manufacturer:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">SANOFI WINTHROP INDUSTRIE<br\/>\r 1, rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">SANOFI WINTHROP INDUSTRIE<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2 - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">CHINOIN PRIVATE CO. LTD.<br\/>\r L\u00e9vai u.5.<br\/>\r 2112 Veresegyh\u00e1z - Hungary<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">SANOFI-AVENTIS, S.A.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Ctra. C-35 (La Batlloria-Hostalric), km.\r 63.09<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">17404 Riells i Viabrea (Girona) \u2013 Spain<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For any information about this medicinal\r product, please contact the local representative of the Marketing Authorisation\r Holder.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Belgi\u00eb\/<\/span><\/b><b><span lang=\"CS\">Belgique<\/span><\/b><b><span lang=\"MT\">\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: <span style=\"layout-grid-mode:\r   line\">+32 (0)2 710 54 00<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">UAB sanofi-aventis Lietuva<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +370 5 2755224<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Bulgaria EOOD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b<\/span><span lang=\"IT\">.<\/span><span lang=\"BG\">: +<\/span><span lang=\"IT\">359 (0)2<\/span><span lang=\"IT\"> 970 53 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR-LU\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-LU\">T\u00e9l\/Tel: <\/span><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">+32 (0)2 710 54 00 (<\/span><span lang=\"FR-BE\">Belgique\/Belgien)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis, s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 233 086 111<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">SANOFI-AVENTIS Zrt.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel.: +36 1 <\/span><span lang=\"HU\">505 0050<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +45 45 16 70 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +39 02 39394275<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi-Aventis Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 0800 52 52 010<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel. aus dem Ausland: +49 69 305 21 131<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Genzyme Europe B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +31 20 245 4000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Estonia O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +372 627 34 88<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Norge AS<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +47 67 10 71 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis AEBE<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"CS\">: +30\r   210 900 16 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">sanofi-aventis GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 1 80 185 \u2013 0<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">sanofi-aventis, S.A.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Tel: +34 93 485 94 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel.: +48 22 280 00 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">sanofi-aventis France<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">T\u00e9l: 0 800 222 555<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Appel depuis l\u2019\u00e9tranger : +33 1 57 63 23 23<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Sanofi - Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +351 21 35 89 400<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +385 1 600 34 00<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PL\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Romania SRL<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PL\">Tel: +40 <\/span><span lang=\"FR\">(0) 21 317 31\r   36<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Ireland Ltd. T\/A SANOFI<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +353 (0) 1 403 56 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +386 1 560 48 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"CS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SK\">sanofi-<\/span><span lang=\"CS\">aventis Slovakia\r   <\/span><span lang=\"SK\">s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +<\/span><span lang=\"SK\">421 2 <\/span><span lang=\"IT\">33 100 100<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 800 536389<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Oy<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Puh\/Tel: +358 (0) 201 200 300<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Cyprus Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +<\/span><span lang=\"FR\">357\r   22 871600<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi AB<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 (0)8 634 50 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Latvia SIA<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +371 67 33 24 51<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +44 (0) 845 372 7101<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu\/<\/span><\/p> <span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Package leaflet: Information for the user<\/span><\/b><\/p> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><b><span lang=\"EN-GB\">Karvea<\/span><\/b><span lang=\"EN-GB\"> <b>300<\/b> <b>mg\r film-coated tablets<\/b><\/span><\/p> <p align=\"center\" class=\"EMEABodyText\" style=\"text-align:center\"><span lang=\"EN-GB\">irbesartan<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Read all of this leaflet carefully\r before you start taking this medicine because it contains important information\r for you.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">Keep this leaflet. You may need to read it again.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you have any further questions, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">This medicine has been prescribed for you only. Do not pass it on to\r others. It may harm them, even if their signs of illness are the same as yours.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">If you get any side effects, talk to your doctor or pharmacist. This\r includes any possible side effects not listed in this leaflet. See section 4.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><u><span lang=\"EN-GB\">What is in this leaflet<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">1.       What Karvea is and what it is\r used for<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">2.       What you need to know before\r you take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">3.       How to take Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">4.       Possible side effects<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">5.       How to store Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">6.       Contents of the pack and other\r information<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>1.       What Karvea is and what it is used for<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea belongs to a group of medicines\r known as angiotensin-II receptor antagonists. Angiotensin-II is a substance\r produced in the body which binds to receptors in blood vessels causing them to\r tighten. This results in an increase in blood pressure. Karvea prevents the\r binding of angiotensin-II to these receptors, causing the blood vessels to\r relax and the blood pressure to lower. Karvea slows the decrease of kidney\r function in patients with high blood pressure and type 2 diabetes.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is used in adult patients<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to treat high blood pressure (<i>essential hypertension<\/i>)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">to protect the kidney in patients with high blood pressure,\r type 2 diabetes and laboratory evidence of impaired kidney function.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       <\/span><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;text-transform:none'>What you\r need to know before you take<\/span><span lang=\"EN-GB\" style=\"text-transform:none\">Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Do not take Karvea<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>allergic<\/b> to irbesartan or any other ingredients of\r this medicine (listed in section 6)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>more than 3 months pregnant<\/b>. (It is also\r better to avoid Karvea in early pregnancy \u2013 see pregnancy section)<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><span lang=\"EN-GB\" style=\"font-family:Wingdings;color:black\">\u00a7<\/span><b><span lang=\"EN-GB\">if you have diabetes or impaired kidney\r function<\/span><\/b><span lang=\"EN-GB\"> and you are treated with a blood pressure\r lowering medicine containing aliskiren.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Warnings and precautions<\/span><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\" style=\"font-weight:normal\">Talk to your\r doctor before taking Karvea<\/span><span lang=\"EN-GB\" style=\"font-weight:normal\">and <\/span><span lang=\"EN-GB\">if any of the following\r apply to you:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you get <b>excessive vomiting or diarrhoea<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>kidney problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you suffer from <b>heart problems<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you receive Karvea for <b>diabetic kidney disease<\/b>. In this\r case your doctor may perform regular blood tests, especially for measuring\r blood potassium levels in case of poor kidney function<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">if you develop <b>low blood sugar levels<\/b> (symptoms may include\r sweating, weakness, hunger, dizziness, trembling, headache, flushing or\r paleness, numbness, having a fast, pounding heart beat), particularly if you\r are being treated for diabetes.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">if you are <b>going to have an operation<\/b> (surgery) or <b>be\r given anaesthetics<\/b><\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:27.5pt;text-indent:-27.5pt\"><a name=\"_BPDC_LN_INS_1001\"><\/a><span lang=\"EN-GB\" style=\"font-family:Wingdings;\r color:black\">\u00a7<\/span><span lang=\"EN-GB\">if you are taking  any of the following medicines used to treat high\r blood pressure:<\/span><\/p> <p class=\"EMEABodyTextIndent\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">an ACE-inhibitor (for example enalapril,\r lisinopril, ramipril), in particular if you have diabetes-related kidney\r problems.<\/span><\/p> <p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-.25in\"><span lang=\"EN-GB\" style='font-family:\"Courier New\"'>o<\/span><span lang=\"EN-GB\">aliskiren<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may check your kidney\r function, blood pressure, and the amount of electrolytes (e.g. potassium) in\r your blood at regular intervals.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">See also information under the heading\r \u201cDo not take Karvea\u201d.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Karvea is not recommended in early\r pregnancy, and must not be taken if you are more than 3 months pregnant,\r as it may cause serious harm to your baby if used at that stage (see pregnancy\r section).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Children and adolescents<\/span><\/p> <p class=\"EMEABodyText\">This medicinal product should not be used in children and\r adolescents because the safety and efficacy have not yet been fully\r established.<\/p> <p class=\"EMEAHeading3\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Other medicines and Karvea<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor or pharmacist if you\r are taking, have recently taken or might take any other medicines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Your doctor may need to change your dose\r and\/or to take other precautions:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\"> If you are taking an ACE-inhibitor or aliskiren\r (see also information under the headings \u201cDo not take Karvea\u201d and \u201cWarnings and\r precautions\u201d).<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">You may need to have blood checks if\r you take:<\/span><\/b><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium supplements<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">salt substitutes containing potassium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">potassium-sparing medicines (such as certain diuretics)<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">medicines containing lithium<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">repaglinide (medication used for lowering blood sugar levels)<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you take certain painkillers, called\r non-steroidal anti-inflammatory drugs, the effect of irbesartan may be reduced.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Karvea with food and drink<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea can be taken with or without\r food.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Pregnancy and breast-feeding<\/span><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Pregnancy<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">You must tell your doctor if you think\r you are (<u>or might become<\/u>) pregnant. Your doctor will normally advise you\r to stop taking Karvea before you become pregnant or as soon as you know you are\r pregnant and will advise you to take another medicine instead of Karvea. Karvea\r is not recommended in early pregnancy, and must not be taken when more than\r 3 months pregnant, as it may cause serious harm to your baby if used after\r the third month of pregnancy.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading2\"><span lang=\"EN-GB\">Breast-feeding<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Tell your doctor if you are\r breast-feeding or about to start breast-feeding. Karvea is not recommended for\r mothers who are breast-feeding, and your doctor may choose another treatment\r for you if you wish to breast-feed, especially if your baby is newborn, or was\r born prematurely.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Driving and using machines<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is unlikely to affect your\r ability to drive or use machines. However, occasionally dizziness or weariness\r may occur during treatment of high blood pressure. If you experience these,\r talk to your doctor before attempting to drive or use machines.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains lactose<\/span><\/b><span lang=\"EN-GB\">. If you have been told by your doctor that you have an intolerance\r to some sugars (e.g. lactose), contact your doctor before taking this medicinal\r product.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">Karvea contains sodium. <\/span><\/b><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet,\r that is to say essentially \u2018sodium-free\u2019.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>3.       How to take Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Always take this medicine exactly as\r your doctor has told you. Check with your doctor or pharmacist if you are not\r sure.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Method of administration<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea is for <b>oral use<\/b>. Swallow\r the tablets with a sufficient amount of fluid (e.g. one glass of water). You\r can take Karvea with or without food. Try to take your daily dose at about the\r same time each day. It is important that you continue to take Karvea until your\r doctor tells you otherwise.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">The usual\r dose is 150 mg once a day. The dose may later be increased to 300 mg\r once daily depending on blood pressure response.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><b><span lang=\"EN-GB\">Patients with high blood pressure and type 2 diabetes with\r kidney disease<\/span><\/b><\/p> <p class=\"EMEABodyText\" style=\"margin-left:28.35pt\"><span lang=\"EN-GB\">In patients\r with high blood pressure and type 2 diabetes, 300 mg once daily is\r the preferred maintenance dose for the treatment of associated kidney disease.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The doctor may advise a lower dose,\r especially when starting treatment in certain patients such as those on <b>haemodialysis<\/b>,\r or those <b>over the age of 75 years.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The maximal blood pressure lowering\r effect should be reached 4-6 weeks after beginning treatment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">Use in children and adolescents<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea should not be given to children\r under 18 years of age. If a child swallows some tablets, contact your\r doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you take more Karvea than you should:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally take too many\r tablets, contact your doctor immediately.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">If you forget to take Karvea:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you accidentally miss a daily dose,\r just take the next dose as normal. Do not take a double dose to make up for a\r forgotten dose.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you have any further questions on the\r use of this medicine, ask your doctor or pharmacist.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>4.       Possible side effects<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Like all medicines, this medicine can\r cause side effects, although not everybody gets them.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Some of these effects may be serious and\r may require medical attention.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">As with similar medicines, rare cases of\r allergic skin reactions (rash, urticaria), as well as localised swelling of the\r face, lips and\/or tongue have been reported in patients taking irbesartan. If\r you get any of these symptoms or get short of breath, <b>stop taking Karvea and\r contact your doctor immediately.<\/b><\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of the side effects listed\r below is defined using the following convention:<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Very common: <\/span><span lang=\"EN-GB\">may\r affect more than 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common: may affect up to 1 in 10 people<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon: may affect up to 1 in 100\r people<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Side effects reported in clinical\r studies for patients treated with Karvea were:<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Very common (<\/span><span lang=\"EN-GB\">may affect more than 1 in 10\r people)<\/span><span lang=\"EN-GB\">: if you suffer from high blood pressure and\r type 2 diabetes with kidney disease, blood tests may show an increased\r level of potassium.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Common (<\/span><span lang=\"EN-GB\">may affect up to 1 10 people)<\/span><span lang=\"EN-GB\">: dizziness, feeling sick\/vomiting, fatigue and blood tests may show\r raised levels of an enzyme that measures the muscle and heart function\r (creatine kinase enzyme). In patients with high blood pressure and type 2\r diabetes with kidney disease, dizziness when getting up from a lying or sitting\r position, low blood pressure when getting up from a lying or sitting position,\r pain in joints or muscles and decreased levels of a protein in the red blood\r cells (haemoglobin) were also reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7<\/span><span lang=\"EN-GB\">Uncommon (<\/span><span lang=\"EN-GB\">may affect up to 1 in 100 people)<\/span><span lang=\"EN-GB\">: heart rate increased, flushing, cough, diarrhoea, indigestion\/heartburn,\r sexual dysfunction (problems with sexual performance), chest pain.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">Some undesirable effects have been reported\r since marketing of Karvea. Undesirable effects where the frequency is not known\r are: feeling of spinning, headache, taste disturbance, ringing in the ears, <\/span><span lang=\"EN-GB\">muscle cramps, <\/span><span lang=\"EN-GB\">pain in joints and muscles, <\/span><span lang=\"EN-GB\">decreased number of red blood cells (anaemia \u2013 symptoms may include\r tiredness, headaches, being short of breath when exercising, dizziness and\r looking pale), <\/span><span lang=\"EN-GB\">reduced number of platelets, abnormal\r liver function, increased blood potassium levels, impaired kidney function, inflammation\r of small blood vessels<\/span><span lang=\"EN-GB\">mainly\r affecting the skin<\/span><span lang=\"EN-GB\"> (a condition known as\r leukocytoclastic vasculitis),<\/span>severe allergic\r reactions (anaphylactic shock) <span lang=\"EN-GB\">and <\/span><span lang=\"EN-GB\">low\r blood sugar levels. Uncommon cases of jaundice (yellowing of the skin and\/or\r whites of the eyes) have also been reported.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of side effects<\/span><\/u><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">If you get any side effects, talk to\r your doctor or pharmacist. This includes any possible side effects not listed\r in this leaflet. You can also report side effects directly via <span style=\"background:silver\">the national reporting system listed in <\/span><\/span><span class=\"MsoHyperlink\"><span lang=\"ES-TRAD\" style=\"background:silver;text-decoration:\r none\">Appendix V<\/span><\/span><span lang=\"EN-GB\">. By reporting side effects you\r can help provide more information on the safety of this medicine.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>5.       How to store Karvea<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Keep this medicine out of the sight and\r reach of children.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not use this medicine after the\r expiry date which is stated on the carton and on the blister after EXP. The\r expiry date refers to the last day of that month.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not throw away any medicines via\r wastewater or household waste. Ask your pharmacist how to throw away medicines\r you no longer use. These measures will help protect the environment.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading1\"><span lang=\"EN-GB\" style='font-family:\"Times New Roman Bold\",serif;\r text-transform:none'>6.       Contents of the pack and other information<\/span><\/p> <p class=\"EMEAHeading1\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea contains<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The active substance is irbesartan. Each tablet of Karvea 300 mg\r contains 300 mg irbesartan.<\/span><\/p> <p class=\"EMEABodyTextIndent\"><span lang=\"EN-GB\" style=\"font-family:Wingdings\">\u00a7  <\/span><span lang=\"EN-GB\">The other ingredients are lactose monohydrate, microcrystalline\r cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium\r stearate, titanium dioxide, macrogol 3000, carnauba wax. <\/span>Please see\r section 2 \u201cKarvea contains lactose\u201d.<\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"EN-GB\">What Karvea looks like and contents of\r the pack<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated\r tablets are white to off-white, biconvex, and oval-shaped with a heart debossed\r on one side and the number 2873 engraved on the other side.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated\r tablets are supplied in blister packs of 14, 28, 30, 56, 84, 90 or\r 98 film-coated tablets. Unidose blister packs of\r 56 x 1 film-coated tablet for delivery in hospitals are also\r available.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Marketing Authorisation Holder:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris<\/span><span lang=\"FR-BE\">- France<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEAHeading3\"><span lang=\"FR\">Manufacturer:<\/span><\/p> <p class=\"EMEAAddress\"><span lang=\"FR-BE\">SANOFI WINTHROP INDUSTRIE<br\/>\r 1, rue de la Vierge<br\/>\r Ambar\u00e8s &amp; Lagrave<br\/>\r F-33565 Carbon Blanc Cedex - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">SANOFI WINTHROP INDUSTRIE<br\/>\r 30-36 Avenue Gustave Eiffel, BP 7166<br\/>\r F-37071 Tours Cedex 2 - France<\/span><\/p> <p class=\"EMEAAddress\"><\/p> <p class=\"EMEAAddress\"><span lang=\"FR\">CHINOIN PRIVATE CO. LTD.<br\/>\r L\u00e9vai u.5.<br\/>\r 2112 Veresegyh\u00e1z - Hungary<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">SANOFI-AVENTIS, S.A.<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"IT\">Ctra. C-35 (La Batlloria-Hostalric), km.\r 63.09<\/span><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">17404 Riells i Viabrea (Girona) \u2013 Spain<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">For any information about this medicinal\r product, please contact the local representative of the Marketing Authorisation\r Holder.<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"MsoNormalTable\" style=\"margin-left:-1.7pt;border-collapse:collapse\" width=\"624\"> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Belgi\u00eb\/<\/span><\/b><b><span lang=\"CS\">Belgique<\/span><\/b><b><span lang=\"MT\">\/Belgien<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">T\u00e9l\/Tel: <span style=\"layout-grid-mode:\r   line\">+32 (0)2 710 54 00<\/span><\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LT\">Lietuva<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">UAB sanofi-aventis Lietuva<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +370 5 2755224<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EN-GB\">\u0411\u044a\u043b\u0433\u0430\u0440\u0438\u044f<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Bulgaria EOOD<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"BG\">\u0422\u0435\u043b<\/span><span lang=\"IT\">.<\/span><span lang=\"BG\">: +<\/span><span lang=\"IT\">359 (0)2<\/span><span lang=\"IT\"> 970 53 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR-LU\">Luxembourg\/Luxemburg<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">Sanofi\r   Belgium <\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR-LU\">T\u00e9l\/Tel: <\/span><span lang=\"FR-BE\" style=\"layout-grid-mode:line\">+32 (0)2 710 54 00 (<\/span><span lang=\"FR-BE\">Belgique\/Belgien)<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u010cesk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis, s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +420 233 086 111<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"HU\">Magyarorsz\u00e1g<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">SANOFI-AVENTIS Zrt.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel.: +36 1 <\/span><span lang=\"HU\">505 0050<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Danmark<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi A\/S<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +45 45 16 70 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"MT\">Malta<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +39 02 39394275<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Deutschland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Sanofi-Aventis Deutschland GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: 0800 52 52 010<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel. aus dem Ausland: +49 69 305 21 131<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Nederland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Genzyme Europe B.V.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +31 20 245 4000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ET\">Eesti<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Estonia O\u00dc<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +372 627 34 88<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">Norge<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis Norge AS<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tlf: +47 67 10 71 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u0395\u03bb\u03bb\u03ac\u03b4\u03b1<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis AEBE<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb<\/span><span lang=\"CS\">: +30\r   210 900 16 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"CS\">\u00d6sterreich<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">sanofi-aventis GmbH<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"DE\">Tel: +43 1 80 185 \u2013 0<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"ES\">Espa\u00f1a<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">sanofi-aventis, S.A.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Tel: +34 93 485 94 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Polska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">sanofi-aventis Sp. z o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel.: +48 22 280 00 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td colspan=\"2\" style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">France<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR-BE\">sanofi-aventis France<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">T\u00e9l: 0 800 222 555<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Appel depuis l\u2019\u00e9tranger : +33 1 57 63 23 23<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"PT\">Portugal<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"PT\">Sanofi - Produtos Farmac\u00eauticos, Lda<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +351 21 35 89 400<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\" style=\"page-break-after:avoid\"><b><span lang=\"IT\">Hrvatska<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Croatia d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +385 1 600 34 00<\/span><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Rom\u00e2nia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Romania SRL<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +40 <\/span><span lang=\"IT\">(0) 21 317 31\r   36<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"FR\">Ireland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Ireland Ltd. T\/A SANOFI<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">Tel: +353 (0) 1 403 56 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SL\">Slovenija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">sanofi-aventis d.o.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +386 1 560 48 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IS\">\u00cdsland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Vistor hf.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EN-GB\">S\u00edmi<\/span><span lang=\"CS\">: +354 535 7000<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SK\">Slovensk\u00e1 republika<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SK\">sanofi-<\/span><span lang=\"CS\">aventis Slovakia\r   <\/span><span lang=\"SK\">s.r.o.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"CS\">Tel: +<\/span><span lang=\"SK\">421 2 <\/span><span lang=\"EN-GB\">33 100 100<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Italia<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi S.r.l.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: <\/span><span lang=\"FR\">800 536389<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"IT\">Suomi\/Finland<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Sanofi Oy<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Puh\/Tel: +358 (0) 201 200 300<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"EL\">\u039a\u03cd\u03c0\u03c1\u03bf\u03c2<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"FR\">sanofi-aventis Cyprus Ltd.<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"EL\">\u03a4\u03b7\u03bb: +<\/span><span lang=\"FR\">357\r   22 871600<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">Sverige<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi AB<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +46 (0)8 634 50 00<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr style=\"page-break-inside:avoid\"> <td style=\"border:none;padding:0in 0in 0in 0in\" width=\"2\"><p class=\"MsoNormal\"> <\/p><\/td> <td style=\"width:232.2pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"310\"> <p class=\"MsoNormal\"><b><span lang=\"LV\">Latvija<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">sanofi-aventis Latvia SIA<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"IT\">Tel: +371 67 33 24 51<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <td style=\"width:233.9pt;padding:0in 5.4pt 0in 5.4pt\" valign=\"top\" width=\"312\"> <p class=\"MsoNormal\"><b><span lang=\"SV\">United Kingdom<\/span><\/b><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Sanofi<\/span><\/p> <p class=\"MsoNormal\"><span lang=\"SV\">Tel: +44 (0) 845 372 7101<\/span><\/p> <p class=\"MsoNormal\"><\/p> <\/td> <\/tr> <tr height=\"0\"> <td style=\"border:none\" width=\"2\"><\/td> <td style=\"border:none\" width=\"310\"><\/td> <td style=\"border:none\" width=\"312\"><\/td> <\/tr> <\/table> <p class=\"MsoNormal\"><\/p> <p class=\"EMEABodyText\"><b><span lang=\"EN-GB\">This leaflet was last revised in<\/span><\/b><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicine is\r available on the European Medicines Agency web site: http:\/\/www.ema.europa.eu\/<\/span><\/p> <p class=\"EMEABodyText\"><\/p> <p class=\"EMEABodyText\"><\/p> <\/div>","ID":"002ddf86-bc56-497d-a851-f81a205acd94","Styles":"None","Classes":"['WordSection1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ","ParentId":"01eb8368-4855-42c8-957d-03facd0bb3d4"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"74373455-3300-4c6d-92fc-0de3c8333f2a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7a178691-5d93-41ed-9a26-bcac9290e2ff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7959a575-48f8-468b-bd75-a0efc9bd620d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"791bd2a4-cb10-4a43-a268-c8d2d2711acc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"49b9bcd1-4731-42d6-93f7-51ab58c6ec48","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7860b6a5-428a-4868-be9b-88a089a3ade2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0529fe1f-7ec1-4f7a-855b-7ebfda28b24d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3a23900e-522d-49a5-b378-bb60dddc2a4d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"566e1b6a-7430-49af-a134-368999a58a7c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3aabf19b-d212-41a2-93b6-f2539187c50c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"70210fa3-6cbc-4489-be01-f92a8ecec1b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"88d2b7d6-5022-42a8-b128-6ab8c25ba5c8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f12cea8a-b8ac-4f3e-a986-cce392adaa15","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"74761398-8843-4851-9a46-414657b04bd5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"03139d9a-bb58-4351-9cef-9cebd320086f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"944323b4-b224-4ef4-850e-e9c04cadb1b3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"89d54ca4-435d-4524-acce-1661a15e58a1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3d5eee03-01bd-4604-b83f-91afe4dc3b0f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"62d99521-c9bf-4a51-a1a6-b655aeb33bc9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"063961dd-725b-4607-9bb1-5c12578a313c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"454eab36-7321-4886-abdb-07a002e1c61b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bffe3c38-4bd9-4888-a516-dd34ffb94a17","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c69c7b47-1f9c-4c00-8394-f151269e78c5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEATitle\"><span lang=\"EN-GB\">ANNEX I<\/span><\/p>","ID":"7c36a854-eeeb-4b3d-914d-f3fc36d84b64","Styles":"None","Classes":"['EMEATitle']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":null,"IsULTag":null,"Text":"ANNEX I","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5859f2a4-0819-45ce-a20c-defab057eca5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEATitle\"><span lang=\"EN-GB\">SUMMARY OF PRODUCT CHARACTERISTICS<\/span><\/p>","ID":"f3ffd4d8-ffa1-4c18-833c-1e68e904033b","Styles":"None","Classes":"['EMEATitle']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"SUMMARY OF PRODUCT CHARACTERISTICS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"4d35a1ab-a29a-49e7-b816-f5d1474fa1db","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"3e7d7542-c879-41c7-a95e-a1b1abbfef43","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ntext-transform:uppercase","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"4d35a1ab-a29a-49e7-b816-f5d1474fa1db"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"fa4ff024-2a8f-49f4-8651-214a40f1e325","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"3e7d7542-c879-41c7-a95e-a1b1abbfef43"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p>","ID":"d89dc92f-ab6f-4c56-97cd-f3fe7762fb77","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"1d5f56d9-0bb6-462e-a035-4b65e735be03","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg tablets.<\/span><\/p>","ID":"bd6b46c9-1fea-4929-8cdf-253a1daed809","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 75 mg tablets.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"81e6f9a5-195b-4396-8abe-99fd4dda5898","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e3da598d-3a42-4d45-a54a-cd4e3db45ef1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p>","ID":"4b2d8717-17be-4fe1-ac21-f80f6a547ffd","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"24292027-0526-4bd6-85ae-c6c2be2ebfa4","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each tablet contains 75 mg of\r irbesartan.<\/span><\/p>","ID":"914d9b58-2711-4bde-a8d2-fe060897e76d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 75 mg of\r irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3499552a-9a3e-4b91-830a-6cd116459f4f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 15.37 mg of lactose monohydrate per tablet.<\/span><\/p>","ID":"ecf3bc66-b80a-4af9-9f98-6e38d68fb405","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: 15.37 mg of lactose monohydrate per tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"77cd24bf-ea8b-433a-b451-66ac230fa489","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p>","ID":"06edb92a-4a69-419f-a376-cb098ac1d6ff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see\r section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2d3bc5de-0caf-488f-abde-4d6f0e8083b7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"246a80b2-d894-4d64-aeb7-5c9400634c35","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p>","ID":"e2626def-44f4-4ed1-9038-70d346c6dbe9","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"e58468a9-5cd1-4d9e-b930-ae45bedff735","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet.<\/span><\/p>","ID":"6a69b1a9-c1a1-4698-a08e-a91a1eff0c0b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2771 engraved\r on the other side.<\/span><\/p>","ID":"b1667c66-59bb-447d-bb98-9eb0be4bf98d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2771 engraved\r on the other side.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"26a8f7a7-ef23-45fc-8417-e75711dc8646","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"edce6056-7d95-478b-81f3-82771fefb061","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p>","ID":"dab69afc-c0f8-4434-864d-92eee6cb52ff","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"07408786-d06d-455b-85d3-9603f42dd8a6","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p>","ID":"cd3c3095-939c-45ce-880c-574e547947cc","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"1fddcd6d-f20a-4018-99ae-27758829b2fa","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p>","ID":"03e90f92-abc2-4b1b-9485-f99fc8cd6861","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea is\r indicated in adults for the treatment of essential hypertension.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"598dce52-22d9-45dc-bae1-9d16cbc6bcae","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"19ab8b34-7121-4124-b2c3-c70db90f63bd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p>","ID":"c7d7c77a-5ac6-4e87-9dd4-c0af93765128","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and method of\r administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8630ed32-371b-4a29-b1f7-6a00f0102420","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"c38700fc-30f5-4ed8-bfde-d0c8050d7729","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"c2891d9f-0539-4b5c-957f-29e8f5f40706","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p>","ID":"70a87f80-646b-46d9-89a1-b29258440ed1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"827fc6f9-87cd-4d48-ae00-67e52feb955a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled with\r 150 mg once daily, the dose of Karvea can be increased to 300 mg, or\r other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).\r In particular, the addition of a diuretic such as hydrochlorothiazide has been\r shown to have an additive effect with Karvea (see section 4.5).<\/span><\/p>","ID":"87bc8a5c-5725-4fec-be03-a08ae527c479","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients insufficiently controlled with\r 150 mg once daily, the dose of Karvea can be increased to 300 mg, or\r other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1).\r In particular, the addition of a diuretic such as hydrochlorothiazide has been\r shown to have an additive effect with Karvea (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0d4da113-8cc3-4d99-9085-5ecc96056300","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p>","ID":"4e77d3ba-7503-4bc0-b8d6-b406b0e5831d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"de802e5a-da65-4e3d-9f70-f3cf24b3c166","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d05aa69d-b225-4aac-bfa9-aab8916b12d7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p>","ID":"2cbb8b2f-0a85-4f30-8066-c0cfb64e6a74","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special Populations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"dfed5bf1-839d-4723-b280-a1dccfc42131","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"77b48a38-e31f-4b3b-a0d7-db11d4a2c794","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"752cd40a-a9b1-4e93-b873-25e1c9da9cb5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p>","ID":"3ef1be98-6d8a-4e23-a69f-4ee2f362cba9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1594b712-51d8-4834-bcee-18d6fba0a2c9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"66c6dfe8-1fda-4751-9e84-438bcb83b717","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"084ef000-74cf-4c49-9d4f-47196dfc5fdb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p>","ID":"fc7d9666-4649-42eb-8b6f-5af706dccc14","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c2bcef17-1a13-4c98-821a-7c3456bb2d34","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p>","ID":"aa0bf161-24ab-4d29-b54b-c90d5e26ae0a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Older people","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"711e0275-da29-4a76-ab3f-3798ebe324d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for theolder people.<\/span><\/p>","ID":"6f4e82c7-b975-4af2-b3c2-76a3edc1d454","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for theolder people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"88fd4dc3-10c3-4ec4-b387-835ef793edc8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"7e8697c3-5d2d-496c-bd4c-cc3dec5694b6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a6d0e457-ca84-442c-8b2e-5609d4040423","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p>","ID":"0ebc8c21-c975-4e1d-b339-ad5d955dc685","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0cc037ef-7a70-4d50-a0f9-76ec20fccc8d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p>","ID":"ebde41a9-fcf5-4b90-bb01-31235b6801c8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of Administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bd5303fd-3134-4ec3-bd62-9992f9d3c302","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"e00f796d-c6a3-4926-918f-65cff703c77e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For oral use.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b5b17789-ae4f-411b-9d24-41a17c378061","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p>","ID":"7ccddaa4-94d7-4235-9c8b-a27237e9c74f","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"0787724e-d6fb-4547-9bb6-ff60ce8ebfd0","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"7f3575bc-9ef9-4cb3-8bc1-a56298485334","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p>","ID":"32bb5ae8-4501-4189-83c8-c10ddc72ee7b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"30651b49-a1e0-4df6-9fd0-e3b6394f2b31","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\"> The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p>","ID":"6c2fcbab-c588-441a-ac0a-e8545db7dbd4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) <60\r ml\/min\/1.73m2) (see sections 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"baf45da2-c000-450e-a453-34426561fec4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p>","ID":"526cb009-79d8-4269-9810-314dff740147","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions\r for use","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"f6882905-5707-45d5-8b03-8776850a9b18","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p>","ID":"ad3b68c6-70bd-458a-93ff-5526dbf0e097","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Intravascular\r volume depletion: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"efc283c4-f14a-4887-8653-a2581be906e9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p>","ID":"19cb156f-a359-43f1-96a8-e7c94d9f3cb3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renovascular hypertension: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"79c2b5e9-81bd-49ae-9a89-5fa6c87d7483","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p>","ID":"1006968c-0c32-4c80-bec9-88f8870947ac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment and kidney\r transplantation: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"a9593bd6-9353-4492-b637-c14e902486f0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p>","ID":"3e581711-6aed-407d-9925-e17fdb109578","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypertensive patients with\r type 2 diabetes and renal disease: the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"9f42386a-4cbb-49f3-93d8-cdd2178ae5f9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):<\/span><\/u><\/p>","ID":"fb6ad45d-62e5-4ab2-b0de-12f5fc5ae703","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">T<\/span><\/u><span lang=\"EN-GB\">here is\r evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p>","ID":"7c0292cd-9c13-4b60-9631-1f961bc985ad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is\r evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c019920d-4f5c-4c3d-bc71-daa8b70aad27","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p>","ID":"ed819095-c6be-43d5-af93-d323ae089489","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hyperkalaemia: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"621f05b0-8fe4-441a-8b52-b93e055c2012","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia: <\/span><\/u><span lang=\"EN-GB\">Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p>","ID":"cf859c56-b8a7-4ac3-a6ab-30ee4f1d5629","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"837e6ec3-449d-4597-875d-777be5bdd837","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).<\/span><\/p>","ID":"da683445-29a5-4c2b-9f0a-443e7f1ec9cb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"152afdb7-a752-4ea8-8d49-0bdd8ece6997","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p>","ID":"01bd9c5a-5ed7-499b-8dbe-6d7f5caabba6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"944acc45-5a7c-4948-b4be-00c3865a3fcd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the renin-angiotensin\r system. Therefore, the use of Karvea is not recommended.<\/span><\/p>","ID":"1020b6c4-1dd3-4371-a1f1-ae343a8e25ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Primary aldosteronism: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the renin-angiotensin\r system. Therefore, the use of Karvea is not recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"ee287909-4f4e-4fe8-95fb-86947e70d839","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p>","ID":"313c3e39-ac3c-4b69-be8a-d07209b1c398","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p>","ID":"87f4e3b2-59f2-4f7e-bb47-ff47e87d230f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"19db0ffa-4676-4cf9-81e9-26f83384161b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p>","ID":"ea0bf6a1-267b-439d-9e05-b987cd95c764","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8fe0132f-ce0e-4d33-9112-4a78edfe1aac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p>","ID":"fea3bc96-ad78-4e5f-9ec2-5a7615ae53f7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c24d5689-9a94-4f3c-88b3-c6e7e4c25bc7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p>","ID":"27cf373b-4b6d-4e40-b4fc-b1c1904e5a03","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipients:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><a name=\"_Hlk37089325\"><span lang=\"FR\">Karvea 75 mg\r tablet contains lactose. <\/span><\/a><span lang=\"EN-GB\">Patients with rare\r hereditary problems of galactose intolerance, total lactase deficiency or\r glucose-galactose malabsorption should not take this medicine.<\/span><\/p>","ID":"8e76d912-024f-42cb-a1a4-916d06a6d0d8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 75 mg\r tablet contains lactose. Patients with rare\r hereditary problems of galactose intolerance, total lactase deficiency or\r glucose-galactose malabsorption should not take this medicine.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"10fcb003-c1de-49b1-887a-8c04f60a0576","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 75 mg tablet contains sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p>","ID":"6fc8a410-3181-4817-a412-ddc117396840","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 75 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5cc652a0-dbd6-443b-9688-4b8f91acdc54","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p>","ID":"c14cfd6b-5854-4d67-9ce3-edb264bbcd20","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal\r products and other forms of interaction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"ccb646ac-3d0d-4eb5-85d4-210d96edf2c2","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers, long-acting\r calcium channel blockers, and thiazide diuretics. Prior treatment with high\r dose diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).<\/span><\/p>","ID":"605ba876-041e-4823-9d8f-fbd0bbe3a383","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Diuretics and other antihypertensive\r agents: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers, long-acting\r calcium channel blockers, and thiazide diuretics. Prior treatment with high\r dose diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"604a7ebd-de24-4f35-b10a-e73a6e232bff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).<\/span><\/p>","ID":"15922c85-27b5-49eb-bd94-254a96c5e006","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aliskiren-containing products or\r ACE-inhibitors: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dd277b5e-6eec-4b83-ab2a-38f2e93566f5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the renin-angiotensin\r system, concomitant use of potassium-sparing diuretics, potassium supplements,\r salt substitutes containing potassium or other medicinal products that may\r increase serum potassium levels (e.g. heparin) may lead to increases in\r serum potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p>","ID":"b70a23f1-2c6a-439a-8e00-e385ca89ee20","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Potassium supplements and\r potassium-sparing diuretics:based on\r experience with the use of other medicinal products that affect the renin-angiotensin\r system, concomitant use of potassium-sparing diuretics, potassium supplements,\r salt substitutes containing potassium or other medicinal products that may\r increase serum potassium levels (e.g. heparin) may lead to increases in\r serum potassium and is, therefore, not recommended (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"7e754e33-baa1-4553-b1a1-b0f2f05dcedc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported with\r irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p>","ID":"9c709ffb-197f-44cc-ae70-0db30094a887","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported with\r irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"56f205f0-4739-48ab-ae6e-4dcc9765a384","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: w<span style=\"color:black\">hen angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p>","ID":"5a74124a-a389-44b2-b27c-542499f086b7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (> 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3b6b9a71-f4e1-4063-be9a-128c025301f7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p>","ID":"86de0bb8-e3fa-49b9-80b8-9c0f0225520d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"824379de-df7d-4cf9-9632-1f530d84b021","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p>","ID":"0c96d71b-6111-4451-bbb5-a6f8725b57fc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Repaglinide: irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the Cmax\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"966a933e-133f-431c-ab8e-dce6fe733337","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p>","ID":"88f21262-2ccd-4e8c-83e6-8db0289f7ad5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Additional information on irbesartan\r interactions: in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a1c911ca-6eb5-43de-a815-642083d008da","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and\r lactation<\/span><\/p>","ID":"43b54b69-7a9d-4d0d-a211-d498b19a8871","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and\r lactation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"fcac2105-5a7a-4428-80f5-efdf5fa94f86","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"8cef2d9e-6dee-48e9-99c5-40686aebd8f7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"5d41eb3e-0862-439f-9c73-ed1a15b93fdd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div>","ID":"357ad4bb-5595-4423-84d6-818a551e7a77","Styles":"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":true,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"  ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p>","ID":"2cd9244b-6d08-4bc3-b9d8-13db677cc15a","Styles":"border:none;padding:0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).","ParentId":"357ad4bb-5595-4423-84d6-818a551e7a77"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8e6cb473-967b-4c3f-9a10-2d7dfb2266bc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p>","ID":"c505f32f-8ea3-4509-95c8-dd34c97fd7aa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9abcc83a-793e-446a-8573-5999f3c58046","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p>","ID":"9dd7efe6-3bd7-4da6-a271-327faa75d41b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p>","ID":"665324b5-461f-4752-98d1-9a657a889be0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"74b0d878-310e-4801-b458-b3fc3b9f51bf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p>","ID":"9a67dcca-f6e5-4551-a0e3-b86d90b75e03","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0fe6e882-9e7a-4bd9-8365-4b52d3bc4156","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"e1fb6158-2d82-40f9-90da-4c52ae2c2bae","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"2db364ec-b12a-455d-8b03-44dbf4fd7e4a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p>","ID":"a9111347-5696-4c91-8989-9d38c57d60ed","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm infant.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"97f7d827-1fc5-471d-8987-f29253296f77","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">It is unknown whether irbesartan or its metabolites are\r excreted in human milk. <\/p>","ID":"33383bb4-a9ff-476a-a140-3ab04d8c0795","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether irbesartan or its metabolites are\r excreted in human milk. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"520ac4cb-0702-4e95-a5fc-b0a771b81725","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).<\/p>","ID":"87c99a02-ac73-4057-8b4b-d9516bf3d131","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7d5f2901-e577-451d-9972-13572ab5bea5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"a4cd5b2e-6c2e-4671-98e1-9f6f72be455e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cc202f92-11fe-4a58-8b89-5eb40f1df691","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3).<\/span> <\/p>","ID":"9d1a8db6-afcd-462c-ab1c-b3369c26b3c2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3). ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"39227cb0-eebf-4a58-93b2-ff44ab15f1b7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p>","ID":"1d65ca98-435b-4368-81b2-6f8293de9e67","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and\r use machines","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"9ca204b0-0dca-42cf-83e8-c861da8f94bc","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the ability to drive and use machine. When\r driving vehicles or operating machines, it should be taken into account that\r dizziness or weariness may occur during treatment.<\/span><\/p>","ID":"caf2b1ce-9469-4f6c-a309-a43bf1e22b39","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the ability to drive and use machine. When\r driving vehicles or operating machines, it should be taken into account that\r dizziness or weariness may occur during treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e43acaa5-aec7-49b2-9afa-58171a7a8e62","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p>","ID":"bc0c79f0-a4ba-45cf-90f1-bb3f66abeae9","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"cf269e3d-8fbb-4881-9e8f-0ad553772f8c","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.<\/span><\/p>","ID":"1a5d09ec-df53-476a-a31d-6bae7969078d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"01ea0faa-dc92-4c38-a308-1a57fb45375c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients\r (i.e., uncommon) but in excess of placebo.<\/span><\/p>","ID":"638e8901-a2d3-478c-8042-486cbbb6f3e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients\r (i.e., uncommon) but in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9e25d442-cd2b-4d80-a2a0-6a98c553008d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p>","ID":"14d02ad5-8732-48da-9fd5-fc87c48cdffc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in > 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3b25a146-31bf-4e0d-a543-143ff48cdd09","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p>","ID":"c34910b7-6e94-473c-bf9a-80c2252169ee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The frequency of adverse reactions\r listed below is defined using the following convention:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p>","ID":"f053e7eb-ad84-46c9-9d95-a2cbb0bde506","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"very common (\u2265 1\/10); common\r (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to\r < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare\r (< 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"66d3bd1a-ebe6-4fcf-b67b-8be0d46c164a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p>","ID":"c31c6224-5aa4-4a9e-a34c-9208ad430e3d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"8cdd3ac2-17ff-48a5-92b4-ed5ae13da649","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p>","ID":"a6eac8b6-aa7a-410f-8dc4-97778927525f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Blood\r and lymphatic system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p>","ID":"0f86adc3-f9e6-477f-8691-1decb5165fd2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       anaemia, thrombocytopenia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"681f876b-d6c4-4be5-9eb3-df9dafefc459","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p>","ID":"29a9cc37-4b76-4235-a6e3-3edc421e2569","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Immune\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p>","ID":"74cf21a3-5497-44e1-bff1-3a1404093058","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"6fa0be50-07bd-4a40-80e2-388818b532bd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p>","ID":"44f06da5-e738-4dd5-a948-5657a7f56246","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Metabolism\r and nutrition disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p>","ID":"1d242c25-6d23-4a0a-8adb-d929a20b65bf","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hyperkalaemia, hypoglycaemia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"3294d3e2-7172-4d59-8365-122b9324248a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p>","ID":"cde48de3-140d-4fb6-a24c-e1956408a523","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Nervous\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p>","ID":"9a9b05cc-f290-4c91-a0fd-1f945ca44266","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         dizziness, orthostatic\r dizziness*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p>","ID":"130ed777-28b3-40da-8b82-1bd77501a919","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       vertigo, headache","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5aecd0da-7b68-4f98-9a06-62e5d1a571eb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p>","ID":"0891fa4a-bb5e-4bbc-89e9-9dc1d30f1f43","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ear and\r labyrinth disorder","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p>","ID":"edce235b-7f69-4f0d-b2d1-a367bc01b347","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       tinnitus","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"8bf8ca2d-5c8b-4bb4-8dd1-143d02914471","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p>","ID":"41787223-38c5-47c0-a4fd-52128f6c3833","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Cardiac\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p>","ID":"a6f192a5-49e8-4358-a61a-5bbef4779e18","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      tachycardia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"9be53f65-1c85-444c-9d46-1a6a687e63f7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p>","ID":"242de99f-ef8f-4fee-a85d-4431b4a4cf3d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Vascular\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p>","ID":"7b661138-5fe1-4b7a-9283-001e1688ab4c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         orthostatic\r hypotension*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p>","ID":"3acceb82-4ec7-4d51-a12a-eb5fb10ce72e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      flushing","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"8f5c50bd-ebe0-48c7-bcb4-bc2bb823a165","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p>","ID":"f2b5ce5b-66ce-41b9-adcd-3b3b805d886f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Respiratory,\r thoracic and mediastinal disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p>","ID":"58b52a67-c68a-4794-9f17-ab1154758e1d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      cough","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cff49cb7-43e2-45c4-9bfb-67dabdd0a270","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p>","ID":"fa08fb60-e49f-4b51-926d-ad5f18ccb73d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Gastrointestinal\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p>","ID":"e5f881d8-f831-4d19-b20d-6ce73e19fc05","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         nausea\/vomiting","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p>","ID":"4413194c-2536-4620-b943-f8222785cf53","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      diarrhoea,\r dyspepsia\/heartburn","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p>","ID":"b5f23bec-611a-4dc6-92cf-545d3c5692ec","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       dysgeusia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"54a68d1f-f47d-41e2-a0bc-ccd4c59d1b7c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p>","ID":"f8d6cb77-41a1-499f-a367-446cdcdbda51","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatobiliary\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p>","ID":"c0e3cd18-1171-4b9b-b0b7-f6fdfaa43898","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      jaundice","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p>","ID":"f731240c-cf8e-4dbf-92c1-0be6a7c3c14d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hepatitis, abnormal liver function","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"77019060-7fb4-4a8c-82d7-1cc3104eeefd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p>","ID":"a54f55ea-7425-4ca2-bd54-808d62553495","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Skin\r and subcutaneous tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p>","ID":"0cc49851-332a-41a3-802f-60184a742e1b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       leukocytoclastic vasculitis","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"bd2b76d2-dbc9-4f84-ae7e-93ffe911b972","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders<\/span><\/u><\/p>","ID":"2f63b232-fe77-46c6-a6ab-6f58b6d62965","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Musculoskeletal\r and connective tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p>","ID":"eac2fda6-9584-4ebe-b6ad-ba28b1542277","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         musculoskeletal pain*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in\r some cases associated with increased plasma creatine kinase              levels),\r muscle cramps<\/span><\/p>","ID":"8b731c9f-1de2-4649-909b-0ba8cd34b7c0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       arthralgia, myalgia (in\r some cases associated with increased plasma creatine kinase              levels),\r muscle cramps","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"25d68f64-d4ea-4199-a4cc-e2cea67e8b8f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p>","ID":"a063ce12-d182-4275-ab49-acde0bcfba5b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal\r and urinary disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p>","ID":"af4a2362-b1dc-48c5-a69f-b8ae62f3c25e","Styles":"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r\navoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"139c1eb0-1831-406c-9d9b-fadb7b436c63","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive\r system and breast disorders<\/span><\/u><\/p>","ID":"ba302e68-5164-4870-9917-a6b6eb88c083","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reproductive\r system and breast disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"EN-GB\">Uncommon:      sexual\r dysfunction<\/span><\/p>","ID":"531fbecd-cdac-42d8-b292-db350af2f53d","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      sexual\r dysfunction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7a4deada-1c4d-4a24-88d5-de358d3df888","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p>","ID":"dad2e267-1a62-4bb0-9b5a-65b7ae3f6caa","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General\r disorders and administration site conditions","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p>","ID":"9c0bdc0a-d521-488d-848a-baf40f8def08","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         fatigue","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p>","ID":"41d0c803-595a-4905-b1da-5cdb2fec6de8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      chest\r pain","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"36f06487-ad70-4e5f-ae3d-6908136fa1ed","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p>","ID":"d45206b8-86d4-4dd7-aff4-9bb1d38d989d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Investigations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p>","ID":"29ceef2c-7136-43d3-8edd-9e969870286b","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p>","ID":"0af3009a-8ef2-46bd-bf2f-ef132acb5107","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a4d42cfe-cdad-4827-a542-0ddf521c3022","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"73ca0e1d-e1f7-4836-803e-1df6973ca346","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p>","ID":"0b718c03-ad28-449d-b117-30dc2f0912c7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"afb0e897-475f-479c-96ad-39410ff87265","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p>","ID":"02725929-8738-45f4-9a3e-0ba565cc92ea","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse\r reactions ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p>","ID":"e3251833-cefb-4840-9052-9befc88ecf6e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"84a9c0e3-fb62-4fae-baea-719b8763df91","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p>","ID":"47f631ea-8465-4ce6-84b2-21cc7341115b","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"111a9bcf-5258-4699-a73c-4c602ac4a5c6","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.<\/span><\/p>","ID":"8d123166-474b-445d-8fd3-4a26b40e38c9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ab55e7b-b185-401d-b979-2a6a26638bd2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"405dcff0-5069-4212-a943-627dbb416392","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p>","ID":"a4af38b3-6982-452b-89f7-36dc1c791151","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"6861040e-2566-44d9-9baf-c42d4e98d427","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p>","ID":"e16e60e8-5e47-4f86-bac0-89cd28a97bbb","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"05f7c230-60bd-42c6-9b56-b589101e1437","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.<\/span><\/p>","ID":"6ea53673-1466-44a0-b21b-4f064b5574a3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ATC code:\r C09C A04.<\/span><\/p>","ID":"8087e992-ebcd-4245-b081-1053d48fff35","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ATC code:\r C09C A04.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3d0744db-0e8e-458e-acad-3ed990e82e24","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"35e21022-333a-4a0e-86a5-db2bb3b0d02b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9eb28710-faa1-486c-b41b-6aeed9319d9a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.<\/span><\/p>","ID":"b008fc0f-f0f3-42ee-8c36-92bc5e216f6b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT1) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT1\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT1) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fb840253-63bb-4488-97fe-b9682b5ddf8d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p>","ID":"b8745f79-387b-4b2f-bb23-fe75b3e08572","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clinical\r efficacy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"05ab5621-1cac-4a3b-a387-2c1a556f2d99","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p>","ID":"c8c9cc64-5a0a-49c6-80dd-33db71650780","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p>","ID":"37083c2e-873c-46a1-ae17-f3a2b27521c5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"69b6b82f-11ec-4188-b9e6-4cb060e19489","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p>","ID":"e505d996-e333-4591-bccd-b17a6c512ac8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"319f37ca-7a90-4469-9151-fa0729b7baac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p>","ID":"183b4ce8-7232-4639-a06a-229aaf684f26","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"af7183d5-82b7-450e-bec5-0d559ad7c6be","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p>","ID":"c75e04f5-6564-4958-827f-4fb8e0b18e59","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3a8405ab-f1dd-4f2d-a2bb-af1f09588191","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p>","ID":"5f5f9f5d-79b8-4090-86be-0c83cbf1712c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4083c422-c7b4-4350-801c-21fd5c14324f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p>","ID":"1e31046b-e965-43c9-bcbf-5656e7f53b38","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e7050747-b5e8-4cb4-b0b5-9bfb73c2b20a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"e53e8f99-3ff1-41fe-a883-56fb53dcaa57","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).<\/span><\/p>","ID":"107824c0-7434-4fc8-a05e-6c237de357bc","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2c004c71-3270-4418-9a4f-45346118e075","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p>","ID":"130215f0-be3b-408a-b168-f486b88c016f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension\r and type 2 diabetes with renal disease","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"b46d7080-6be5-4a49-bea6-021bb8d0935f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine\r and placebo. In 1,715 hypertensive patients with type 2 diabetes,\r proteinuria \u2265 900 mg\/day and serum creatinine ranging from\r 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p>","ID":"6d3d0370-886f-4470-9ddf-db263ee429c1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea, amlodipine\r and placebo. In 1,715 hypertensive patients with type 2 diabetes,\r proteinuria \u2265 900 mg\/day and serum creatinine ranging from\r 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg\r amlodipine, or placebo as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r > 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3aed51aa-8f7d-4192-908c-53a6b530d3f5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p>","ID":"1ad91444-99a8-46bb-8452-c87261f73c4a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6807cdae-94b5-4191-a863-e14a3f5a59dc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the placebo\r group (21%).<\/span><\/p>","ID":"5dbb1715-619e-45e9-93db-64182292870a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r < 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) > 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (< 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the placebo\r group (21%).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f51c655f-a2d2-4098-b6b7-3d693c274c24","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p>","ID":"d4886c6a-f145-412e-a904-8f74a509f1da","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ed86cf1a-d1db-4f6f-aa89-07f3ce0e7e71","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials (ONTARGET\r (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint\r Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have\r examined the use of the combination of an ACE-inhibitor with an angiotensin II\r receptor blocker. ONTARGET was a study conducted in patients with a history of\r cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus\r accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in\r patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p>","ID":"608d0532-ed6f-4500-aafd-4c8a54daf009","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Two large randomised, controlled trials (ONTARGET\r (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint\r Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have\r examined the use of the combination of an ACE-inhibitor with an angiotensin II\r receptor blocker. ONTARGET was a study conducted in patients with a history of\r cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus\r accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in\r patients with type 2 diabetes mellitus and diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p>","ID":"60d6f6e7-c70d-4d8a-8e1b-5f42ccb9e880","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p>","ID":"88b50955-60a5-4de5-9614-51282c232386","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p>","ID":"eface2fc-83e1-4de0-8e90-7f56dedf7d3e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ab09afe1-a20c-461c-b89c-a902edc1bc8a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p>","ID":"4e21719b-c328-4ffb-ab6f-c7e59e127a8e","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"4de74a4b-7242-4435-be00-956c34f4ed4b","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"dac46c73-c738-436b-a3fc-a452c6dcd371","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Absorption","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"e4d6d5ef-442a-48c5-aad5-959b515a4d43","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p>","ID":"23dd99c5-c739-46b2-8206-9ffa113875ea","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"41e83552-d2c8-4059-86bd-6839f1ccf918","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"bc1fc8b2-e4fe-47f1-97c4-0c0eeb61a151","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Distribution","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"6637e852-9fcd-4f39-8385-51e52025d7aa","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. <\/span><\/p>","ID":"76ac0495-ddda-4d6e-acb8-68a0c277a3b8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"155585f2-1664-4808-9d86-bf1983950623","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"c41a4eed-86b5-408a-9fb2-04036ae30743","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Biotransformation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"20cbf4c7-848c-4895-82ab-cb63f56bf30b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p>","ID":"c7c50df2-ddc7-4b98-890e-ee6f6d36ee82","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following\r oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ef805c72-1e15-443b-9a9c-525774037692","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity \/ non-linearity<\/span><\/u><\/p>","ID":"1035867b-36f1-41fb-bd04-bf3a53c7f9e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Linearity \/ non-linearity","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8cdc39f3-ad36-48dc-8da0-385041a23226","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157\u2011176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of\r irbesartan is 11-15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan\r were observed in female hypertensive patients. However, there was no difference\r in the half-life and accumulation of irbesartan. No dosage adjustment is\r necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span>\r values were also somewhat greater in oldersubjects (\u2265 65 years)\r than those of young subjects (18-40 years). However the terminal half-life\r was not significantly altered. No dosage adjustment is necessary in older\r people.<\/span><\/p>","ID":"3eab6edf-c198-4add-894f-1aa9b508cd5d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157\u2011176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of\r irbesartan is 11-15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (< 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan\r were observed in female hypertensive patients. However, there was no difference\r in the half-life and accumulation of irbesartan. No dosage adjustment is\r necessary in female patients. Irbesartan AUC and Cmax\r values were also somewhat greater in oldersubjects (\u2265 65 years)\r than those of young subjects (18-40 years). However the terminal half-life\r was not significantly altered. No dosage adjustment is necessary in older\r people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"252aece6-f5d0-4b1f-ae71-37c842f8767a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"223be2dc-b7f5-49b4-92a4-d099cbe647fd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elimination","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f91c05a2-00c5-4554-b0a2-b15b1de2f8e4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p>","ID":"e486d806-28fa-4a07-8bf1-6ef7556dc8f1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of 14C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ee499061-e286-4e9f-9c64-701626ed6625","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"98dd1c68-086d-462f-9cc7-a3a1fa5a385e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"59e4b0aa-2ee7-4040-9b41-b50045092dab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p>","ID":"31a233ef-c64d-439f-844d-f1ad6d9a1267","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5d070f3e-b36b-4be4-8367-dd9af431d039","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"12313aed-c0da-44b8-ac59-9e182a3ca663","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2959baa3-5b7f-4b8b-bf1f-1b6194a0ec08","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"731d54a0-edcb-459f-879b-2f3337c81a9c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"09a9a7a3-c272-40aa-9f3e-c91a39f1ecd0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p>","ID":"87021001-9dd0-4882-8939-d728db615dd5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"30095714-0699-4e69-b375-c807716c6f45","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.<\/span><\/p>","ID":"65bc802b-0809-41ae-8d6e-b04afb14e2d2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"59e986ff-d793-4d87-a3d0-85e5a1eee3c9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p>","ID":"4f50b67a-0c6c-4679-8795-a1c189b8f198","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Studies have not been performed in\r patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9473af9c-3dde-41b7-bf71-3423be0821ec","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p>","ID":"0bbd02a1-b7d8-4ed7-8805-ec74c941cf7d","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3Preclinical safety data","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"eff262ab-0fe0-4ddc-b2bb-0b52bc9d89d5","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically relevant\r doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p>","ID":"f4e03f08-d6f8-4c27-8aa7-96ca6fdc054e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was\r no evidence of abnormal systemic or target organ toxicity at clinically relevant\r doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"636bd61a-1f6d-4f15-bb58-c742992fb1d3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p>","ID":"a8eab130-17d1-4736-9d86-73d9555a3e0e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1572f8d6-4f6f-421e-a676-a5a15d174ad3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p>","ID":"4df3bddb-a5e6-4916-8fea-d4707c192f84","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ebdae8e2-7cd8-4e36-9b51-7d842d28d81a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p>","ID":"fa30c797-4fde-4ad0-a472-411c00e9da62","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5c8ef46c-fa49-4cef-a6a9-e6241f96b912","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"56e7a943-53f5-439f-ad6c-17ce8472c4ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p>","ID":"e0e9b4fb-cf58-4ef1-be5a-137b77473d8d","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"b620ccc2-dc97-4882-afb7-55afa4430213","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p>","ID":"15d7f237-9ab8-4861-9782-1a1c93817ef0","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"881fefbb-df16-4267-93df-e2d05cf0738c","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Microcrystalline\r cellulose<\/span><\/p>","ID":"c406362c-4dd4-4c11-8172-1401a8efaa09","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Microcrystalline\r cellulose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p>","ID":"0f9e2cfa-b8de-46a2-94a6-a1256068f3fe","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p>","ID":"5b9ac66a-b493-4b58-965c-004974b6159e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Magnesium stearate<\/span><\/p>","ID":"74c8246b-d70f-4b38-bf13-798873c6eae2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Colloidal hydrated silica<\/span><\/p>","ID":"b61f1ef7-819a-42c5-915c-856b97da903d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Colloidal hydrated silica","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pregelatinised maize starch<\/span><\/p>","ID":"3797c8ff-247c-4f49-9e6d-dcacd156e7c6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregelatinised maize starch","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Poloxamer 188<\/span><\/p>","ID":"563c4743-2a88-4e40-957c-16da096fd729","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Poloxamer 188","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"06e79097-e8d5-4f14-881e-f76117e1b5c8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p>","ID":"a3e47ac8-3957-4ef3-8032-40be7fb66dbe","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"298c8d35-b568-4c23-879b-2b82b09b92b8","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r applicable.<\/span><\/p>","ID":"034d739d-9b0f-4ca0-b876-40afdd9ea449","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r applicable.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2b0f8cfe-6daa-4d7a-988b-8e55f148fa64","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p>","ID":"28dd0d22-592c-4abc-ac72-9206f58a478a","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"f2e3d1ec-847a-4e17-87ed-460d7e7782cc","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"47bc3e84-d6ad-478e-bd9c-1335dfbc42c7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a0da8d8a-5966-4150-a20b-45d6b9f6a399","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p>","ID":"2cb2a096-762f-4d23-9bbc-d4d883dbd639","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"557dc5f2-8fde-458b-a6e3-203ea4c578a1","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not store\r above 30\u00b0C.<\/span><\/p>","ID":"abeb921b-cb20-49f4-ac69-397552470c25","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not store\r above 30\u00b0C.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e7c2269a-9a70-4975-b9d3-71d148a0d17f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p>","ID":"fd3faf31-868d-4156-9389-368b10280617","Styles":"margin-left:0in;text-indent:0in","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature\r and contents of container","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"cf66436d-15c5-4ffc-b900-82e407b87424","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"2fcc4859-af80-409c-ab83-7b1554f4f04b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"178e25dc-2a27-423b-8da5-eaf3bf1ee76f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"0a56ce6c-93ec-439d-8408-452163778b56","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"d6fd6863-fade-48a7-966d-6bf416c62d3e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.<\/span><\/p>","ID":"7ff6e447-c080-4a76-a6ba-1226f40ac4f3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"00436099-807a-40cf-a0b5-61b62820c756","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"365f7cd7-5be8-43a6-8ea3-a4250c7593df","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"35563293-e12b-4917-a523-57baabaf8128","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p>","ID":"e458bcc5-392d-4004-bbb7-7aaae4fd2f7a","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"0c6f6b1c-1fa2-40e6-abb2-d6abc1681b1d","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/p>","ID":"acdbc21e-9a33-4573-ba2b-4e03be03db0a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ef191ed5-b056-4f01-9178-9a70d49463fc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c1c4dc07-6a33-43e2-85b4-4b5344739c21","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p>","ID":"4bb43905-2f1a-4a36-b12e-293468c66848","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"adf37bf4-ce8f-4853-aa00-5f205166e97c","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p>","ID":"1bb36aad-1ccb-479c-9a6a-c78f6a4c3b4f","Styles":"None","Classes":"['EMEAAddress']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"sanofi-aventis groupe\r 54, rue La Bo\u00e9tie\r F-75008 Paris - France","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b0452fa9-fc11-422a-a696-9ec6a950ed32","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"81ec9884-ade8-42f3-8398-d6f31ae3b3ae","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p>","ID":"7b0529a2-744e-4891-a25c-d65eddd0dd74","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBERS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"78ee58e5-f9c0-4e57-a056-c7f86ca45ad3","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"NO-BOK\">EU\/1\/97\/049\/001-003<br\/>\r EU\/1\/97\/049\/010<br\/>\r EU\/1\/97\/049\/013<\/span><\/p>","ID":"1d34c932-d649-4597-b1ab-0550bc76baf9","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/97\/049\/001-003\r EU\/1\/97\/049\/010\r EU\/1\/97\/049\/013","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e27ccc7c-5421-4c55-940f-96e99a99871f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f507dab1-3bf3-4691-874b-c4933ab053d3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p>","ID":"0caeec98-6bd2-4ec3-8e07-35e0e5b5787b","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"49235aef-1d5e-48fd-9dcf-11971080b2cf","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p>","ID":"b163a620-8f4e-4742-b490-8e04103dbe6e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 27 August\r 1997\r Date of latest renewal: 27 August 2007","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c43536b0-ef16-4c4f-89c0-2ffdce32f138","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b54945ff-4cf9-4c58-9fd5-3a0afb4ab193","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p>","ID":"2202f407-4d37-456f-829c-8c9addccd278","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"23bee775-d2f7-42a3-84d8-1b503c9847c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu<\/span><\/p>","ID":"e2a55ad7-5e88-4184-bd97-a586c7f2fa75","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency http:\/\/www.ema.europa.eu","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"1bd06af4-520e-442b-9916-8724892fcfcd","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"99d09e53-43f8-461b-bb02-36dac1c0cb54","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"d90c560d-bf11-4190-8974-e9076b1423aa","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ntext-transform:uppercase","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"99d09e53-43f8-461b-bb02-36dac1c0cb54"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"6ac37b34-beb9-4b77-ae33-243bf90b8658","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"d90c560d-bf11-4190-8974-e9076b1423aa"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p>","ID":"3e4caf23-e2ab-49cd-8449-d6afa51eb77c","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"701c65bf-1d10-499d-9eda-03a27ac17b3b","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg tablets.<\/span><\/p>","ID":"0a7517a6-1daa-48b8-85f0-504a7567f0bf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 150 mg tablets.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ffca3d7c-93b1-4b93-9998-c12a3c9089cb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d16479ba-8448-413c-b66b-9d66373a1212","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p>","ID":"dfff920e-5a8d-4ea6-a44d-66ccc266aba5","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"14cd8e69-0aa9-4ee1-8c20-b88301c1d551","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each tablet contains 150 mg of\r irbesartan.<\/span><\/p>","ID":"28f80795-fc02-420f-84ce-cf52932b9cf9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 150 mg of\r irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cc797bfc-caef-4a78-ba2d-df39939a9992","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 30.75 mg of lactose monohydrate per tablet.<\/span><\/p>","ID":"f6992770-5351-4196-905e-4fed3a691977","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: 30.75 mg of lactose monohydrate per tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5b37d9c2-1907-47f8-88c1-7fa0255c87b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p>","ID":"e07406d0-de34-49d2-bfd5-deac1134e7fa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see\r section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9987448a-54b8-4ec2-ac3c-9a3d4c41d42e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2be00fed-64c4-40de-b935-9d1ed89fa157","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p>","ID":"d9c41eea-98fd-450e-8c33-a53af42b9b63","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"f0d5a8aa-0e89-4c21-8321-324ed4531531","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet.<\/span><\/p>","ID":"6e71a515-728b-4300-bc74-599f60ee64d6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2772 engraved\r on the other side.<\/span><\/p>","ID":"4110f08e-aed1-4106-b5cb-c929c658d85c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2772 engraved\r on the other side.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ac2170ca-1b19-4148-a1f8-196f79e86fee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1c955444-b027-4f3d-b3f0-481a64954567","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p>","ID":"65c42a31-8ab5-4816-b6c5-5a70a12096bb","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"2fe8cd95-2138-4e76-a311-1c5f06c5716e","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p>","ID":"0dcb8fc6-9a22-4970-a28a-7fb7be06c19b","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8beb6158-c49f-4ef2-a47c-b11c8f425f6a","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p>","ID":"3ac494ac-8b52-42a1-81e0-8f5dee0776e8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea is\r indicated in adults for the treatment of essential hypertension.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"e7fbdf39-309b-4aa1-b03a-a36ce0ded681","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"bc56c453-27ab-44d1-90d6-a49e3d4372f8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5752d200-3701-4f04-88da-4a953bceebbd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p>","ID":"ab53f111-2f22-4962-b447-b98b2ae4a904","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and method of\r administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"3fb21b66-a628-4ba4-a566-8b73f1307870","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"76cff365-e05f-4419-8a54-293f3fb9e16c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"acbc2275-973c-4ad9-b895-5d75bb19a0d2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p>","ID":"67880011-c03a-413f-9906-cf93a3fee399","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"02765f09-7703-465b-85fa-1aa739fd7875","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p>","ID":"ea8fd069-8b82-494a-8e9c-fe06e795af5a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"92d150e5-4fab-49e3-b11d-d991477fc363","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p>","ID":"715719c0-9932-4251-ab0c-2782bb862dd2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"5d1fe038-e8a9-419f-825d-fc658a440820","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5e873deb-adda-47ae-b34c-dfc004773471","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p>","ID":"d59b65a7-19b9-4d09-bfa8-28bd5cc918b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special Populations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"24a32812-9586-4e3e-b0de-8f55a2192e2e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"715fded9-b6cb-4016-80a9-5b93a33dedf2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fe4ea12e-874f-47ba-8d82-41ca46857dcf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p>","ID":"e9603655-63cb-4459-b851-cec67a42f2e8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3bc76179-e33a-48c5-ae2f-28bb7b97198b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"46ae45f8-ff37-4f82-bfb3-383d0751fa7c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ca639d0f-aeb1-4dd9-970e-ce9e2de31af7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p>","ID":"1b0aafce-de23-4216-8118-00974c5e096b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"71d0d7a2-593b-4ed0-a943-c0683ed66158","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p>","ID":"5ff95f8d-50f1-4854-95f4-e9ad0eb0821a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Older people","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"66007842-a7a0-47b5-a8d5-b7c9b8286084","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.<\/span><\/p>","ID":"e6e349ef-3e0d-4710-8f52-c19d59ba8d49","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1c2d0454-9184-4652-b32a-c8c3c7bc95ba","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"c7f7371f-ec90-4bde-9643-99aa1051ce5a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4344eb2e-088c-468b-9e48-79fcdd17e47c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p>","ID":"601f8997-e8b8-4c09-ac9e-c79f95742c50","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c82dec67-aa23-4e18-86d0-3b97c33068e9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p>","ID":"3093c5b0-d3d5-4385-bbb8-59d92e1146d9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of Administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9f8de5ca-e558-4b8c-ba45-e3899eacf1e8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"4ba348db-d568-402b-85f8-6884e6eb5526","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For oral use.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"35ff5c6e-78db-40de-8921-6acbc209957a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p>","ID":"45b40731-3de5-4f3a-91e2-e93743ff3eec","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"52bab933-8925-477e-a410-c1b942092400","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"ff432c58-366f-455b-912a-4ab79205221a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p>","ID":"bb3c3b4c-4997-44f0-bd4d-3c8cf0333859","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"faea2125-bf66-461a-801c-69f2c600c1e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\"> The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p>","ID":"f37f9416-1631-47ce-ab0e-e4a9093c3cb9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) <60\r ml\/min\/1.73m2) (see sections 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fa1ede63-614e-46ed-b24f-0c05cf5f9406","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p>","ID":"1103e2c3-9781-439e-b83e-ae5d79a26854","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions\r for use","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"ab0fde35-8a55-41f5-baae-2c263e0c7922","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p>","ID":"1d1bb3ad-1e5d-4244-9c1b-b29a30ed9cfd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Intravascular\r volume depletion: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"f06ffc51-a4c4-4294-a4d4-d70269c3076b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p>","ID":"861fedaa-c38b-4de3-b6d0-7b67f4ea41b2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renovascular hypertension: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"55e2ce69-0cd6-4a8a-a70a-ef91dc6b0db4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p>","ID":"c239a3a7-bc14-4345-ac3e-2e6a1be2e48f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment and kidney\r transplantation: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"3a0e1389-20bc-45a2-b3ce-14c18b179138","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p>","ID":"1fb393f6-b7bb-4ab1-a048-6b08368c83a3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypertensive patients with\r type 2 diabetes and renal disease: the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"736ba847-b19e-423d-bb0e-45a6bca92b50","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS<\/span><\/u><span lang=\"EN-GB\">): <u>t<\/u>here\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p>","ID":"18309e3d-8764-4f06-b3e2-7f1a74d6813c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2c108522-4402-47be-8af7-5ed24fc1b61e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p>","ID":"1e764533-b09a-4307-9c43-ddb87b5f02e0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hyperkalaemia: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"17252df5-cef5-408e-aefb-141142e0f994","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia: <\/span><\/u><span lang=\"EN-GB\">Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p>","ID":"995a068d-bdb3-45ce-8705-d2519ad94069","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"2e28eaa4-a019-45de-9bd8-da756e3537b2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see section 4.5).<\/span><\/p>","ID":"948cce7c-9408-47d5-acc7-e5372305e3fa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:\r the combination of lithium and Karvea is not recommended (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cc8ac5de-e8e1-4fce-b7bb-65b9506e70fd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p>","ID":"80830acb-c6ce-420a-a662-613e623fd201","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"db5262e6-deb0-40a0-bd30-8c34f491b054","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p>","ID":"df23fdab-f530-40ce-9fc6-16641e274d5c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Primary aldosteronism: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"c0d72ee5-1a68-4a03-8772-ca6fe7993d55","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme inhibitors\r or angiotensin-II receptor antagonists that affect this system has been\r associated with acute hypotension, azotaemia, oliguria, or rarely acute renal\r failure (see section 4.5). As with any antihypertensive agent, excessive blood\r pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p>","ID":"8d657aa7-f897-4347-9860-e6420f3e66f9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme inhibitors\r or angiotensin-II receptor antagonists that affect this system has been\r associated with acute hypotension, azotaemia, oliguria, or rarely acute renal\r failure (see section 4.5). As with any antihypertensive agent, excessive blood\r pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p>","ID":"12f737de-d65f-4cd4-97a2-abb864c05d9a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dfc24efe-5040-4220-b9ac-c710dbde5f95","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p>","ID":"0b30af72-2a64-4186-ba61-9cdc6ca60b0a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"e6b008fd-4701-431f-8b80-d86ddbfe531f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"63b3b770-9bf4-4064-858a-aff59a469ddd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p>","ID":"06996435-e248-48d7-adfe-032364a12c2c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"98dd501e-fab1-4cfe-98a5-4ef0ef3ff31c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p>","ID":"c7bdde97-4679-4a6a-9b03-894e724d7104","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipients:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 150 mg tablet contains lactose.\r <\/span><span lang=\"EN-GB\">Patients with rare hereditary problems of galactose\r intolerance, total lactase deficiency or glucose-galactose malabsorption should\r not take this medicine.<\/span><\/p>","ID":"f95d9299-85ce-46e0-953d-e9497935065a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 150 mg tablet contains lactose.\r Patients with rare hereditary problems of galactose\r intolerance, total lactase deficiency or glucose-galactose malabsorption should\r not take this medicine.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a2b90e91-4c99-4419-8150-208862026cd4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 150 mg tablet contains sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p>","ID":"f5e445e4-311a-4764-8ff4-a6684bfc9812","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 150 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"18dc2ec3-225e-4606-b503-2423fcf71a08","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p>","ID":"915a19f3-7c29-43c5-a8fc-3055b2e8c737","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal\r products and other forms of interaction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"b32b9478-712e-4194-abd6-a2fa06597c44","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely administered\r with other antihypertensive agents, such as beta-blockers, long-acting calcium\r channel blockers, and thiazide diuretics. Prior treatment with high dose\r diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).<\/span><\/p>","ID":"a25fd289-4a16-4f48-b55c-ddac7c0bc233","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Diuretics and other antihypertensive\r agents: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely administered\r with other antihypertensive agents, such as beta-blockers, long-acting calcium\r channel blockers, and thiazide diuretics. Prior treatment with high dose\r diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"531b9ebe-ee31-4f5d-b021-1d87da278d11","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing productsand\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">:.clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).<\/span><\/p>","ID":"4f0930f2-3245-4b06-b502-f46fabdfe586","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aliskiren-containing productsand\r ACE-inhibitors:.clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"677ba9ad-37bd-42e2-9352-06f7e22457ae","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and potassium-sparing\r diuretics<\/span><\/u><span lang=\"EN-GB\">:based on experience with the use\r of other medicinal products that affect the renin-angiotensin system,\r concomitant use of potassium-sparing diuretics, potassium supplements, salt\r substitutes containing potassium or other medicinal products that may increase\r serum potassium levels (e.g. heparin) may lead to increases in serum\r potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p>","ID":"cf818c73-7de1-47fc-95b5-4511d49df466","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Potassium supplements and potassium-sparing\r diuretics:based on experience with the use\r of other medicinal products that affect the renin-angiotensin system,\r concomitant use of potassium-sparing diuretics, potassium supplements, salt\r substitutes containing potassium or other medicinal products that may increase\r serum potassium levels (e.g. heparin) may lead to increases in serum\r potassium and is, therefore, not recommended (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"ea67f079-4a57-4ce8-8c1c-8da3ba550204","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p>","ID":"c60254a8-2f7f-45f2-ba0b-e72f153682b5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"b3e389a3-f53b-441c-b2d4-2b00a1a90e59","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: w<span style=\"color:black\">hen angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p>","ID":"f1250e38-ede2-4b6d-92d0-054ac3460f7b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (> 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p>","ID":"9945e7e8-4545-4328-a31b-2898ba2b26c5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"0f716ce4-67d9-4311-8047-52ad3f3ce60d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p>","ID":"1e48d0b0-f731-4f3d-ad43-c0893ac88c65","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Repaglinide: irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the Cmax\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"9e6402cd-5996-471b-a597-dd3f940269f7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by\r glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions\r were observed when irbesartan was coadministered with warfarin, a medicinal\r product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p>","ID":"58ef8899-1d62-4dfb-bfac-e40d67033b1b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Additional information on irbesartan\r interactions: in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by\r glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions\r were observed when irbesartan was coadministered with warfarin, a medicinal\r product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c4838569-95b1-4f50-a4f5-09f4b1174b73","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and\r lactation<\/span><\/p>","ID":"32ec0408-73c2-4da9-866f-157e007f7c98","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and\r lactation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"54375435-3b6d-4fcd-afec-fad613490025","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"8dbdd421-b016-4137-a5e0-0c25a136313f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"7e70a341-95c0-4162-8857-0d640e581149","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div>","ID":"b7ec5417-455b-473c-b543-f9f99a768061","Styles":"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":true,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"  ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p>","ID":"ad6eba3c-5788-4932-8d26-f162f0f307d7","Styles":"border:none;padding:0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).","ParentId":"b7ec5417-455b-473c-b543-f9f99a768061"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bef0131b-303d-46a2-873b-727129b6f7d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative antihypertensive\r treatments which have an established safety profile for use in pregnancy. When\r pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started.<\/span><\/p>","ID":"3b1f5623-cea5-401c-8bbe-fa545f12e3ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative antihypertensive\r treatments which have an established safety profile for use in pregnancy. When\r pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"558b1f0f-6d3b-4ff1-9fcc-7b39d35dc886","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p>","ID":"bf568ded-e8d7-41e3-9dbd-db4bbeb479ae","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d646eae0-c78f-47d2-961c-865149808395","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p>","ID":"83429e4e-3295-46ad-b65e-40461b8e3fac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p>","ID":"c77e2076-661e-4ca8-86ed-16e4bf8047c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4dfd6598-9b38-4f66-92b4-63af18d5bcf5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"c0a954a6-1c2c-41e4-befe-6d71bcc5cd35","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"285ddb52-2dc8-4ad4-a6fc-ed6c05a2afa2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm\r infant.<\/span><\/p>","ID":"dea63451-ebc0-4255-8410-b095cc116ede","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm\r infant.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"6721dd81-523b-4354-9959-e851d2728b07","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">It is unknown whether irbesartan or its metabolites are\r excreted in human milk. <\/p>","ID":"24cbc6c3-b861-4f7d-b8b8-20c3006894ab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether irbesartan or its metabolites are\r excreted in human milk. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).<\/p>","ID":"4e060f22-4aa8-4a0b-b5cf-6e8fb066b4b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"08c3568a-f1f7-4a3a-aee9-9a3e94a7812d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"c979c756-4547-444a-9b8d-2f7d46590647","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cafcfb8d-c715-4fe5-8f78-1c8d53e0a5ff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3).<\/span> <\/p>","ID":"e4fb9b9d-90ab-4023-8274-8afa6f4e73bb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3). ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"93c70cdc-bca1-467a-b568-8102e84b53c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p>","ID":"4599ff58-46d8-4d16-ad95-960a285f3017","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and\r use machines","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"01bd91c3-12f1-467f-9596-6e14467a0d60","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the ability to drive and use machnes. When driving\r vehicles or operating machines, it should be taken into account that dizziness\r or weariness may occur during treatment.<\/span><\/p>","ID":"97ae2557-4f58-4698-8a61-f0dc71b707ee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the ability to drive and use machnes. When driving\r vehicles or operating machines, it should be taken into account that dizziness\r or weariness may occur during treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5b160dc3-93fe-42fe-ae7d-6dbac3a76dbd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p>","ID":"9c71be0d-ffef-4dac-8aa2-3464c5736835","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"95d8615f-7722-4c58-a661-4b3576d14247","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.<\/span><\/p>","ID":"07d26583-7b29-4fbf-8816-7a232a94b73e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"be91a257-1e56-4397-a301-f60ae5267770","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients\r (i.e., uncommon) but in excess of placebo.<\/span><\/p>","ID":"11d7f6e6-1a04-41ec-af14-5712f3cc2d5f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients\r (i.e., uncommon) but in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c0895a83-3369-4604-93be-0d01f86f3cbb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p>","ID":"0d8729c0-05c3-46c6-87e5-e1cf04260d27","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in > 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ee466ef5-c4c8-4e86-849b-7a731db9f49b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p>","ID":"ad6482e3-1a92-434a-9aa4-e6c3180af568","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The frequency of adverse reactions\r listed below is defined using the following convention:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p>","ID":"2a01234f-8a36-428b-984c-95e8c92b3666","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"very common (\u2265 1\/10); common\r (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to\r < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare\r (< 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2dfbbd75-5893-4cba-a611-38563a7bda19","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p>","ID":"02a6086a-38af-49dd-b2e0-7910b757110b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"2df468c1-fb44-4845-b558-b246f5abf29a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p>","ID":"e68c9854-7eb7-4847-8671-0be02ef7fe75","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Blood\r and lymphatic system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia <\/span><\/p>","ID":"e8ab2775-bbe5-4d53-8e84-92ff80185cf2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       anaemia, thrombocytopenia ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"7a12c0b7-1297-45b0-aebe-6f2e4bf68f9e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p>","ID":"7790222d-f9a7-4d09-8786-f03b6efa51ef","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Immune\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p>","ID":"9a3becb5-a1b9-497d-8529-961c43391fc6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"d3a4c7b7-8819-4458-966c-5c2aaeb817e3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p>","ID":"d341a1d0-abda-4d70-aae2-0aff2b7fff24","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Metabolism\r and nutrition disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p>","ID":"c191138f-e870-4439-b9d4-b3e693a91574","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hyperkalaemia, hypoglycaemia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"d26e1d86-8179-46d6-9cdf-c7a122734045","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p>","ID":"036e746b-9e24-4bcd-8f79-73219ca50450","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Nervous\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p>","ID":"1a7d3f14-c9d0-4096-b106-7f863aec8fb3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         dizziness, orthostatic\r dizziness*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p>","ID":"9536ca61-19f9-4fe3-bd72-d7846ed9fedd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       vertigo, headache","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"83485d69-c5b1-4bec-b385-e6c0c404860f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p>","ID":"308ddac0-0f6c-4ba0-a08b-dfa845321a55","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ear and\r labyrinth disorder","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p>","ID":"716ce96a-c00d-458f-96aa-b00909802eb8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       tinnitus","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"3fa13ca7-c219-42f8-b106-939c6cc5251d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p>","ID":"e1759719-6d50-44f2-bef4-7c4b0c7bda38","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Cardiac\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p>","ID":"7832facb-1b2f-4c31-bb97-07a38a6e9938","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      tachycardia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"a23dd0c6-6d9d-4abb-a5ab-ec8cb6c145b7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p>","ID":"49a38590-3df9-4f97-9acc-b70eb3dc37eb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Vascular\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p>","ID":"d937f066-3bff-4724-9b4e-d81296228a8b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         orthostatic\r hypotension*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p>","ID":"35c69254-deaa-4ac1-bd2a-3778657053af","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      flushing","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"fccf35a1-6b94-4571-88aa-2397389616aa","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p>","ID":"bd932c20-d16f-4785-b985-acee896c9b4b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Respiratory,\r thoracic and mediastinal disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p>","ID":"c458a253-df32-40bc-932d-e41919b86e64","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      cough","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7e011794-6bc0-437a-9632-1dbe7915c7cb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p>","ID":"d046dc76-99f9-4cc3-a0b9-1eab861bf0c3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Gastrointestinal\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p>","ID":"434f8a21-5827-4c71-957e-4d827be7ede5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         nausea\/vomiting","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p>","ID":"b7861feb-1275-4d19-ab78-c798749ec59b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      diarrhoea,\r dyspepsia\/heartburn","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p>","ID":"5317a270-874d-4186-8475-629563884c07","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       dysgeusia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"df0f0a48-b745-4c7f-9501-47561e9cc3e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p>","ID":"7ae6c4d7-ff43-4cfa-bb2a-04c2d3acfca8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatobiliary\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p>","ID":"03077425-f3b6-4bcb-8b6b-88e561e42718","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      jaundice","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p>","ID":"344783ad-3fcf-4f30-9ddc-de8095804e6e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hepatitis, abnormal liver function","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"5add4775-cbed-46a2-9f64-0d44a9da5ae5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p>","ID":"b514c29f-9905-4764-93b7-e850a831ea62","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Skin\r and subcutaneous tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p>","ID":"2e78a172-ffba-47d8-99fc-5b257d383818","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       leukocytoclastic vasculitis","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"8c2c14d9-5fe0-4d87-96a3-792fe1453369","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders<\/span><\/u><\/p>","ID":"0fea036d-5649-4dfa-83a0-12dc5fa0e1df","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Musculoskeletal\r and connective tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p>","ID":"e8f6a398-f2c3-44a5-b1f5-97f76e751d1d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         musculoskeletal pain*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p>","ID":"54be15c8-28f5-491c-a906-7e346888b89e","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8aa630f6-ad62-4545-8cae-5c7329e7c189","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p>","ID":"4e2d392f-996f-47ef-9d78-90dc09387664","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal\r and urinary disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p>","ID":"7652e35c-31fe-4fc5-a341-c571cda8af94","Styles":"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r\navoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1ccce432-4751-4946-9d7a-1aae97af44dd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive\r system and breast disorders<\/span><\/u><\/p>","ID":"d7707f66-4ed7-41f7-88c1-51f3995bf4fa","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reproductive\r system and breast disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"EN-GB\">Uncommon:      sexual\r dysfunction<\/span><\/p>","ID":"d32d5a97-5a68-4623-bfe9-89c008f7ce49","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      sexual\r dysfunction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"06a2bddb-9341-4d58-bc91-438570dc5c08","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p>","ID":"3e0526a9-3df1-4357-9fb5-1480529d9767","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General\r disorders and administration site conditions","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p>","ID":"6bf086c9-e0af-4186-9727-3924368cc251","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         fatigue","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p>","ID":"a637419b-d353-4067-8309-7c2a252f810f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      chest\r pain","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"c82617f9-3c56-4085-bd2d-05596ded4943","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p>","ID":"98e744d4-e874-4d45-800b-e362e489cd77","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Investigations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p>","ID":"505b7aa5-1947-4728-bc26-8d0c67dcdce6","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p>","ID":"856d0098-8b67-45d8-9593-1802f5d3bb24","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3add77c6-82e7-4ff1-8dc7-847718a2f31b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"37ad3536-c9c3-4d8f-b75d-5e9881a61dcb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p>","ID":"e640003a-7d75-4cde-aed2-b07c93c074f3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1f067aca-a3e9-4564-8523-972bd740fef9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p>","ID":"2cd2bcbd-cde3-4b87-8fbc-fd9496041e68","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse\r reactions ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p>","ID":"1d6be770-583d-4e06-801d-e8700098c383","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"aa148b43-3bab-47bc-bd4e-1351ec9a4fc4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p>","ID":"dbd69a26-3e55-469e-a193-c2ae85357c87","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"339bff5b-3f5a-498d-8586-5abfaab3513b","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.<\/span><\/p>","ID":"66ea523f-860d-4ace-ae09-3db8afb0d0ac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dc541e72-7d59-4834-bfcf-284d7d5755dd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"861103fa-263c-48a8-af4d-02d6d18074ef","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p>","ID":"2fad3189-c101-421a-90fd-979e3c74002e","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"6d029fca-179f-4305-93db-cbc07d00ba6d","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p>","ID":"acf99a00-8a37-4809-a652-80ea602a4ac9","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"b5c1503a-0fde-4f18-ba27-0c10cae31a91","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.<\/span><\/p>","ID":"6bd84213-072a-4043-8e31-ebe617458680","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ATC code:\r C09C A04.<\/span><\/p>","ID":"ed4fa21f-3d65-41ef-b0d6-28b8e26a4663","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ATC code:\r C09C A04.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2475e22e-1722-41f7-990a-99377bbb8349","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"43c2ba20-7bc9-4857-9378-94723a59e29a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active, selective\r angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is expected to\r block all actions of angiotensin-II mediated by the AT<sub>1<\/sub> receptor,\r regardless of the source or route of synthesis of angiotensin-II. The selective\r antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.<\/span><\/p>","ID":"0537e2f9-1f96-413f-b35a-962baabd93c8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan is a potent, orally active, selective\r angiotensin-II receptor (type AT1) antagonist. It is expected to\r block all actions of angiotensin-II mediated by the AT1 receptor,\r regardless of the source or route of synthesis of angiotensin-II. The selective\r antagonism of the angiotensin-II (AT1) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0be51bb4-f1d4-42b1-91a4-4b63fc6a7682","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p>","ID":"5aabdf3b-3eb5-4767-b656-61c5d598646d","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clinical\r efficacy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"6a19ce5f-93e9-462e-9f9a-cb6a13b92037","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p>","ID":"280930f8-215f-4eb3-8a69-5d55ea644190","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p>","ID":"c8a0eac5-4ee8-43fa-905d-3c3a0c1d2538","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing on\r the same total dose.<\/span><\/p>","ID":"4eb572f6-b445-455a-b71c-d351751c8c78","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing on\r the same total dose.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p>","ID":"958068a3-9091-47c5-a0bb-41f1f7aea9c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p>","ID":"9ad44733-cbaf-462f-ba91-dd51652cb274","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p>","ID":"432badce-4a0e-4076-abee-e02121f75814","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p>","ID":"e68c95d0-c78d-4282-a9c6-2a2101ccd5ae","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"686fae90-82f1-4917-8fef-c5ba8ec7868d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"296b1796-72df-4c6d-9802-4400ffa5269d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"93f2ea7c-7b1a-435b-b6c0-5ab8b7e241e1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).<\/span><\/p>","ID":"e754fafd-c02e-46c4-bec9-e58f283f37ac","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5682e5dd-170d-497e-bd8d-5b98f453078e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p>","ID":"2ab565f8-c509-43af-a773-2d6e0815f700","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension\r and type 2 diabetes with renal disease","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p>","ID":"35292139-7c7a-42fe-818e-2e4940ecb87b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg\r amlodipine, or placebo as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r > 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"49f24118-bf84-4bbc-a605-d06ff36fa650","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p>","ID":"2492dad0-ca31-41cd-9821-4fa72c5be8dc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6d4265ba-e8d1-4899-ac99-14513c97e755","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo\r (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of\r overt proteinuria, demonstrating a 70% relative risk reduction versus placebo\r (p = 0.0004) for the higher dose. An accompanying improvement in the\r glomerular filtration rate (GFR) was not observed during the first three months\r of treatment. The slowing in the progression to clinical proteinuria was\r evident as early as three months and continued over the 2 year period.\r Regression to normoalbuminuria (&lt; 30 mg\/day) was more frequent in\r the Karvea 300 mg group (34%) than in the placebo group (21%).<\/span><\/p>","ID":"8b1ff725-4920-443e-b93e-a0ca0f4e8853","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r < 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) > 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the placebo\r (14.9%) or in the irbesartan 150 mg group (9.7%) reached the endpoint of\r overt proteinuria, demonstrating a 70% relative risk reduction versus placebo\r (p = 0.0004) for the higher dose. An accompanying improvement in the\r glomerular filtration rate (GFR) was not observed during the first three months\r of treatment. The slowing in the progression to clinical proteinuria was\r evident as early as three months and continued over the 2 year period.\r Regression to normoalbuminuria (< 30 mg\/day) was more frequent in\r the Karvea 300 mg group (34%) than in the placebo group (21%).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6999dc06-9cf6-4ca0-8a6c-266085c2cb88","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p>","ID":"18835c09-cee0-443d-a95f-4a21693f3840","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p>","ID":"84d0a03c-13c5-48fd-9b8d-8721d595a6c0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p>","ID":"33eb7ae1-64bd-4125-86f6-11e6a78c43a2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p>","ID":"dae2b392-103d-4eba-9824-4aae4f8772d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p>","ID":"4a7b39b5-e4a9-4a4c-8ce0-0cab207d7e21","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fe9e82c4-3b99-4fe3-9028-53ce6db058bf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p>","ID":"bd46f2d2-868c-4593-89d7-2ee99873cc13","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8163fc93-c037-4e60-8b89-8f89fe5a49bc","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"d9108620-7511-47e5-b62c-e29052e08920","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Absorption","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"5176d41a-ca26-49e9-98ac-317e1ae0dd9b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p>","ID":"624e495e-512b-4ee8-9b08-b93e16d1e2e3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"e3c12167-f4a4-4b66-bc6b-4acef4b8ecb9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"8e68e590-6280-428c-9b24-6f565754cd84","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Distribution","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"b1ef9a19-ff8d-4b40-8b91-5e93bcc0eb42","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. <\/span><\/p>","ID":"92262f0e-ba54-4c19-b5f4-d672ba17f18d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"59c58071-b512-4087-96f8-05c3f1a60be0","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"51eb41bc-c2c2-43c9-b38c-f3af6e52f3e4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Biotransformation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"88048b6c-571c-4c00-ba3b-cd5792817637","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p>","ID":"c79a3c96-666a-4c51-ba99-d28145610ee9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following\r oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dc1f8f89-a424-4b4c-89f5-774342f1dbf8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity\/ non-linearity<\/span><\/u><\/p>","ID":"1f28b646-bd1d-427b-b20f-cb500b84a134","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Linearity\/ non-linearity","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ceb3a733-4e78-4379-a977-df6b0d652862","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157-176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of irbesartan\r is 11-15 hours. Steady-state plasma concentrations are attained within\r 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in oldersubjects\r (\u2265 65 years) than those of young subjects (18-40 years).\r However the terminal half-life was not significantly altered. No dosage\r adjustment is necessary in older people.<\/span><\/p>","ID":"c119715b-38c8-442a-97ef-4b63be46ff43","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157-176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of irbesartan\r is 11-15 hours. Steady-state plasma concentrations are attained within\r 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (< 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in oldersubjects\r (\u2265 65 years) than those of young subjects (18-40 years).\r However the terminal half-life was not significantly altered. No dosage\r adjustment is necessary in older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ff20711-3dda-42ee-9be0-e20c9bc94cd9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"d45a4cf5-207d-4ba6-b208-69531a38e228","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elimination","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b24efe36-c411-4bb5-9936-5149d722c55a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p>","ID":"0a238a1a-e1df-45a8-8f0b-90f11d718fd1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of 14C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ac332c0-b8a9-417a-b9b3-13104b845d95","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"b5fc6abd-8a48-4cf0-9709-43b30df7bf2e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"6ea76536-aa21-4999-bc70-8755021a19ab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p>","ID":"76691af0-9044-453d-87de-b08902b78822","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"34d06a0f-1803-4f62-8121-d6b22c86b908","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"771f75d7-c638-45f5-a181-6242963f4176","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fd03540e-d589-4084-a579-54f125303f30","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"2ebb1f6e-d76b-45c6-8e87-120da3ac80fc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"41b9cc53-a8bc-45ac-bbc6-b4f88537494f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p>","ID":"03356322-85c6-447f-95ad-78b5ed7ff995","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6c44645f-5222-4ca4-a979-58f8361ffa5a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.<\/span><\/p>","ID":"a59eb148-da12-442a-b7ad-fa7b67ca472f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p>","ID":"8a26e0a6-fe93-4e10-8ac4-4ed403f370a9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Studies have not been performed in\r patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6870c1dc-0b80-41d4-8b5c-ca9305cba15c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p>","ID":"1241ee1d-2b42-4f0d-bc91-b399b2f10850","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3Preclinical safety data","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"cce4a354-ae8d-42f8-bb2b-d58102186023","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p>","ID":"7ecde270-2a7a-4e57-aec6-5ffa72949559","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"19293da3-f12a-40b5-8328-c3a71aae7571","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p>","ID":"b8d87cdc-99a1-4f1f-a4a2-7fb49573aca4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7755475d-9e32-4478-a9d2-2a4a60dca82a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p>","ID":"38c5b16d-3344-475e-954e-e1f6d796daa5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"563c3ea7-aed4-4e73-a2e1-c2f45d3ff8e3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p>","ID":"8424d552-cf82-4969-9fca-8cc760d32c78","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1089b671-2309-4951-9a3a-dcc19e62d57a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"77c23f1b-aa69-4eff-a833-445bf7d9750e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p>","ID":"4f6d451c-c90b-4882-9c5b-d227eebc841c","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"1f8ac64a-65b5-46df-ab74-ed8ded0cc235","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p>","ID":"9f709278-dc69-4735-9acd-beb37729fe78","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"9909357a-9195-474d-bc2d-bb5848f4ff22","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Microcrystalline\r cellulose<\/span><\/p>","ID":"5385cad5-7a9c-4893-a883-a04d7cfdaff5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Microcrystalline\r cellulose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p>","ID":"32f9bdc0-277a-488f-a802-06615ff3b9f3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p>","ID":"0038cbc6-c92a-4d28-927a-c63dca558c46","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Magnesium stearate<\/span><\/p>","ID":"36441d8c-9e6d-4f8a-9cf0-f712d75c9954","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Colloidal hydrated silica<\/span><\/p>","ID":"39c76883-e1d7-40b3-8088-a45bb256c990","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Colloidal hydrated silica","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pregelatinised maize starch<\/span><\/p>","ID":"f65cd91d-6fda-4abd-a561-3a1e556d23ef","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregelatinised maize starch","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Poloxamer 188<\/span><\/p>","ID":"5bca9b39-3fbb-48a7-abe9-d85b343f742c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Poloxamer 188","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d1f6a333-98e6-489e-b691-ae8d22d877c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p>","ID":"7799eee8-8d63-4e5e-898e-16e3406037fd","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"d5b30126-15a5-4e57-b69c-81f4929d3232","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r applicable.<\/span><\/p>","ID":"8f5c0283-577b-4654-a506-5dfc08d8eef7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r applicable.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fe34bdd5-3acb-4202-9c2d-3ddfa14ec6f5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p>","ID":"16231e41-b368-48ec-a040-8dff2301c2b1","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"4a6621b3-7946-4c7e-8c84-62207208197b","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"d8d668cf-23bb-43f4-a34e-a0fe15353c41","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ed7db306-f612-452e-a5d7-c0713f545bb2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p>","ID":"d308c8c6-e38c-4de8-b790-4eeaf17280cc","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"599acffe-9491-414e-9869-d3c815caa522","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p>","ID":"4d21cb88-1723-4372-b4e3-e8fec2bd8ec6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not\r store above 30\u00b0C.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9fc8cee6-13ef-484f-8ad1-68d89852ede1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p>","ID":"d0d8cd39-9872-480b-bf48-d45ba0da2011","Styles":"margin-left:0in;text-indent:0in","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature\r and contents of container","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"77e1cd57-95d6-4164-b61b-2689eddee6b5","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"8dd7c41a-265d-463b-9c58-f39332010008","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"35c0408b-8253-42f6-a037-22bce207a07b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"70fbadbd-976d-4ae6-8987-4fe821a228e0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"2846845b-db31-4299-83ed-4a9553557a7e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.<\/span><\/p>","ID":"31cf00ef-63f8-4a55-b626-96213cda502d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2f518a23-8dbd-42f4-8025-0e49c2f6a4be","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"97e578fa-5ae0-48a9-bf51-bb71061152a3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d70c92f9-ad73-41b1-b007-d5ffc5cbdd1a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p>","ID":"c3665193-69d7-42e1-98eb-c2e4a8e30fa7","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"2efa7ab3-b99b-4476-9619-f2bdcc2fab0c","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/p>","ID":"6282541d-261e-4a72-8658-648fc5dc04bc","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"31c7c8e6-b4d5-4fd9-bda7-c3276f0ae168","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8d8a6308-adb5-48ac-9816-fc7a5f668ebf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p>","ID":"1a3e7320-d8f6-4c99-b9ec-9e4e77999b2a","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"529a28a9-02aa-468c-95ed-92ba34d4695e","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p>","ID":"d762c826-2d5b-42be-83ce-5a6f1a185a71","Styles":"None","Classes":"['EMEAAddress']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"sanofi-aventis groupe\r 54, rue La Bo\u00e9tie\r F-75008 Paris - France","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"17dcd834-f694-4ff5-b12c-8bb64cc1ebfb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"557fc688-3fff-4fc3-b176-84f85ae61326","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p>","ID":"3cb535aa-86cd-48f6-be9d-3ab01177c103","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBERS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"aceff883-a557-454e-9285-b7c66c0fe96b","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"NO-BOK\">EU\/1\/97\/049\/004-006<br\/>\r EU\/1\/97\/049\/011<br\/>\r EU\/1\/97\/049\/014<\/span><\/p>","ID":"13931d89-7aed-421e-ade0-bbedcd95a91a","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/97\/049\/004-006\r EU\/1\/97\/049\/011\r EU\/1\/97\/049\/014","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e1de3162-fb47-48a9-b450-426f70be28ad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fed42b41-5098-4f3f-a30f-db57f26968ac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p>","ID":"33530a80-5557-45a1-af4f-392af68041f2","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"989318d9-3ed6-489b-ba3f-3815e87a05bf","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p>","ID":"27028726-492b-4f96-a7d5-a7bb2118d450","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 27 August\r 1997\r Date of latest renewal: 27 August 2007","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ccbc06e9-24a7-4805-8ee8-d43f1bf6d2d7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"058fbab1-b627-4c00-98c0-6074d123e93c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p>","ID":"34490e3a-e6d4-45dd-8d91-8e9e8b4c3978","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"705c63d1-73cc-453a-b53a-a580416cd837","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p>","ID":"dba006ad-6b7f-4924-861a-4b8984c6bd6b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"cf4f3256-5316-4dc8-9c4e-7e375f903c84","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"048ba925-9f2d-4a2d-b0da-268705e8c963","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"95a4aacf-4535-4a81-80f9-a7be691f2f90","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ntext-transform:uppercase","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"048ba925-9f2d-4a2d-b0da-268705e8c963"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"565b113e-fe2c-4aa3-bd73-1a93ec27ff06","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"95a4aacf-4535-4a81-80f9-a7be691f2f90"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p>","ID":"b3613d89-733a-48c8-be7f-9e1e288113f6","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"26a1dc1d-69b0-4107-a226-7653b2347bd2","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg tablets.<\/span><\/p>","ID":"6ad70153-a0eb-4b90-9740-002012269fdb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 300 mg tablets.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3d19d0a2-a0bf-47a7-a571-34e40a6c4919","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"51a8d917-5989-4f8d-948e-38adba7aea4c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p>","ID":"cb370902-fc4e-4768-bbc7-0b57370b04a8","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"5ffba528-103e-43d9-87da-725c4d1cd921","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each tablet contains 300 mg of\r irbesartan.<\/span><\/p>","ID":"2323d4d5-a3fd-4235-94ae-430e8c1e4c14","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each tablet contains 300 mg of\r irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b70eec99-8bb8-482d-a7bd-cd1e5b64729f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 61.50 mg of lactose monohydrate per tablet.<\/span><\/p>","ID":"28cf1290-cf95-43e5-8a6f-ca5a1a683435","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: 61.50 mg of lactose monohydrate per tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"10e9966f-8381-4399-b0a8-b445d052bee6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p>","ID":"0b94657a-85f5-4961-aa48-5d01260adcfe","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see\r section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d50454b9-8f24-4553-a0c1-efd6919feb23","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ec56f1b1-4a54-4aad-bcbc-1306645ed3a7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p>","ID":"f4531383-408b-4fae-b3ae-bc16ab0af459","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"662cafa3-dff1-4f6e-8eec-d109fde7f191","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet.<\/span><\/p>","ID":"48b975a4-daa0-4fc5-9e34-c024f31648d5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2773 engraved\r on the other side.<\/span><\/p>","ID":"a2d2f545-c20d-4a46-b28b-d9d89e0aee8a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2773 engraved\r on the other side.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"29a72533-90f2-4fa7-b026-88c42bbab07f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cd483bca-a069-4551-91c3-861c9db57282","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p>","ID":"1f14394e-1089-4694-8e7d-bb88cc6ab360","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"020872cc-37b0-4f17-b5cc-59b39af6678c","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p>","ID":"c97df2d2-6684-4f61-9766-785f40b69621","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"09229046-f274-4435-a9f0-32ab2da8e36e","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p>","ID":"2c3a321e-5c40-4641-8d26-0878f6278143","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea is\r indicated in adults for the treatment of essential hypertension.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"07f23aae-07fb-49b1-85c2-c76bbb19174c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"75c7149b-8f6b-4b95-ac8c-5544dea4aa07","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p>","ID":"ef773bdd-c062-432f-a284-86985aecd245","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and method of\r administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"1ae565c0-3301-47cf-98fd-06794c9dd338","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"0c82ba01-5050-4833-b6e0-433cc4f11deb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"86fecf77-2420-4c43-9bbf-0e7731e8c5e8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p>","ID":"51cc9f17-4f82-4082-aff6-fa778b502d80","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2913a116-3672-4002-97a2-192cb17a13a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p>","ID":"cd46186b-dd09-46dd-8275-2863a9bbd9f9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a440de23-54d6-42bb-9138-149f2adf2431","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p>","ID":"5f679b40-245f-41c8-9b2a-017c077a08e1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"57e362de-cb52-4b95-a737-65ac68d845e9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6f70f455-488c-454a-9291-d6d51a33d342","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p>","ID":"c6aca785-37e8-4edd-b866-c5dc1d919b91","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special Populations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a6c1ec70-d6e4-41c9-bbda-6c0855d49ed0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"c96ab43c-b8c2-4db6-bff4-ae6c3a46b680","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"21c71201-fd10-4f2c-a844-3e04c559c076","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p>","ID":"9bf9b81d-5a99-4f0d-ba8e-f04881d476e1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"444af3ab-86e4-49ee-bef7-9a87f5b53bb4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"701e3aae-2af3-4469-9340-a5fc325d1f71","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ab919bc6-c33e-4f37-bacd-dc3c3454e70e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p>","ID":"704b30c2-0e95-49bf-9b83-15bc0d0a3e6c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3d547bad-736d-4131-b1dc-a5e25ebea8b0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p>","ID":"044f2c40-202e-4a01-9bed-50ade3038cd1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Older people","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"89cc80dd-2033-46f9-accc-a65a9f0b059a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.<\/span><\/p>","ID":"5f3cf51c-929a-406a-81a8-c2e19fd37e55","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e905313c-3051-429c-90be-94348a0fe883","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"bf3c2fbc-6f7a-472d-82f5-41a0f29f4936","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a00bb75d-6861-4071-a0a0-4b57258275ba","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p>","ID":"f74c947c-4a9f-4fd5-91a5-3e3469f62487","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can\r be made.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c973a1b8-6b46-42c4-be36-5fdb00fc1ef5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p>","ID":"f1f3c462-b400-4831-ac9e-7e548cb7a337","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of Administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bb22fe26-3cbd-471f-bb0d-fa30d7623fe9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"bfacf7f7-3727-4e53-bb58-8ae06a501700","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For oral use.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"926323f9-aab8-4de3-bda7-87174737007a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p>","ID":"3510589c-e9ed-41d3-83d9-ece950bed6ce","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"abefbefd-840c-4306-b0c8-4d3f66684950","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"f9ce6bb4-3bc5-4e9d-bfa3-25283e3e5bcd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p>","ID":"1d8235ff-e15c-4d2b-a254-b4914f7dfa20","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e1d40ea5-3e6f-42a8-93e4-f042fd6e90ee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p>","ID":"62e83272-b246-4f4a-84cb-a4d56ef1bba3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) <60\r ml\/min\/1.73m2) (see sections 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1cfabe30-15c0-4c50-8124-d8db6763fdb3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p>","ID":"6e89d57f-2ba9-4a0a-ac1b-9029e556bc4e","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions\r for use","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"6ebba756-021e-4927-a8f2-415d8c752792","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p>","ID":"1d2c5e87-a5d2-4201-9148-773c7612c940","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Intravascular\r volume depletion: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"c1a433b4-fb93-422d-be2b-bd7087d4e559","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p>","ID":"a6d77410-feeb-4624-83e1-15af8905d39a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renovascular hypertension: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"c38f0952-38c2-44b0-a08d-99edc7076fd6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p>","ID":"6a5bdee8-a558-470d-a11b-17f391041f1b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment and kidney\r transplantation: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"c32f5e6b-ddc0-4767-b5b0-254779062b45","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p>","ID":"703edc0e-ca62-4443-91c9-e2724e70d36b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypertensive patients with\r type 2 diabetes and renal disease: the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"7cd586df-5f4b-4815-8599-98c91320acc9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):<\/span><\/u><span lang=\"EN-GB\"> there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p>","ID":"1cb351ac-3412-4d7b-9536-89846f3a86db","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bb5e99ee-4d0e-4fc7-bf4d-c40b01676bee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p>","ID":"d410e269-68dc-413f-9066-f9b03cb5ee10","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hyperkalaemia: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"0f3f2d80-0359-40f2-bb62-c3df852d2e69","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><span lang=\"EN-GB\">: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p>","ID":"86fa3edb-442a-45a2-864f-21bef0cd3bc8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"de545067-cc9c-4cd0-b67e-0eeb60d7fe63","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see section 4.5).<\/span><\/p>","ID":"c5315e43-3964-403f-98be-d2fb28fc36f2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:\r the combination of lithium and Karvea is not recommended (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6f92cf17-b775-4d98-9316-8389ef090a90","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis, obstructive\r hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with other\r vasodilators, special caution is indicated in patients suffering from aortic or\r mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p>","ID":"6a50fee7-0199-4841-bed2-4b30dea0f976","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aortic and mitral valve stenosis, obstructive\r hypertrophic cardiomyopathy: as with other\r vasodilators, special caution is indicated in patients suffering from aortic or\r mitral stenosis, or obstructive hypertrophic cardiomyopathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"0f11a0ec-e41c-4506-b938-41289b123941","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the renin-angiotensin\r system. Therefore, the use of Karvea is not recommended.<\/span><\/p>","ID":"20b73434-edee-4c6b-81ea-d1d52bca0c63","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Primary aldosteronism: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the renin-angiotensin\r system. Therefore, the use of Karvea is not recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"cde4ecaa-969f-42ad-9d16-c8abcb1610c8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p>","ID":"61019676-eb1a-4eb1-a48e-5927cfaa6907","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p>","ID":"53651b51-478d-4f65-8aff-d53580137366","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f66372d6-d03b-4561-9614-66772ddd9e12","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p>","ID":"1a7643cf-db8e-4b46-ae9e-a0526a956acd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"efc5bbbb-32c1-40b2-aefe-d71b97b58426","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p>","ID":"708c9b8b-0a85-4642-8619-cd6eb96de64c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fe4ee932-6d3f-4ee3-9328-217c0f4aef44","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p>","ID":"a2ae3bf0-b027-4856-98f8-2d42daaf5b6a","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipients:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 300 mg tablet contains lactose.\r <\/span><span lang=\"EN-GB\">Patients with rare hereditary problems of galactose\r intolerance, total lactase deficiency or glucose-galactose malabsorption should\r not take this medicine.<\/span><\/p>","ID":"4c113f87-929a-4ccf-ab7c-8e6b00310cbd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 300 mg tablet contains lactose.\r Patients with rare hereditary problems of galactose\r intolerance, total lactase deficiency or glucose-galactose malabsorption should\r not take this medicine.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"31728cb5-5413-4292-b93a-2cbe0f1d66bc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 300 mg tablet contains sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p>","ID":"2b24db6f-3348-4879-b8dd-594df019a4c2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 300 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"079c94a2-ddfc-4d1c-8db7-478497391d3c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p>","ID":"4f939157-b211-4490-8d07-97b2a364df8b","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal\r products and other forms of interaction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"1c490a4d-424a-4cc4-8d19-7e61770bfcc7","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).<\/span><\/p>","ID":"cc7c2b8d-5298-4c44-a315-f3dc2dfb2aff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Diuretics and other antihypertensive\r agents: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"20e63d42-c2d8-44d5-a6bb-15eec94f1fa4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<\/span><\/p>","ID":"8c0000a2-310a-47b9-9abc-f6a7711a5367","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aliskiren-containing products or\r ACE-inhibitors: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8c77d29d-d4aa-470a-892e-fe13ff247fad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see\r section 4.4).<\/span><\/p>","ID":"7c34729b-25e9-4192-bebe-7ca277f1b787","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Potassium supplements and\r potassium-sparing diuretics:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see\r section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"8dace82f-d51c-44f0-9c4b-40e4ca94e28f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p>","ID":"a3279307-85b9-45e2-ba99-ab235a1e30d8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"e89eba4f-2fca-46d4-a09a-f8c1f62cdbd0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: w<span style=\"color:black\">hen angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p>","ID":"0fd7d0b0-d40e-464e-b70f-2a69a48f209b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (> 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p>","ID":"ea367ce7-53cc-43f8-b96e-58345067c59c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"74c3d00e-1137-4692-bc3e-17cc845e9b5a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p>","ID":"1f690caa-4e98-43c0-9489-fa22049560a6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Repaglinide: irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the Cmax\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"4116592e-658a-4db9-9b56-d4ee8aac2f2a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p>","ID":"22bd7240-92df-4acb-aa3c-571e77cf0766","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Additional information on irbesartan\r interactions: in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b2935fe2-2f0c-40ee-a69b-b7495e24fb85","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and lactation<\/span><\/p>","ID":"2cf40a6a-4a54-4f90-9474-586340fe9d30","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"19bd51f7-7c1a-4c69-9da9-838bdfce5e30","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"d246422e-b82d-4b0a-acc8-4f8ebae2c91b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"b64007bc-2d0f-47d7-8bd6-611888a387d8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div>","ID":"47f660d2-7496-493b-b5f4-16f57bce292f","Styles":"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":true,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"  ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p>","ID":"f53eadec-5595-47aa-b977-1f7ceefb2409","Styles":"border:none;padding:0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).","ParentId":"47f660d2-7496-493b-b5f4-16f57bce292f"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ad30e24c-fef0-454c-948f-ab9014f67ad9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in risk\r cannot be excluded. Whilst there is no controlled epidemiological data on the\r risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may\r exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p>","ID":"e75d69ec-1f11-46b9-95ab-e59ac99daa7c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in risk\r cannot be excluded. Whilst there is no controlled epidemiological data on the\r risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may\r exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"84bd8399-c023-4ade-9add-882e73c915ac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p>","ID":"a2481caf-0990-4f86-bb77-49a764a69ef8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p>","ID":"4842ff0e-2dc7-4f7c-a9d1-275e23cd3511","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3 and 4.4).<\/span><\/p>","ID":"f7951bf7-562a-48d3-be19-971ccb1258be","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3 and 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"16923442-33a5-4757-9804-7f9be077afaf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"c2851333-9cf1-4544-ac50-dfd864efb1f3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"94e3472b-6fcf-467c-b22e-ad613ab1d2f5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available regarding\r the use of Karvea during breast-feeding, Karvea is not recommended and\r alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm\r infant.<\/span><\/p>","ID":"6971273c-2fcf-4ed5-8fcb-758e58265c4a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Because no information is available regarding\r the use of Karvea during breast-feeding, Karvea is not recommended and\r alternative treatments with better established safety profiles during\r breast-feeding are preferable, especially while nursing a newborn or preterm\r infant.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"9de82556-27c1-4ad5-aae6-b1bc4642d885","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">It is unknown whether irbesartan or its metabolites are\r excreted in human milk. <\/p>","ID":"b80b6e89-0584-4719-8b78-138193a39723","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether irbesartan or its metabolites are\r excreted in human milk. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).<\/p>","ID":"863322fc-6246-4cac-ad2a-cd95b495bb2f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Available pharmacodynamic\/toxicological data in rats have\r shown excretion of irbesartan or its metabolites in milk (for details see 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"785c57ba-f09d-4b7f-9a17-916403c123c8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"8a79e3c7-5193-46d1-9ac4-c1cbdb5b5601","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"acf94bd5-598a-4dec-b6fa-6c032f30c315","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3).<\/span> <\/p>","ID":"4de3c8ce-8048-401c-94b7-5819ac5b7360","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan had no effect upon fertility\r of treated rats and their offspring up to the dose levels inducing the first\r signs of parental toxicity (see section 5.3). ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"59b01366-d6e1-4260-acce-edc85050e911","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p>","ID":"529f43db-52d4-4b18-a460-5238d82998f5","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and\r use machines","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8bbfb42b-8920-475c-b6d5-1430507c3fd8","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the abilityto drive and use machine. When\r driving vehicles or operating machines, it should be taken into account that\r dizziness or weariness may occur during treatment.<\/span><\/p>","ID":"6aa127c6-aa80-4bbd-a5a5-3f3d130a2aa7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Based on its pharmacodynamic properties,\r irbesartan is unlikely to affect the abilityto drive and use machine. When\r driving vehicles or operating machines, it should be taken into account that\r dizziness or weariness may occur during treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"be530ae9-aa83-4ac4-bda8-6e09496bb51a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p>","ID":"aaac5028-9686-4e20-becd-994e8e8892f0","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"de553ee3-e1d5-4696-b044-d5c990ffaade","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.<\/span><\/p>","ID":"5612376a-c427-4992-bf1e-4b4b94cc3973","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In\r placebo-controlled trials in patients with hypertension, the overall incidence\r of adverse events did not differ between the irbesartan (56.2%) and the placebo\r groups (56.5%). Discontinuation due to any clinical or laboratory adverse event\r was less frequent for irbesartan-treated patients (3.3%) than for\r placebo-treated patients (4.5%). The incidence of adverse events was not\r related to dose (in the recommended dose range), gender, age, race, or duration\r of treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5243a8a8-4779-4cd5-bd16-47f820db203b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon)\r but in excess of placebo.<\/span><\/p>","ID":"4ad22af6-9334-45b2-981a-f1df716ad714","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon)\r but in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"05f52c6c-0db8-4c8d-abe3-435a9f27a151","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p>","ID":"d76fffa1-4b83-4b9c-8788-759420b2e431","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in > 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5e1ce8c8-46a7-46e5-b069-630817a3773a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p>","ID":"4bcb7cc5-4362-4392-85d0-3520bdf3f3f0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The frequency of adverse reactions\r listed below is defined using the following convention:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p>","ID":"833e8854-0ad9-4baa-a02a-20635925059f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"very common (\u2265 1\/10); common\r (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to\r < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare\r (< 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9acad9f0-0415-4b64-b370-94350d8e35a8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p>","ID":"6e94df95-6afb-4aa4-b9c5-e2e32e268076","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"7949a431-c422-4b56-b85d-7154665dbfc8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p>","ID":"3da64373-85d8-40cd-aea4-032465a8fc70","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Blood\r and lymphatic system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p>","ID":"9d41db22-8fcd-43a8-b3f1-648c659c4223","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       anaemia, thrombocytopenia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a63e55d9-313e-4448-90fb-bcb50704fee8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p>","ID":"57302396-112f-4654-9742-d0130928cae3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Immune\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p>","ID":"f2744208-7486-4c87-82c1-b947a3956870","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"bb866f8b-bc47-420f-8cd7-cb6f9c70903b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p>","ID":"41443526-e155-4aaa-94be-db016554f663","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Metabolism\r and nutrition disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p>","ID":"1da545c2-3acf-4544-96e6-48d14c21545d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hyperkalaemia, hypoglycaemia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"748ac58f-3a33-4483-8b2a-813e05878d54","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p>","ID":"349e63bc-5e0a-425c-8943-1d4fbec38761","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Nervous\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p>","ID":"78fd27c4-bfc9-4997-9ef3-0be17e39eb54","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         dizziness, orthostatic\r dizziness*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p>","ID":"8373266a-2ff2-40e7-b309-b7e7588a67ef","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       vertigo, headache","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ac6bed9b-3b4c-4ae4-aca6-541abf05554e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p>","ID":"0c2ce611-eafe-482f-9141-019c98ff3d97","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ear and\r labyrinth disorder","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p>","ID":"6f6441c7-50c8-489c-939c-18d870ca5eea","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       tinnitus","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a8909537-91e2-4652-8b89-932171845610","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p>","ID":"a9d1141e-a507-4988-a7f1-1588313bfcb2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Cardiac\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p>","ID":"6cc0889a-4db6-4d17-8dcb-76f6877407ec","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      tachycardia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"d5055593-3bfc-4f6c-a133-11aa92a27245","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p>","ID":"7e4b6707-fffd-4ed1-b6b4-7e005053c9f5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Vascular\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p>","ID":"6bd0269a-392b-4703-805c-0b34d451680b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         orthostatic\r hypotension*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p>","ID":"6f05c831-0721-4aaa-8f84-8589ff2fe9a8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      flushing","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"8e3f2435-482b-4bbf-a8af-0a06cb6b6f0b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p>","ID":"c22f17ea-5995-440f-887c-ac00b26e3571","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Respiratory,\r thoracic and mediastinal disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p>","ID":"9da6ef5c-10ca-4f2e-a03d-baf245650396","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      cough","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ec368c2b-d4f7-4f4d-980b-99deeef2a670","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p>","ID":"19936d9d-48fa-4123-a91b-7b631dbdc524","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Gastrointestinal\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p>","ID":"23941db7-5c28-4166-bd91-694ca60963b2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         nausea\/vomiting","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p>","ID":"90211cb3-14be-4b49-af3a-0d088ba89ae7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      diarrhoea,\r dyspepsia\/heartburn","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p>","ID":"aae8bed6-b98c-4c8c-a9d7-b7b110d53e80","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       dysgeusia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4a6e9a84-0788-4d45-8b21-906120875b49","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p>","ID":"93d0e68b-2140-4e11-8af9-5cce43eaca17","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatobiliary\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p>","ID":"d5b9be93-5a94-4203-9624-1270b457e0e4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      jaundice","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p>","ID":"13f9228d-5ac5-4472-8d0c-9d403ee5709f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hepatitis, abnormal liver function","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"c821e19f-4f26-498c-b9d0-73e5258da906","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p>","ID":"a0d22b0e-51d2-4331-bbce-d1c048ce8c8c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Skin\r and subcutaneous tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p>","ID":"f43e9cab-0055-46d5-a23d-ea97ef670d59","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       leukocytoclastic vasculitis","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"8776a364-dc24-48b5-8c89-26413799380a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders<\/span><\/u><\/p>","ID":"0961c465-d537-4a2d-b03b-bd46bd602730","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Musculoskeletal\r and connective tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p>","ID":"bc6206b1-1eb3-4c80-bb3f-8a0be4496b4c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         musculoskeletal pain*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p>","ID":"15da6a7a-d4c2-494a-a8dc-c8d4d7800aa7","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9d632959-2ff9-4eb6-8c11-e54618c61a4b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p>","ID":"1dc761e9-e482-40c9-a9b5-05cdbf70d98c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal\r and urinary disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p>","ID":"1481ae1b-ac77-4012-bd23-63527f5447f0","Styles":"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r\navoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c1410b6f-c86a-4d44-ac3a-372bd048b697","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive\r system and breast disorders<\/span><\/u><\/p>","ID":"86c3f8bb-6453-4f2d-a890-fb9484f80d15","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reproductive\r system and breast disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"EN-GB\">Uncommon:      sexual\r dysfunction<\/span><\/p>","ID":"08928890-e035-4e7f-9189-f0abcb402220","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      sexual\r dysfunction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f9a6c8bd-9cd8-4d6b-b723-81bc7039cf23","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p>","ID":"4d4b4a70-bc48-4c99-9ab9-e79c8ae482fb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General\r disorders and administration site conditions","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p>","ID":"be34b229-961d-4e69-85a5-2e4c4ab1c06c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         fatigue","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p>","ID":"cba3584a-99e0-4f81-ac25-947166b5847f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      chest\r pain","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"5414bba8-e03b-4eb3-978e-d7339e4fba06","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p>","ID":"aeac926d-75f2-403a-bf9c-989de1a1004f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Investigations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p>","ID":"5908c048-3149-40d6-8827-297fb13a85ad","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p>","ID":"c08f22a2-04bb-48b1-a2e0-8facbc47bcc6","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9128f13c-404f-481a-8018-c06d841c1142","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"0b69de3d-86ec-43f0-9971-8c2bdbe308c6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p>","ID":"dc0d68e4-8911-41ee-bdb4-72cc212682cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In a randomised trial of\r 318 hypertensive children and adolescents aged 6 to 16 years, the\r following adverse reactions occurred in the 3-week double-blind phase: headache\r (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the 26-week\r open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c22fa73e-cb05-4466-b558-5cebd34ab413","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p>","ID":"be93dc80-6cd2-42e1-820a-5a1c6530258e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse\r reactions ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p>","ID":"ebaf772f-e2bf-4cf5-8417-44ff9e473262","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"21e23e09-e94e-478e-bc04-bfae93adb9c9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f6203af7-57b2-4238-a97b-0f03e9424a8a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p>","ID":"c0e9c614-5d68-4051-ac3c-ea9fbac36de2","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"7677a0d9-44e3-4a1f-8f90-9b4771b1ffd6","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.<\/span><\/p>","ID":"bfd8d2cc-deb5-41d7-855a-26922b8761e5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Experience in adults exposed to doses of\r up to 900 mg\/day for 8 weeks revealed no toxicity. The most likely\r manifestations of overdose are expected to be hypotension and tachycardia;\r bradycardia might also occur from overdose. No specific information is\r available on the treatment of overdose with Karvea. The patient should be\r closely monitored, and the treatment should be symptomatic and supportive.\r Suggested measures include induction of emesis and\/or gastric lavage. Activated\r charcoal may be useful in the treatment of overdose. Irbesartan is not removed\r by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8f33fd8f-3166-4e76-b6d9-fa9cab947207","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2eb0fcc4-7814-495a-9839-b8d7eb46bd9d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p>","ID":"c25fd65d-fda6-4ebd-938d-522c4ac9a3a3","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"b2b7eea5-53a9-4143-a118-24726a8ebac1","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p>","ID":"dc2f05fa-243f-407d-a3a1-6497f000e415","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"29e1e247-4b49-48e4-a03f-0261371fc8b0","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.<\/span><\/p>","ID":"57c612e8-e362-49cb-9ef9-89a16f341e48","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic\r group: Angiotensin-II antagonists, plain.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">ATC code:\r C09C A04.<\/span><\/p>","ID":"305f9f9e-939a-40c8-bad0-007566828e57","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ATC code:\r C09C A04.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7b9aee38-b2d7-4f26-b616-582854c32bde","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"88f52c94-a9a3-43c4-a477-f118dc2c9877","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6fc2c3e6-0b95-414c-9552-b9e467cfa843","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.<\/span><\/p>","ID":"88909653-d192-4e57-abae-57fee37f5306","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT1) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT1\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT1) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"93017271-63b3-421d-b60f-dd3eed969b02","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p>","ID":"c94c3914-ff82-4871-a90c-41acb171efa6","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clinical\r efficacy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"56875f24-9d61-412d-bfcb-29e38e11c1fb","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p>","ID":"0db43426-df46-4328-830b-2bd4b0cf6a1d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p>","ID":"73349425-12a9-47f4-9c1c-5ea9b2cd9a45","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p>","ID":"3cfcf73b-40c4-4400-b7b5-4278098e123b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p>","ID":"c673d133-5cda-48dc-859c-c323f6a3f158","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p>","ID":"ddae0c01-dc7c-40ef-962c-190d524cb85e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p>","ID":"955f32c5-f538-43b0-bc19-e197e345e573","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p>","ID":"c877cfd0-d8b3-460f-aed0-72649dea18a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"571e854a-630a-46d8-8536-1f862252be79","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"c597b300-3ac4-43e0-a095-24cc4b9f1e9b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"cc2db78a-3d61-402b-bffa-5638f5b2d1f1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).<\/span><\/p>","ID":"26dfccd4-2227-484b-ba5e-d3453a00f35b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reduction\r of blood pressure with 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and\r 4.5 mg\/kg (high) target titrated doses of irbesartan was evaluated in 318\r hypertensive or at risk (diabetic, family history of hypertension) children and\r adolescents aged 6 to 16 years over a three week period. At the end of the\r three weeks the mean reduction from baseline in the primary efficacy variable,\r trough seated systolic blood pressure (SeSBP) was 11.7 mmHg (low dose),\r 9.3 mmHg (medium dose), 13.2 mmHg (high dose). No significant\r difference was apparent between these doses. Adjusted mean change of trough\r seated diastolic blood pressure (SeDBP) was as follows: 3.8 mmHg (low\r dose), 3.2 mmHg (medium dose), 5.6 mmHg (high dose). Over a\r subsequent two week period where patients were re-randomized to either active\r medicinal product or placebo, patients on placebo had increases of 2.4 and\r 2.0 mmHg in SeSBP and SeDBP compared to +0.1 and -0.3 mmHg changes\r respectively in those on all doses of irbesartan (see section 4.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1c934512-cf8b-470d-a69b-69c3f979518e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p>","ID":"356dc886-3651-492c-9f1b-5ac77a375b40","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension\r and type 2 diabetes with renal disease","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p>","ID":"53c2cf7e-815a-4c8a-be27-a90c9ecb5d50","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg\r amlodipine, or placebo as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r > 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f72aa2bf-8578-4923-9f06-368374880541","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p>","ID":"c2e634b3-4bdf-4abf-86c7-67dfae558d84","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fb97e2bf-88a7-47c8-b86d-396158dc5419","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the\r placebo group (21%).<\/span><\/p>","ID":"79abdc67-bbb6-4fa8-b1cd-2b640816452e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r < 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) > 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (< 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the\r placebo group (21%).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"81fb3a79-2b2f-422d-a91e-8b1df0c679eb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p>","ID":"14d1c348-5922-45aa-90cb-916f1b5122cb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials (ONTARGET\r (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint\r Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have\r examined the use of the combination of an ACE-inhibitor with an angiotensin II\r receptor blocker. ONTARGET was a study conducted in patients with a history of\r cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus\r accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in\r patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p>","ID":"7837aed0-b13b-4665-8d6d-be8b69822d3a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Two large randomised, controlled trials (ONTARGET\r (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint\r Trial) and NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have\r examined the use of the combination of an ACE-inhibitor with an angiotensin II\r receptor blocker. ONTARGET was a study conducted in patients with a history of\r cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus\r accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in\r patients with type 2 diabetes mellitus and diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p>","ID":"539ded79-6122-49d0-9261-5f8d9ef6feff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p>","ID":"11df5216-acf7-45a9-9774-072c36409545","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p>","ID":"a795b90f-131e-44f2-a0ac-89263347df6f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"abff38f4-3570-45c5-bfd2-0615540458ea","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2055b71c-b57a-4a2e-a55b-a7579bbd7dee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p>","ID":"8ddefd9f-65aa-463e-9d63-cb956691c594","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"d0286c59-c825-404b-9582-1d0b13b394fa","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"ce09b2a3-986d-4ffc-a25f-17d442d5c6a1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Absorption","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"7e66f960-132b-463a-ac2a-257eae7714b9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p>","ID":"310a5f01-61a6-4e9c-bf26-c97db1316e20","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"003449f4-a082-442d-afb4-c101a39c794b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"a0158406-94db-4036-a0f9-802349c82c9d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Distribution","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"21e9c2f8-782e-460d-9ebd-d3108f4a0073","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. <\/span><\/p>","ID":"8146a7c7-d4e5-4865-acb3-e8cf6b6e0ee1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53-93 litres. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"dcbce9d1-3b29-41ea-88f0-8100fd03f64e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"84bc0a95-d2b9-4ae7-9b80-c9feb255141e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Biotransformation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"f00806ec-4f3d-42d9-9f3a-ba475d42d6ef","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p>","ID":"a1dc37db-9b34-4747-a7a7-59b3e5aec51a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following\r oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ee9ea88f-d9ab-492c-a64a-a1645cd67889","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity \/ non-linearity<\/span><\/u><\/p>","ID":"6e86f3a2-b9a7-4f3f-883a-85a4b50698aa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Linearity \/ non-linearity","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"16772269-b83f-49d0-ab6d-711dc889ac57","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157-176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of\r irbesartan is 11-15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan\r were observed in female hypertensive patients. However, there was no difference\r in the half-life and accumulation of irbesartan. No dosage adjustment is\r necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span>\r values were also somewhat greater in oldersubjects (\u2265 65 years)\r than those of young subjects (18-40 years). However the terminal half-life\r was not significantly altered. No dosage adjustment is necessary in older\r people.<\/span><\/p>","ID":"63b72fd2-74d9-4c43-ab79-5004a7bc4cce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at 1.5-2 hours after oral\r administration. The total body and renal clearance are 157-176 and\r 3-3.5 ml\/min, respectively. The terminal elimination half-life of\r irbesartan is 11-15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (< 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of irbesartan\r were observed in female hypertensive patients. However, there was no difference\r in the half-life and accumulation of irbesartan. No dosage adjustment is\r necessary in female patients. Irbesartan AUC and Cmax\r values were also somewhat greater in oldersubjects (\u2265 65 years)\r than those of young subjects (18-40 years). However the terminal half-life\r was not significantly altered. No dosage adjustment is necessary in older\r people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"659eb59c-6031-494d-bc97-51d32dd64f89","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"78ca2cbf-f2fe-454b-b637-0a84a434e17d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elimination","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"16e63389-e53b-46d8-a1f6-1a777a9e886c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p>","ID":"b76da548-f67e-4a8a-b11a-3965ed7bffa1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of 14C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7630602e-c995-4d4d-89ce-03abae8f2b7c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"b509df08-40c8-4f0a-aee0-0e4c64f2d41b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"50e00c80-ab24-468b-ac01-4f0a3de22da2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p>","ID":"1831957e-1c5f-4999-b179-2580803ece42","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3e647d33-f6aa-496b-bcb8-5210088f75ea","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"698feb47-e164-4fcf-87fb-2b47cb0fbe1f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f0d31650-d259-481d-a50f-46fd1827ec96","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"d97447dd-0319-4bcb-94b3-d1900d7b62fc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"17e49aad-d116-4023-8162-09e9f918f65f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><span lang=\"EN-GB\">:<\/span><\/p>","ID":"d6af440d-f7b3-449b-9559-a3f7d4fd741d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hepatic impairment:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"366eb4b8-4a06-4154-bb27-d8370361ae3e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.<\/span><\/p>","ID":"277d1976-4998-477a-ad6e-eadbeba378ca","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p>","ID":"fbff9d50-24d0-45c3-a505-bc48d917e5e5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Studies have not been performed in\r patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fed9a58a-2efc-4bec-8dfe-2acc383ade4b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p>","ID":"d45f5daa-d080-4790-b74e-965d3f1549e5","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3Preclinical safety data","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"65955967-b6b0-4470-88a9-6a506576e535","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p>","ID":"f7ad82f5-9ffc-4666-a9cd-c06c5031735e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0ef992b0-4eb4-4aee-b4a0-c6384632b29e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p>","ID":"e8bf8fe2-549a-4023-a468-3e2440fb07e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5703097e-c770-4653-8180-ce8f2a9169ee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p>","ID":"d9c326d2-fe42-4f1c-ba22-bfec4df152ab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c0df3956-a5cb-4c14-bd56-361968c00c26","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p>","ID":"1778c4e2-0c20-45fc-be89-3b3cc7f6daf9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"936b5d7f-0ff1-465e-b7c7-f45a7e6b9db1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c0694c6b-feea-482e-8808-b9ac21d3c8b3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p>","ID":"b63caba2-04d8-4ce5-a58f-6da581270646","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"e8c7f414-b07c-49ba-8a18-76c3b19e2032","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p>","ID":"22dd11cb-eefc-4b1c-90db-c091a6257a80","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"9c8e77b2-4603-463a-bb97-bf3826c17e9e","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Microcrystalline\r cellulose<\/span><\/p>","ID":"311d07d0-1d1d-4c1a-bee1-cda1f4e12728","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Microcrystalline\r cellulose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Croscarmellose sodium<\/span><\/p>","ID":"c4fd3b5b-6352-4a18-91b9-c275d91a0837","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Lactose monohydrate<\/span><\/p>","ID":"fca09c44-6db4-4ed8-840b-3a20327657f8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Magnesium stearate<\/span><\/p>","ID":"84f6b9f0-483a-42ba-a220-34ddb6ef3e64","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Colloidal hydrated silica<\/span><\/p>","ID":"7eba5fed-2a39-4376-99bf-4d196d30e4c2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Colloidal hydrated silica","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pregelatinised maize starch<\/span><\/p>","ID":"3f41d87e-0d08-4586-b5e0-7fd2d7aae25c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregelatinised maize starch","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Poloxamer 188<\/span><\/p>","ID":"7fd886b0-fa86-43e9-bb19-2c35be1a8a34","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Poloxamer 188","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"17e247f2-4ef4-498a-8927-99e3b12c6fce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p>","ID":"0e06558b-7fe0-4229-a4a9-fa700508d167","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"f7940a8a-4a64-4221-b3ca-f654c0ec972a","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r applicable.<\/span><\/p>","ID":"03b3f2be-b754-4ca8-94f2-46367e8fe903","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r applicable.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2cb804ce-f628-455e-be24-9bb8cf3148ca","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p>","ID":"d3283de6-8e67-4473-bbf5-406d3b308c52","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"28b39609-6488-4eb3-97a0-82c06f5fdd4d","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"4d4e4b66-a367-4e05-99d5-8a65dacd74fd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a96b5f30-be64-4407-8b7d-f4aa1296e7e1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p>","ID":"4777253e-75cc-4169-941d-5840b58d0688","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"3f9d7e91-f35a-49ba-bc5d-561b693fb085","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Do not\r store above 30\u00b0C.<\/span><\/p>","ID":"12b00403-31a5-4a0a-b8ba-e694ab249fa4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not\r store above 30\u00b0C.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6bbb6d76-6a43-4d06-9744-95f12051d920","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p>","ID":"e4ee9a21-ee33-437b-9aed-9d1e676f8d54","Styles":"margin-left:0in;text-indent:0in","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature\r and contents of container","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"6e6ba22e-ea1f-4977-85bd-bc9719f653bc","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"435bab49-bdd5-4a58-90b5-6bef71e53bf7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 14 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"4a43a786-4010-4b9e-b620-e91b949a1492","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 28 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"9fc341d1-ab0a-4b6a-aec5-b8b361f6dc5e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"cb835c0c-84d4-47ef-b1b2-0d9c45575d18","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 98 tablets in\r PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.<\/span><\/p>","ID":"8be2c0cc-a70a-4842-9824-44ac9a031ccb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 x 1 tablet\r in PVC\/PVDC\/Aluminium perforated unit dose blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"452d5b6f-a6a5-446e-bb5f-2ecdd87e18bf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"716a92f9-9b08-4a0f-8e3f-ddecd523c799","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"81f4c19e-687b-4829-b93d-c9f162db023b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p>","ID":"e4268ee6-d8cc-4cff-acbb-2af6dfcf14a0","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"1663f93e-bf29-46bf-ae0c-6fb65be0571d","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.<\/span><\/p>","ID":"9bc8e876-0b15-4b8e-877c-fe4f3ae25428","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any\r unused medicinal product or waste material should be disposed of in accordance\r with local requirements.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ace7bfd0-956e-4b06-9941-397dfc63c2e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3089b0cf-6d2a-434a-8043-04e8aa420153","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p>","ID":"35c906cf-fa63-4b19-8f91-7062db59ac52","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"23767fef-e5bc-47bd-9a92-821daa02e305","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p>","ID":"b0cefa50-ecd5-4a9d-9f17-71cd5464ea89","Styles":"None","Classes":"['EMEAAddress']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"sanofi-aventis groupe\r 54, rue La Bo\u00e9tie\r F-75008 Paris - France","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7203f727-f1ec-4c7b-9cac-dd75a588ce2c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ab9dd764-a70c-4ff8-9697-45049b96151f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p>","ID":"f646e262-ee37-40bf-91b1-53556881201b","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBERS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"593a3b30-90de-4253-9b18-023ee71c7630","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><span lang=\"NO-BOK\">EU\/1\/97\/049\/007-009<br\/>\r EU\/1\/97\/049\/012<br\/>\r EU\/1\/97\/049\/015<\/span><\/p>","ID":"6db3052c-3363-4f39-8be5-6f193f672c05","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/97\/049\/007-009\r EU\/1\/97\/049\/012\r EU\/1\/97\/049\/015","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"77bb568f-581b-447d-8996-4a443afdfb90","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1753c170-797c-4889-9147-2ff474907211","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p>","ID":"5bbdb942-76df-48d2-b7ec-36873d256586","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"4856692a-dda5-4887-ae18-dbdb8c5ec5db","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p>","ID":"af686c6c-3f0b-49d7-8f15-abb1e77bc015","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 27 August\r 1997\r Date of latest renewal: 27 August 2007","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"35ef02ea-b908-4631-ab28-4d165f870069","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"27685c93-fe98-4925-9a5f-b861ffaca7f4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p>","ID":"580e1991-f348-4c76-8d84-251308571070","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"448b9e9f-d802-44af-b2a7-31c2064feb61","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p>","ID":"b27a68a0-0ec0-42fa-a95e-501dcc740636","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><\/p>","ID":"e101e9e7-f0ef-4c53-93fe-0c4b0034f841","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"fde6be95-67cd-4d9d-9084-8941b47c637e","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"42e116f7-0779-43d5-8fa7-724cb4c302ea","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ntext-transform:uppercase","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"fde6be95-67cd-4d9d-9084-8941b47c637e"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"fac84352-edc7-4058-b86f-d1a02009820a","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"42e116f7-0779-43d5-8fa7-724cb4c302ea"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p>","ID":"a9cc96e5-2064-46ab-814a-e6566da5eaa3","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"11c4842c-cde1-4216-be4c-f49ff1df90a5","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated\r tablets.<\/span><\/p>","ID":"967e2083-4c4f-4ea8-b162-86198643a5b5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 75 mg film-coated\r tablets.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ac61985d-9ddd-475c-af0f-756c9e3763a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3b26eefc-4517-4b88-a7b0-2204e8927dba","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p>","ID":"87a39030-1198-404e-9af0-196d74ebc728","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"77e564da-f6c6-47ad-ac99-c2087b8ff5df","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each film-coated tablet contains 75 mg\r of irbesartan.<\/span><\/p>","ID":"2ab034a3-bc54-43f6-a818-e1946a0d6d1e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each film-coated tablet contains 75 mg\r of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1339caff-5204-43d8-b31a-b593f7533bd0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 25.50 mg of lactose monohydrate per film-coated tablet.<\/span><\/p>","ID":"fa9b83eb-d2d8-4517-b3f8-a23b2559a245","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: 25.50 mg of lactose monohydrate per film-coated tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"868facda-8859-40cb-8a6a-ee63676cec51","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p>","ID":"3f411786-9419-4c23-8bc1-fbaa46d16537","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see\r section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f94ff242-e2e8-4532-af81-e5c9870b6b79","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1d473d5d-a47d-42f4-9af3-a8da32c053e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p>","ID":"e2c355a7-e84f-4c20-9326-9e2cd148d26c","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"3a4e65ea-285e-400b-9219-5683888e2371","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Film-coated\r tablet.<\/span><\/p>","ID":"de84baa2-28d8-4312-96d6-f92ba8cab3bd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coated\r tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2871 engraved\r on the other side.<\/span><\/p>","ID":"84598fa2-a801-456c-95ab-d007a9dd9c66","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2871 engraved\r on the other side.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"14ad2ecc-3799-4ae6-94f1-ca09aa2b493c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"34c41a56-253e-4deb-b78c-f18e84405d93","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p>","ID":"f885b2d7-a3de-4ebf-bfa3-9145827fadfa","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"f1a7d007-6f2e-417b-91fd-f8fcaaed1785","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p>","ID":"4dbb2a2e-1f80-47ff-bfab-db3d61efe7e5","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"dd6c7e6e-3787-4ca3-9a84-eab10e060328","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p>","ID":"16f1b673-afab-47f6-9ced-221b213602ae","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea is\r indicated in adults for the treatment of essential hypertension.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"c44ea645-baf3-414f-91a8-1021ad7e1d8d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0d443823-c6dc-4729-b75d-e4c6be675672","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p>","ID":"7f91f14d-ef5b-4fb4-b2e6-1e7d4fed18ab","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and method of\r administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8290798e-d1d0-410f-a0e1-e0cb0b2123d7","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"c7fef31f-3f58-4202-a5cd-bf3572bb1a31","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"a90f6b87-4bc0-4a6f-a04d-9290fc277ab1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p>","ID":"b9bbbe3e-aeca-4fc4-960c-dd14bee5a31c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e5a3de50-e769-4d47-bc56-86bbe76bfe9f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p>","ID":"f0aa7d87-aecd-41df-acff-258e00125e0c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ce4c5009-0e48-4f32-b85a-1509ecb0fede","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p>","ID":"00956443-921b-4bd8-ac5e-0d90bd4c8422","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"60f5b8db-c281-4b22-afee-639932168af2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f707d6e6-2a8a-4a5c-b295-cce90b484a95","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p>","ID":"073087d3-be30-42e7-b52e-ceb42eadf781","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special Populations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"4cef3419-7d7d-486a-adfd-8770b48db3ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"0025ef7d-c17a-4dfd-9191-0cbc61d8e534","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1a2f9ae8-ef23-4562-bc7f-a6b4931be2d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p>","ID":"5965e498-24de-4289-aeb8-5d9e80bf54b0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8b98f9bd-a2e4-4e75-b889-a29440eaadbb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"b528498b-ecf9-4e96-be41-ac8ff4f5907f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0a24667e-b0e1-4557-a678-9714bf17a4fc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p>","ID":"2a476353-9354-4693-b064-40a8e2b754a5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"574439f6-c6dc-4835-a6f5-ca1244a18085","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p>","ID":"21b9837e-acdc-4b1f-96c4-df1adb2e2e6f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Older people","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"672209c9-ad29-4617-9e1b-638f975d550e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.<\/span><\/p>","ID":"7b8b0be5-a250-4c77-acde-71abf882222d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary for older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"970f9ca4-498a-4e46-ac07-9844b1dbc7cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"9b5c2193-30c5-447f-877c-3544cdab608a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dc569fa7-7493-4c5c-8cbf-ef6f3f1fa597","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be\r made.<\/span><\/p>","ID":"ab7178fe-80ae-4008-8a73-7135743a0375","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can be\r made.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2160d9f4-e9d4-4032-92be-0359af70c1a5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p>","ID":"258b3857-f4cc-433b-8a43-d0a47667e4e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of Administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"87922975-c5f0-4624-809e-00e71648a925","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"85cdf1aa-71d7-4dc5-bf4c-0fe8a63c6511","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For oral use.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3f0ebb0d-4c5c-4fd5-89a2-7a22f2e48349","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p>","ID":"702ea1d6-2745-4910-8200-afdf063e6499","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"85a882ba-2e8a-4d3d-b429-384ebc966bc7","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"2eed389b-d998-427b-86dc-243f0cb441df","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p>","ID":"c298affa-2fb6-44df-8e6e-e553f8086e40","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f5de70cd-694d-4389-84c7-6ab2dcc5773c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\"> The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p>","ID":"a7dce059-9d92-4c08-b20d-a36581ae938e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) <60\r ml\/min\/1.73m2) (see sections 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"aac83cb9-ca20-4857-b46b-9e26225318da","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p>","ID":"364c768a-e54f-4aa4-9f14-c8c40d5eb119","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions\r for use","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"b41474bf-a3eb-4096-8e70-de46be243b19","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p>","ID":"9c3a413b-94fc-4ed2-8c27-320e8edb9afb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Intravascular\r volume depletion: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c1df5f32-c2a7-450c-bcf7-80a988546363","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p>","ID":"b07a5178-55f0-4f70-b515-fdf26da758ea","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renovascular hypertension: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"31ede132-bd25-45b5-ae9c-bd88d6e6e043","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p>","ID":"6dd1f36d-c42c-4994-b3a6-4c5e05bd24f4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment and kidney\r transplantation: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cbabea13-23fc-4362-ac3e-058b9c4db895","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p>","ID":"22b29779-a4fd-4e01-ae90-790c1499bbb2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypertensive patients with\r type 2 diabetes and renal disease: the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9f0517ed-8172-4c1d-b1b1-d91779ef6a88","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS):<\/span><\/u><span lang=\"EN-GB\"> there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p>","ID":"2cea5936-0e9d-46c1-9aff-6cd5031d9341","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"372162da-e757-4908-920c-95b5084f0857","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p>","ID":"f0eb4a01-65b3-435a-9c0c-288115002105","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hyperkalaemia: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b67677e6-5ed5-40cc-b0a1-ea266955f806","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia: <\/span><\/u><span lang=\"EN-GB\">Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p>","ID":"fa43885e-4873-4c82-b127-cd00642c87f6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In\r patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"42a44473-5ab2-498a-a671-7fa68b37916c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see section 4.5).<\/span><\/p>","ID":"00c1c109-74d9-4a96-bb56-eab41f99d685","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:\r the combination of lithium and Karvea is not recommended (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"29a83d7b-bba9-486a-8d19-beea81ec1d6e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p>","ID":"1a750e26-f5fe-419d-8ccf-6037253ebee5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ab844767-1a1c-4ffc-bec7-7fea4e1c51ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p>","ID":"44dbbe42-34f1-4534-92cf-36481257a45c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Primary aldosteronism: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0453d47f-3b81-4e0b-b793-4eb060e1e88c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p>","ID":"e80e2359-1143-49ef-965d-c3e809680942","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently\r less effective in lowering blood pressure in black people than in non-blacks,\r possibly because of higher prevalence of low-renin states in the black\r hypertensive population (see section 5.1).<\/span><\/p>","ID":"c0ebb14f-14f1-4faa-a586-ee8c2c4b3454","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are apparently\r less effective in lowering blood pressure in black people than in non-blacks,\r possibly because of higher prevalence of low-renin states in the black\r hypertensive population (see section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ff943f7e-64ad-419f-9e31-bc58b05a59b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p>","ID":"fc815cdc-c705-48be-90fd-5f7c9c03cb6e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b4595ef7-84a0-4216-a26b-600719dc465e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p>","ID":"60a5f015-72e5-4a1e-897f-4e654f745a3a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c740f79a-52a4-47c3-b77b-58dcaa913ba8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p>","ID":"3887cb75-219a-4625-924f-0b8b76f0d274","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipients:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.<\/span><\/p>","ID":"437645a1-251e-4846-9969-52fb9b3350f4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 75 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0f638dda-ce33-43d7-8712-ad3ef8a54fc7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 75 mg film-coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p>","ID":"c8505977-f671-42ab-9def-df1feed7cd8a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 75 mg film-coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c8dca780-7694-48d6-b1f6-86076b14ad7b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p>","ID":"7c222525-fda1-4bbf-990a-5fe961e151ba","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal\r products and other forms of interaction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"0d87729f-5256-4188-a6d9-0e165e1f952f","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).<\/span><\/p>","ID":"7bdd497c-fad4-4750-ab9b-b357d0513510","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Diuretics and other antihypertensive\r agents: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3b7115c8-3eb1-4533-95d2-201f33710b8e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is\r associated with a higher frequency of adverse events such as hypotension, hyperkalaemia\r and decreased renal function (including acute renal failure) compared to the\r use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<\/span><\/p>","ID":"107b31a0-0dac-40c2-8973-f26072f71c8f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aliskiren-containing products or\r ACE-inhibitors: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is\r associated with a higher frequency of adverse events such as hypotension, hyperkalaemia\r and decreased renal function (including acute renal failure) compared to the\r use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a9bec2d4-82ec-4dc1-9de1-f3b0f5e757cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dbee614c-5368-4200-a438-49ccc943a73b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p>","ID":"fdb9af04-547c-4ff0-b3f5-6381e287eece","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Potassium supplements and\r potassium-sparing diuretics:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d0ccaf95-b20a-480d-a873-51fc09f7b7dc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p>","ID":"0f7efbbc-184d-410b-b87e-fe9873e0e6be","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"58878ed9-e33e-4322-a4f1-351a9b4b5937","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective\r COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p>","ID":"be548f12-24ce-4ccf-ba36-03fc4a9a83c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e. selective\r COX-2 inhibitors, acetylsalicylic acid (> 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.<\/span><\/p>","ID":"7e67efd0-c5b7-4d40-8846-52648004be57","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As with ACE\r inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may\r lead to an increased risk of worsening of renal function, including possible\r acute renal failure, and an increase in serum potassium, especially in patients\r with poor pre-existing renal function. The combination should be administered\r with caution, especially in the elderly. Patients should be adequately hydrated\r and consideration should be given to monitoring renal function after initiation\r of concomitant therapy, and periodically thereafter.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1b6f52d3-05e1-4626-b253-d18843d3225f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p>","ID":"22451de7-6f09-4a19-8d1f-fe6e4afc25cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Repaglinide: irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the Cmax\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bdfb89e8-267c-4c4c-a2ba-daa8b23e5799","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.\r No significant pharmacokinetic or pharmacodynamic interactions were observed\r when irbesartan was coadministered with warfarin, a medicinal product\r metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the\r pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of\r digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p>","ID":"1ec2c81e-b1f8-4d9a-bb37-452673dc1769","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Additional information on irbesartan\r interactions: in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.\r No significant pharmacokinetic or pharmacodynamic interactions were observed\r when irbesartan was coadministered with warfarin, a medicinal product\r metabolised by CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the\r pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of\r digoxin was not altered by coadministration of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f3da918d-1a85-4d2d-a0ff-017bb5516005","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and lactation<\/span><\/p>","ID":"a2004cb8-9959-43bd-9e2b-a1cfeb5ab1cb","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"2518de7a-44ed-4387-b420-f7aa06a19796","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"91cb3555-2efa-417b-851c-6c8491e9c77b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"dace7825-65db-4509-8e48-67136ba2acf5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of\r pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div>","ID":"fec82394-8c9f-4b46-8523-6e7b6aa6e013","Styles":"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":true,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"  ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of\r pregnancy (see sections 4.3 and 4.4).<\/span><\/p>","ID":"c0df19cf-660e-444a-bccf-61a1cca8863c","Styles":"border:none;padding:0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of\r pregnancy (see sections 4.3 and 4.4).","ParentId":"fec82394-8c9f-4b46-8523-6e7b6aa6e013"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8531652b-b486-491b-9097-5a3da500760a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p>","ID":"455ac6a1-e189-4d98-bfde-6ae45cbdd7c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f7403b79-a98a-440a-bc45-e9ab33bbddbd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p>","ID":"903f5e60-3a26-4877-8a30-ce036d3e5f73","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred from\r the second trimester of pregnancy, ultrasound check of renal function and skull\r is recommended.<\/span><\/p>","ID":"3b16f773-e59c-4e22-aadc-906c95fff46a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Should exposure to AIIRAs have occurred from\r the second trimester of pregnancy, ultrasound check of renal function and skull\r is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p>","ID":"d07b8944-7bfc-440e-a441-f50d669b78ee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"4a77212a-32c6-4722-aa06-3d6dc793dd43","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"da804620-342f-4163-bc75-be5b345012bb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"77983347-5715-4bef-9745-7c137258a9d4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available regarding\r the use of Karvea during breast-feeding, Karvea is not recommended and\r alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p>","ID":"a8e044b0-1a28-4c3d-938a-6cf7e8eff269","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Because no information is available regarding\r the use of Karvea during breast-feeding, Karvea is not recommended and\r alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5db4ab0a-a582-4678-aedc-2e823ab47336","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether irbesartan or its\r metabolites are excreted in human milk. <\/span><\/p>","ID":"35cc69e9-a3d6-4470-990c-b10cb89f2781","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether irbesartan or its\r metabolites are excreted in human milk. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).<\/span><\/p>","ID":"d724414f-3c9c-46ac-8582-f578ac98c5b8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"501ea258-28be-4d0f-b0ac-33a9b2aaff53","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"192049c1-5a22-42dc-95f4-eb8890110ec4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"11a935ec-0a34-465c-b95b-cb16656c8678","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). <\/p>","ID":"caa69dc1-c0cc-4be0-ae92-9c076d6ec3b9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"53a6006e-aa3c-48b2-ab1a-d698948555e8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p>","ID":"84974d8e-2c6c-444f-9137-4a6a00268001","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and\r use machines","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"709b5e8f-de28-4c9e-9109-979841d4a780","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Based on\r its pharmacodynamic properties, irbesartan is unlikely to affect the ability to\r drive and use machines. When driving vehicles or operating machines, it should\r be taken into account that dizziness or weariness may occur during treatment.<\/span><\/p>","ID":"a593f122-fe39-453d-8d64-b098204b2e2d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Based on\r its pharmacodynamic properties, irbesartan is unlikely to affect the ability to\r drive and use machines. When driving vehicles or operating machines, it should\r be taken into account that dizziness or weariness may occur during treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dacdd322-bc6f-4b62-9a75-51f9f2d64c00","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p>","ID":"6f965c5b-632b-4e6a-8f75-ab80a10ff75e","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8a8ab1d2-f7a6-40cd-9649-6cb5e88f7fe3","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for\r irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).\r The incidence of adverse events was not related to dose (in the recommended\r dose range), gender, age, race, or duration of treatment.<\/span><\/p>","ID":"b396751d-4801-419c-9faa-7a1699f684fb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for\r irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).\r The incidence of adverse events was not related to dose (in the recommended\r dose range), gender, age, race, or duration of treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"01d2a776-1951-4e3c-a0a9-b5597d19f64c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with microalbuminuria\r and normal renal function, orthostatic dizziness and orthostatic hypotension\r were reported in 0.5% of the patients (i.e., uncommon) but in excess of\r placebo.<\/span><\/p>","ID":"615bcf95-d5a3-40f6-9489-12498ab4fbb4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In diabetic hypertensive patients with microalbuminuria\r and normal renal function, orthostatic dizziness and orthostatic hypotension\r were reported in 0.5% of the patients (i.e., uncommon) but in excess of\r placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5ee2ee71-09f3-405e-a35b-b7f5c527b0f5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p>","ID":"7b4fe5ba-bf3d-428f-ac10-ddc7dc83d896","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in > 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4e543862-cbbc-49f9-b30a-017aed65d69b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p>","ID":"2a693d48-04c8-4f02-861b-ddd439a94ce4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The frequency of adverse reactions\r listed below is defined using the following convention:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p>","ID":"8af871d2-3544-4ea2-bf40-bca978e0e9b2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"very common (\u2265 1\/10); common\r (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to\r < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare\r (< 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e61fcebe-eef6-485f-9bf7-dffd6af6b0c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p>","ID":"bd0a8337-045c-43df-a601-2a63c2126465","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"180039ac-cb5c-430a-a117-9f15158339d4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p>","ID":"8ad8636d-d650-4fef-a104-1cd3c57abe51","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Blood\r and lymphatic system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p>","ID":"809f2e14-7819-48e9-87d6-ba09c557d66f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       anaemia, thrombocytopenia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"8a11243e-3fcc-4c9f-8084-b470dd046023","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p>","ID":"6308f967-af25-4c3d-ac88-526f884dc75e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Immune\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p>","ID":"be8301a4-876c-4b19-8300-ccae03dd7a0b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"0cbc45ea-de04-4bea-a438-78646c41d261","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p>","ID":"0b6b0855-9b67-4fd9-a914-3048d2ab482e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Metabolism\r and nutrition disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p>","ID":"065216c0-2d84-465b-a1b5-ce0b01653dfc","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hyperkalaemia, hypoglycaemia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"34e551a8-7b29-4e13-80f5-ede2b5a4164e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p>","ID":"c7883cd5-a8ca-4482-853f-ec6929f88e87","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Nervous\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p>","ID":"e6a71539-86a0-4a73-8d29-d711ea51fbe3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         dizziness, orthostatic\r dizziness*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p>","ID":"68bd9e8b-7875-4d84-bb34-1402cf8f4157","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       vertigo, headache","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"026637c5-29ac-4e37-9994-c56dabcce516","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear\r and labyrinth disorder<\/span><\/u><\/p>","ID":"aacb6031-0ff2-4e56-91fb-ad03ed6db23f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ear\r and labyrinth disorder","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p>","ID":"a2cccbc6-f642-4925-b53b-fa2ed08bdf58","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       tinnitus","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"2b6b2002-0b5e-4ac8-b695-c5a893d7e33a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p>","ID":"b3ea1bf5-6f38-4380-8bfd-46641ed21cd3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Cardiac\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p>","ID":"e5b27a98-6a49-412c-854a-be69a33d4bf7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      tachycardia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"534b0807-641b-44eb-afe8-25359f626f48","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p>","ID":"6f83f63c-8a31-479d-beb5-fb418e0143b1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Vascular\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p>","ID":"ec360d12-2a82-4c77-abe7-d03bb30bafb7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         orthostatic\r hypotension*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p>","ID":"86a7c013-d68b-42f5-a74f-2892918cec1e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      flushing","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"171964bc-e59d-4b7e-8e1f-50ceaeb97e69","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p>","ID":"068fb1f8-2fe6-4f9e-99f0-408341d31c50","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Respiratory,\r thoracic and mediastinal disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p>","ID":"559d2100-5705-4a24-a15f-0a58f14f2f34","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      cough","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"26011864-7af0-45ea-a7cf-559a266c62d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p>","ID":"26bc469e-ca59-4f2d-9c7b-98afe975d167","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Gastrointestinal\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p>","ID":"5e04c35b-1ad1-4922-a3c9-8906449f287d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         nausea\/vomiting","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p>","ID":"831130f7-bdc5-4a5c-82c2-d8739b41c455","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      diarrhoea,\r dyspepsia\/heartburn","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p>","ID":"3bf04f76-d38b-4fc5-85aa-3a6fc7abf07c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       dysgeusia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cf329463-c2b8-4bb2-b814-0e9170439d30","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p>","ID":"9b3f544b-4fc2-44eb-bc75-9c8397244a1d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatobiliary\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p>","ID":"fe49ebbe-29ef-42fa-a682-ec194ac06103","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      jaundice","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p>","ID":"9ae8d184-d7c3-45e2-98c3-70eb7b4675c8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hepatitis, abnormal liver function","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"6face92d-3dc5-4bd0-a69f-9a670b3b4232","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p>","ID":"031fc9d9-1fee-46dd-bbdf-07f790a93804","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Skin\r and subcutaneous tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p>","ID":"aabcce56-be7f-4ec7-ac85-857ab5769631","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       leukocytoclastic vasculitis","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"c9c4255b-9cec-4546-9ae6-b0fb35c51942","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders <\/span><\/u><\/p>","ID":"b159c942-eb65-445b-9b47-acbe37224b27","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Musculoskeletal\r and connective tissue disorders ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p>","ID":"be1c9ebd-bea4-4d6b-ae9e-146ccb73a5dd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         musculoskeletal pain*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p>","ID":"47c4581a-0125-477f-afd1-f9c499ea2977","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"06b4e6d7-cfdc-4b46-a219-b625608abe80","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p>","ID":"f89bfe9c-33e8-412e-806f-10d9ded8c820","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal\r and urinary disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p>","ID":"173c534a-a8aa-4fc3-9a86-cdda9a1b658d","Styles":"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r\navoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dffd703b-de56-46f1-830b-e8de4fe16c10","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/u><\/p>","ID":"87579ac4-d220-4c86-b3a0-bcda01e04582","Styles":"text-align:justify;page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reproductive system and breast disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      sexual dysfunction<\/span><\/p>","ID":"2ee25bd8-a594-4afc-b5f1-89fd384998c5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      sexual dysfunction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><\/p>","ID":"77ebee49-f05f-405b-ad40-38b2795d625e","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p>","ID":"5a6b7b50-fa1f-47a7-925d-7bda2f917355","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General\r disorders and administration site conditions","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p>","ID":"98f89356-353b-47f2-a5a6-7a7c3358af63","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         fatigue","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p>","ID":"2b210d4f-f08a-4869-8ba1-a61812d779c0","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      chest\r pain","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"8c00b433-8272-49bf-88f7-236c6572a5a6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p>","ID":"9d84d5f9-25fe-474e-aa93-48ab513a6030","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Investigations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p>","ID":"da15dd3a-d201-4be1-a224-8bad23afc08d","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p>","ID":"af6ea4dc-4a5b-4a24-b004-f7aa3303b3e6","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"c016dd74-b5e5-4376-b3f4-04a66311c7ad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"e270b835-064d-4766-9c58-af0bd3ef3ea4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">I<\/span><span lang=\"EN-GB\">n a randomised\r trial of 318 hypertensive children and adolescents aged 6 to\r 16 years, the following adverse reactions occurred in the 3-week\r double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),\r cough (0.9%). In the 26-week open-label period of this trial the most frequent\r laboratory abnormalities observed were creatinine increases (6.5%) and elevated\r CK values in 2% of child recipients.<\/span><\/p>","ID":"8d226029-0b19-4e51-8fa5-e078cec3132a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In a randomised\r trial of 318 hypertensive children and adolescents aged 6 to\r 16 years, the following adverse reactions occurred in the 3-week\r double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),\r cough (0.9%). In the 26-week open-label period of this trial the most frequent\r laboratory abnormalities observed were creatinine increases (6.5%) and elevated\r CK values in 2% of child recipients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"08b8b51d-4f6f-4c97-862a-52909970a98a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p>","ID":"9f975df7-34ad-4258-857e-8baec9d1a257","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse\r reactions ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p>","ID":"b795d6f3-9d86-4d35-aa93-5be8520167f0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5459b763-74fd-4707-a55a-03455da2c138","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p>","ID":"79455521-0201-4d12-a96f-a64204db275c","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"b9ac78d3-c6ea-4535-a9fc-50c832c42129","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be\r hypotension and tachycardia; bradycardia might also occur from overdose. No\r specific information is available on the treatment of overdose with Karvea. The\r patient should be closely monitored, and the treatment should be symptomatic\r and supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan\r is not removed by haemodialysis.<\/span><\/p>","ID":"e49b09d8-0098-43e6-b5e3-85e0f76b4c30","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be\r hypotension and tachycardia; bradycardia might also occur from overdose. No\r specific information is available on the treatment of overdose with Karvea. The\r patient should be closely monitored, and the treatment should be symptomatic\r and supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan\r is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3addb5e2-357f-457b-9ef0-254f0df8b72f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"cf5ec09c-0190-4ac6-8cce-80fa7fedb583","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p>","ID":"86f6cbeb-311b-4b3f-a30e-0d24504e29eb","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"b00ef369-1a8b-462b-9a1a-aa95b6e6d8ca","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p>","ID":"90b1f83a-a67b-431c-a054-cf6d7f089dd5","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"76112de5-aed9-40e5-9901-531b3f8b9fd9","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.<\/span><\/p>","ID":"d8891b62-1428-4850-8ae9-1125e55fe779","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ATC code: C09C A04.<\/span><\/p>","ID":"b13e51dc-3241-4a11-9d94-8aaffcf7dc01","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ATC code: C09C A04.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f3ca6620-1fa3-4f3d-b886-27104f6ac095","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"0b8ae660-0218-4d0e-85a8-14288ffe2730","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"06031582-854a-4ae1-a994-05de8e0431d8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.<\/span><\/p>","ID":"0aa1328a-c103-48f4-9c32-122d3d05df3e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT1) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT1\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT1) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5a135356-7d25-4ab3-ba5b-48a606d06890","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p>","ID":"87513c3e-c496-42e4-9e21-82238d10fc3d","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clinical\r efficacy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"75a42b83-22e3-43a4-8956-92ba2d91b150","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p>","ID":"c2c5171b-a4e3-4c6f-9fbc-73cce5e479c4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with\r minimal change in heart rate. The decrease in blood pressure is dose-related\r for once a day doses with a tendency towards plateau at doses above\r 300 mg. Doses of 150-300 mg once daily lower supine or seated blood\r pressures at trough (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.<\/span><\/p>","ID":"def194db-7cd4-477e-866e-2d271a80af06","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan lowers blood pressure with\r minimal change in heart rate. The decrease in blood pressure is dose-related\r for once a day doses with a tendency towards plateau at doses above\r 300 mg. Doses of 150-300 mg once daily lower supine or seated blood\r pressures at trough (i.e. 24 hours after dosing) by an average of\r 8-13\/5-8 mm Hg (systolic\/diastolic) greater than those associated\r with placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p>","ID":"99f30e19-be8d-40a7-97b7-bc304f853bfe","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood\r pressure gradually returns toward baseline. Rebound hypertension has not been\r observed.<\/span><\/p>","ID":"2a48762a-b6f8-4fd0-aea0-bdf030939766","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood\r pressure gradually returns toward baseline. Rebound hypertension has not been\r observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p>","ID":"72e22893-cf65-423f-b584-cec2336cfb95","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of\r hydrochlorothiazide (12.5 mg) to irbesartan once daily results in a\r further placebo-adjusted blood pressure reduction at trough of\r 7-10\/3-6 mm Hg (systolic\/diastolic).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p>","ID":"df4a7f8f-c741-469b-a76c-ecbd729f8564","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p>","ID":"de8e3480-9288-44ba-a379-ac14dedb850d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"01e690a8-8f27-4f43-a585-fbb3446b3aaf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"50575678-b0d5-4891-93da-4d8d47c9a053","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"624deaa8-f547-4d8d-88af-18f1d8daabb6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk\r (diabetic, family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean\r reduction from baseline in the primary efficacy variable, trough seated\r systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg\r (medium dose), 13.2 mmHg (high dose). No significant difference was\r apparent between these doses. Adjusted mean change of trough seated diastolic\r blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg\r (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period\r where patients were re-randomized to either active medicinal product or\r placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP\r and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on\r all doses of irbesartan (see section 4.2).<\/span><\/p>","ID":"57d784d8-075b-4a5a-bdc2-8df0185de2f9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk\r (diabetic, family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean\r reduction from baseline in the primary efficacy variable, trough seated\r systolic blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg\r (medium dose), 13.2 mmHg (high dose). No significant difference was\r apparent between these doses. Adjusted mean change of trough seated diastolic\r blood pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg\r (medium dose), 5.6 mmHg (high dose). Over a subsequent two week period\r where patients were re-randomized to either active medicinal product or\r placebo, patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP\r and SeDBP compared to +0.1 and -0.3 mmHg changes respectively in those on\r all doses of irbesartan (see section 4.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5a7d85c0-e111-4d2d-8980-eca8648ce51c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p>","ID":"b3015769-a319-4a7f-b5df-537ab356d511","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension\r and type 2 diabetes with renal disease","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p>","ID":"9ffde506-88a8-41b1-b002-ae95fcc99d41","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg\r amlodipine, or placebo as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r > 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6638ff27-7f12-4e3b-ab83-ceae119075de","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p>","ID":"8164533b-ca72-4997-bafd-391b7baaacf7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d0f3db84-1962-4762-9e06-6667e0996fd3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the\r placebo group (21%).<\/span><\/p>","ID":"010a4303-e279-4e9c-b143-30291ba488cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r < 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) > 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (< 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the\r placebo group (21%).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c0dc8f08-f922-4e7c-87b8-439616497fc9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p>","ID":"a2755ba6-e94a-4d5b-a664-d10110984101","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p>","ID":"43b7d104-4e8a-49e0-b90e-7dfc62ea5814","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"129efacd-40ed-44e1-aecb-aef28e21ca14","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p>","ID":"4f669ab3-e585-47a8-8d95-558ae5ccbd3a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p>","ID":"35e195d4-fb9a-4d9e-8da8-a69558ed8843","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0c40ac47-f816-4b95-96ce-f6b5efab462b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group that in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p>","ID":"f8eacdab-9230-49e8-97ca-fabd6b7fac08","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group that in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2f9e4cd3-4c44-4615-9400-4a7421c18b55","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4258c4ed-e419-449f-b9cf-d16987c3dd28","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p>","ID":"8adfb5a7-67d7-4e1f-9f04-3187c68be1f9","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"cf0f73f0-ee7e-43dc-b5e0-5b6592adf21a","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"0441306f-8a54-49cd-9457-13742c2f5bef","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Absorption","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"2e3203a0-8d7c-4efa-894a-600a9044132c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p>","ID":"6147655b-65c3-497d-9fb3-6739be06b8a3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"c2c4d995-c085-4232-bb66-1b857a7d2612","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"59a6095b-c5d3-4730-852f-f04112dde301","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Distribution","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"5ad69c74-1edc-4fc7-b2c0-86ce98a9137e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. <\/span><\/p>","ID":"b247e4df-84d5-45b5-b4a7-3e800810654d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"8f22e030-3968-4d04-9647-0a822acaa5fd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"24b5bb19-07ab-4ebf-baac-64abf63aec96","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Biotransformation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"db62c6ce-2293-4cfa-9852-80056eccd008","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p>","ID":"be122997-26d3-4f03-aa17-86730df711df","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following\r oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5fb61e49-4d4a-4f9e-8d90-2048c2fbba5f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity\/non-linearity<\/span><\/u><\/p>","ID":"14a3d4c6-fb37-48bc-be65-92f3e2f6006e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Linearity\/non-linearity","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"111d4af3-f144-403c-a9c8-5738222bb94e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.<\/span><\/p>","ID":"803b48b6-ef8c-46a3-9253-0079c36bd652","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (< 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2a4806e5-a189-41ec-9c46-47a7d99ead48","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"67576db8-6216-4c9b-977a-6f7ffe8bdb20","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elimination","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3d5f7c7e-8cb8-4159-a47f-4285ffa159e7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p>","ID":"53b28393-e76e-4dc4-95d5-1933977f758f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of 14C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b9554d6c-9626-400f-89f9-72626902609d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"638121b6-47a4-44e4-af28-67f77f4f9a3a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"6bb7dc44-2cb7-4e43-a0a2-c0a44c766ce4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p>","ID":"98b50c67-eb11-4598-b2fb-6cff32022a8f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a28197b2-1074-4160-866b-f5b87dcb3419","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"02e6122b-a0c4-4ed6-89c9-b3b046b74281","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a377d6b7-ada4-471a-82a8-146d81458402","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are\r not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"37360e92-ae38-492a-ad32-b336685624a9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan are\r not significantly altered. Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9cd9d816-c06d-4065-a9cb-af5dfe951937","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p>","ID":"1ffc0bcc-a634-4473-a9c2-73cdc94faa44","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ecabb13-7222-4908-bcc6-89099c5be2ab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. <\/span><\/p>","ID":"c3b63099-7584-4365-bb73-58c69ae4b5c2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in patients\r with severe hepatic impairment.<\/span><\/p>","ID":"146bf1fb-d8da-4fc4-b2c4-6c9edd44322b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Studies have not been performed in patients\r with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c3ec7999-d84e-4281-912c-41351c5f76f7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p>","ID":"7d40b51c-522b-4a81-baaf-98a9bec381c4","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3Preclinical safety data","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"2bb8d165-49ba-48c1-9071-455db7e1b738","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p>","ID":"3491c9a8-e96d-4e99-9309-a5c57e70648c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"65badf65-b01d-4347-a49a-e9aae960d00a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p>","ID":"f3aa64bc-f856-46c5-ad9c-8700f7e359f6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e969565c-44d9-480b-8cc9-b09be4a5ff00","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p>","ID":"7b93113f-a593-4151-ac10-5a8ddf81761b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"69b3493a-2b07-4bb9-be29-d6e78dbe1064","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p>","ID":"32e19259-b773-4d71-adc1-669e88e91863","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"57d214bf-f88a-4189-be18-46f7d988d398","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"31001adc-2eee-4c98-aaf9-7b742ba43295","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p>","ID":"c0dd7129-e760-4225-a53b-78406acebd18","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"f0ec3326-77e6-4cbf-8fac-081a5d85e597","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p>","ID":"a1366f5a-896b-4c81-b201-ffdeb18e470d","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"e5f736cf-111a-4ea0-abe7-9949798417cb","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet\r core:<\/span><\/p>","ID":"07d6b4e5-b0da-4112-88f7-ecedc65afc6b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet\r core:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p>","ID":"e5f72fb8-8d13-4563-a481-449f8ec2589b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Microcrystalline cellulose<\/span><\/p>","ID":"18598c82-0714-4665-bf9b-ad8c13cea386","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Microcrystalline cellulose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p>","ID":"eb7cfba8-1539-4c93-9d7c-63845092ca97","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p>","ID":"c2ffd4df-82b1-4abe-896a-63eec9e00f30","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Silicon dioxide<\/span><\/p>","ID":"5de3ad3f-7da5-4370-8952-28171139f79c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Silicon dioxide","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Magnesium stearate.<\/span><\/p>","ID":"045366c0-0058-4598-b0a3-8e9f13fb7e90","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8d1c6cdf-a496-4d16-9998-1e7fa6205f6c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Film-coating:<\/span><\/p>","ID":"2915a129-f6a3-478c-9ad9-a4d2b5ce8bea","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coating:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p>","ID":"1fe82853-9ea0-40e6-a477-ae72686f52c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p>","ID":"ef191d48-5d0c-4d70-9609-ebcfcd0f5167","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Titanium dioxide<\/span><\/p>","ID":"30c56f78-10bd-420d-9a45-df6221ad52f1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Titanium dioxide","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Macrogol 3000<\/span><\/p>","ID":"4f679b16-7327-4442-92e3-690aa53576a8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Macrogol 3000","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Carnauba wax.<\/span><\/p>","ID":"3fa26dee-6a34-48df-8fe7-3dd84e59c68a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Carnauba wax.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dd9f3ab0-f3ec-447a-bf4f-50dfccf7153e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p>","ID":"02732c21-26f9-4a49-932c-349315310916","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"277c0c01-eb4e-4e75-97d5-fcb5652d2484","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p>","ID":"e77bf4fa-aec6-4839-8c69-f84338f23de7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not applicable.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5c1e4147-10dc-4040-a884-736d16c91165","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p>","ID":"4c62079e-dfaa-4eae-b328-9995a8a6f01b","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"bbc55812-1862-42d3-ad39-aeec3793d832","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"d06cd899-0d07-46e4-8f4a-0fb5fce88eaa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"12171025-5dfb-4c47-89a7-796c15a91068","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p>","ID":"094254c6-d213-4c05-9235-b2798dfa0065","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"9ae2c3c4-ec13-4a42-8698-d4a529500089","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p>","ID":"e3dc14ad-a8a6-45f4-b544-1cbac5879a0e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not store above 30\u00b0C.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6abdb548-7dcd-467e-8eaa-0ecf88b7ad1a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p>","ID":"3b2330e1-1f73-411c-931a-ff8488382aec","Styles":"margin-left:0in;text-indent:0in","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature\r and contents of container","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"0673ed14-0914-49da-bca2-ad0c9c5ac7d2","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"a0bab8d9-79c6-4ac6-ab09-d1d9cd8b267a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 30<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"56712ef3-5c90-4b18-9727-c4e5bb42c162","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 30\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"009cb311-e13b-4c81-9ebe-b33464912091","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 90<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"05edca71-dc41-4a9b-a8ba-747a05eba305","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 90\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.<\/span><\/p>","ID":"94105683-a3b8-4cec-a044-ce9fcd124abb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fdd1e807-498a-4ad2-9675-34ecdc1a8924","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"2155f9f3-ed7f-4a84-9521-cf8a57122b1d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8460a900-30ef-43bf-bf21-47b396bdec45","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p>","ID":"987b4227-b2c7-43ab-aa4f-a8115a7379ca","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"a1c1423c-3197-41f7-a0a8-9a6d5fe9c6ba","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.<\/span><\/p>","ID":"5850efe2-d5f7-4048-a9ee-08c7377674a5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9651c980-df10-499c-bf04-ecef1c3738de","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"41a87625-fe37-4726-bf55-8cf3c2f97176","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p>","ID":"27172dbf-b50d-4bec-8467-cef069e6129a","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"416ddd27-51ea-43f6-8489-5e526a7bcba8","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p>","ID":"a2529105-fddf-409a-b71d-a903fee6c04e","Styles":"None","Classes":"['EMEAAddress']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"sanofi-aventis groupe\r 54, rue La Bo\u00e9tie\r F-75008 Paris - France","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a204ed00-ec60-4975-8a72-94a19bdb9250","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5463bb99-b95d-4ae5-87ce-7faba7337fd2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p>","ID":"85ab8455-aac2-45b3-acca-73b7c5a386d0","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBERS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"c2ab2d35-588e-4d46-873f-94d87091aae6","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"SL\">EU\/1\/97\/049\/016-020<br\/>\r EU\/1\/97\/049\/031<br\/>\r EU\/1\/97\/049\/034<br\/>\r EU\/1\/97\/049\/037<\/span><\/p>","ID":"cc1bfcb3-ecd3-4bc4-868d-bbee74c9812c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/97\/049\/016-020\r EU\/1\/97\/049\/031\r EU\/1\/97\/049\/034\r EU\/1\/97\/049\/037","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0f244a57-8c68-4b47-865d-95be90aad3be","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3844b56d-f530-427d-b114-91e6b75892bb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p>","ID":"5c194fce-c70d-42b1-847f-5d1263db6258","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"125fccf8-f23b-4f8b-9eb0-2f647d2d6e97","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p>","ID":"2de6a710-df65-4752-ac22-2496ad40301b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 27 August\r 1997\r Date of latest renewal: 27 August 2007","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4939c48c-c4cf-4b81-8100-bad42052059a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ef814742-0666-44af-8d25-fe9eca18e5ca","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p>","ID":"a6441b87-3168-496a-8d34-3654d3b0d75e","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d181637b-1d91-442f-a76f-0838578ba5e4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p>","ID":"26580a74-c609-412d-a72f-8e4382e54369","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"1f038196-e815-4709-82d1-eb29f89cc124","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"1ef40c0f-d510-4214-93a9-a19ecb3d340d","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ntext-transform:uppercase","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"1f038196-e815-4709-82d1-eb29f89cc124"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"c6402b05-dae5-4c00-9db4-dee74fa6efc8","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"1ef40c0f-d510-4214-93a9-a19ecb3d340d"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p>","ID":"7f25ad2b-53d3-4dc4-a7ea-d9c481a6e0ac","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"90a9bff9-a5f0-4ea4-8e34-0a69ea373ac7","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated\r tablets.<\/span><\/p>","ID":"d6eeac4e-8371-45f9-9ab0-f2bace5586d0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 150 mg film-coated\r tablets.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3cbf1783-e212-4892-afd0-abf97edd9956","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a84e9612-79c2-4c4f-9538-54e74ea21122","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p>","ID":"ccec5928-f178-4166-8581-ab6f6a2a1920","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"e0c0923e-5485-4b75-914a-498fc169591e","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each film-coated tablet contains 150 mg\r of irbesartan.<\/span><\/p>","ID":"2da0b6a2-a11a-4a32-bd84-3da5d4655190","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each film-coated tablet contains 150 mg\r of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c5a20aeb-c853-40bc-a6f7-d1808b48cb63","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 51.00 mg of lactose monohydrate per film-coated tablet.<\/span><\/p>","ID":"bf77bdca-3651-4eaf-9bd7-0fa11a976770","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: 51.00 mg of lactose monohydrate per film-coated tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"15c72c39-2a83-4b15-b168-69ce0cbeff76","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p>","ID":"babab316-f397-4aa3-823e-ff0de6aa05ca","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see\r section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"facce97d-ffce-42d8-a103-c7eb0a29b336","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2ffac3eb-acfb-495b-9b12-041a38dd0635","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p>","ID":"6859b41d-54da-41e3-9ad8-8678c786254d","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"fb3fd461-2499-4c40-9fa6-e612241e4b15","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Film-coated\r tablet.<\/span><\/p>","ID":"511fa1d1-594d-4768-8b18-e73d32ad3d85","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coated\r tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2872 engraved\r on the other side.<\/span><\/p>","ID":"c39dd876-e217-47bb-bb3b-528463bd9d74","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2872 engraved\r on the other side.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0f780a4b-17d1-4a5a-a27d-b7ca3a1bc495","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5c7e0424-6745-4258-87ef-7e4690f90795","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p>","ID":"f27225b0-2438-42a0-a0e2-aec3b97d6ebb","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"6d9d87a0-71e3-4cf1-aea6-e24946f21d50","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p>","ID":"e72e0447-3a0e-4529-ac22-58f9be81f57e","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"c69a4e3f-f89a-4b8b-9833-4542fc0b4334","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p>","ID":"9dfd996e-2553-4b97-895d-76a591930963","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea is\r indicated in adults for the treatment of essential hypertension.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"3151e93b-0594-4747-9bf4-9d0080ae0f51","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d73cac6f-d2a5-406f-bf01-9a75e5043830","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p>","ID":"ff6e9f10-8989-48d2-806d-00e5c2a33c43","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and method of\r administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"24b4d9b1-953f-4897-9489-8caa19cbe3a0","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"b41674d3-3354-4b90-9227-95e88edac282","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"1a6b2d85-bcd7-4f52-ac3d-aa6c5c2e71c3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p>","ID":"94c1f529-9c46-4c4b-b691-b7d4ad15303c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"eac98492-9ced-4429-89e1-52470dbdfb00","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p>","ID":"add89af2-a0a3-44c5-8870-1dda0f27d7e1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b31a307b-4480-4462-b63a-92aebb0eb58e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p>","ID":"d2756a5f-9d09-448d-b0af-85414303cc20","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"226fa0da-0a7d-44f0-8c8b-1ac6f1bed95b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"04d34956-c02c-405b-9371-21bc00d46682","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p>","ID":"51a4319b-caf5-402a-b607-33a61adb5dbf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special Populations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"2680bd70-542f-477c-97c8-fa47ce5379cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"75a0c55e-a3f5-4483-996b-58a6e35147c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2149211c-646d-41bd-8128-c9e493e73ac7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p>","ID":"12488fe6-93ac-4826-85ad-3b2fdfd9300b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"af3dc609-2a2a-445e-a51c-64c9710df639","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"80414d94-2709-43b0-a812-532b86e04124","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6a7cf77b-2c6e-4024-bfd5-6e385adfa152","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p>","ID":"895b44bc-81af-416b-b660-c59a8b76132b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"47e2714f-ee26-48b8-a105-278277044d90","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p>","ID":"efecaecb-194b-462e-9f24-f737b698254f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Older people","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c5658336-4a08-441c-8be0-2d10dce1b95f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary forolder people.<\/span><\/p>","ID":"4c0a73b6-f164-47b4-ae75-b5deac7ac516","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary forolder people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"46e4406a-6615-4c69-b902-06f18bef2f02","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"32703d47-ba9a-4eff-9fc7-e001e46f7acf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b5f966d2-c103-4aa4-9ba8-18575137cf54","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p>","ID":"8888c2e5-73f2-49e9-b303-3facc1053b89","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can\r be made.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e4531470-1493-4924-a428-8b9c7e08afbc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p>","ID":"5b5b1971-3f19-464c-b16f-b942df4f801e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of Administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"06408c1a-ad4d-4eeb-afc0-de019b605260","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"e21147c4-b1dd-47cd-adea-2c9276b35936","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For oral use.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6af02459-6892-4751-ac0e-12c93e14ba9e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p>","ID":"ebbec939-c612-4b0b-896e-40a3d1776d97","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"c156e640-164d-47e5-b256-87fa131e90c9","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"38b30e96-97fc-49e5-9db4-3ba4bfec4301","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p>","ID":"d125d213-ddff-4357-9cfc-46842a0ecb23","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e8d3047c-26de-4683-bebe-2414c126852b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p>","ID":"2454a9fd-ee10-426f-b8e2-b1df27da8ec1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) <60\r ml\/min\/1.73m2) (see sections 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9d2a23bb-6250-4d8c-ad1e-70d86509cd1c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p>","ID":"4d738aad-8d01-470f-90b1-b3d7831e1a40","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions\r for use","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"6944daf5-7e03-4713-885d-70269b9e5cf1","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p>","ID":"71148d58-a43d-4691-a6eb-2d9963b39b05","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Intravascular\r volume depletion: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"27714457-1827-4ba9-a919-49918f2461ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.<\/span><\/p>","ID":"03b8db7f-9b45-466d-92d5-7cd300f355f6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renovascular hypertension: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with\r angiotensin-II receptor antagonists.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e94bf10a-7da8-4abd-847e-cd4b06434423","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.<\/span><\/p>","ID":"a96ecb5e-c946-4ab4-b9f6-f6b2d1d237e4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment and kidney\r transplantation: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the\r administration of Karvea in patients with a recent kidney transplantation.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e8f5379e-8e17-419e-a073-90c5856988bd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p>","ID":"20700561-91de-4338-bfee-ad2d12c43eb9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypertensive patients with\r type 2 diabetes and renal disease: the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3daad460-40f2-4b3b-aa09-7e0201b14c32","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): t<\/span><\/u><span lang=\"EN-GB\">here\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p>","ID":"26cad96f-3c3a-419d-9a08-9a9c3a23b31e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c292ce77-4866-4a0d-8e4a-e2ae53cf92c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).<\/span><\/p>","ID":"498650de-6173-4166-bdff-58d892d39b1c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hyperkalaemia: as with other medicinal products that affect the\r renin-angiotensin-aldosterone system, hyperkalaemia may occur during the\r treatment with Karvea, especially in the presence of renal impairment, overt\r proteinuria due to diabetic renal disease, and\/or heart failure. Close\r monitoring of serum potassium in patients at risk is recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"db60c468-43cc-4c3c-b67c-9205f8959ba0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><span lang=\"EN-GB\">: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p>","ID":"bab5d9d5-8728-4bbe-8e54-248c55c43f31","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d6f06de0-6f29-4d9c-9a39-60d28c0d8a5d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).<\/span><\/p>","ID":"17be86f7-5d25-4f34-a11b-63ae93d2325e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9b41ee29-b2d8-4164-9f45-04c82e2ec173","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p>","ID":"e1da0c1b-bcb5-4dc8-a6af-aa69c37b6b2e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy: as with\r other vasodilators, special caution is indicated in patients suffering from\r aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9fbe60b2-7eb3-4007-9df9-0d1bcfbcf293","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p>","ID":"4ce348e2-6137-4558-97f6-6c312e8fc599","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Primary aldosteronism: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0f2442e4-64e0-4d26-a5b1-dbd3815505a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme inhibitors\r or angiotensin-II receptor antagonists that affect this system has been\r associated with acute hypotension, azotaemia, oliguria, or rarely acute renal\r failure (see section 4.5). As with any antihypertensive agent, excessive blood\r pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p>","ID":"54237c88-7af9-4d9f-8289-ba1475494a03","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme inhibitors\r or angiotensin-II receptor antagonists that affect this system has been\r associated with acute hypotension, azotaemia, oliguria, or rarely acute renal\r failure (see section 4.5). As with any antihypertensive agent, excessive blood\r pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p>","ID":"4d19025e-2b83-4207-8c4d-97b73c03cac3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"db9538e3-4639-48a7-aab4-b578ac6fffac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p>","ID":"79029ae0-5d4c-4b97-94e1-7af1d1cfa169","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"540e6790-9d76-42ea-9c86-5f3787067361","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"718d4515-f9d4-4cf9-adee-f5010cd76b2f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p>","ID":"7898eb19-2f52-4809-9c68-99410053bd34","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9a4c31d7-5c23-430b-97b0-ed950fad68f8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p>","ID":"a43d8e3c-c527-46e9-bbbd-b8fafac9ecd0","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipients:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 150 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.<\/span><\/p>","ID":"ca3963b3-56f9-4279-800e-ef666c774e5f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 150 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4230e60e-716a-4028-bf0c-859f51236c6c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"FR\">Karvea 150 mg fil -coated tablet contains\r sodium. <\/span><span lang=\"EN-GB\">This medicine contains less than 1 mmol sodium\r (23 mg) per tablet, that is to say essentially \u2018sodium-free\u2019.<\/span><\/p>","ID":"2b530146-e1dd-4a9a-8558-ea3ff9b3f8d1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 150 mg fil -coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium\r (23 mg) per tablet, that is to say essentially \u2018sodium-free\u2019.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"67f7fb37-81a9-42e5-bd76-6493fe6c732f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p>","ID":"f4960492-bae3-420f-a5f4-07767dd2c88c","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal\r products and other forms of interaction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"c006a1cc-c79e-4174-ad98-bf1597f32c3c","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers, long-acting\r calcium channel blockers, and thiazide diuretics. Prior treatment with high\r dose diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).<\/span><\/p>","ID":"c1eca878-bd81-42a8-bd3d-387613a135ef","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Diuretics and other antihypertensive\r agents: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers, long-acting\r calcium channel blockers, and thiazide diuretics. Prior treatment with high\r dose diuretics may result in volume depletion and a risk of hypotension when\r initiating therapy with Karvea (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"486dac23-6334-4ae9-a3a8-216b145471eb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure) compared\r to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<\/span><\/p>","ID":"4a20029f-241b-432d-b343-83f222178fe0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aliskiren-containing products or\r ACE-inhibitors: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure) compared\r to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d7e77c4c-89d6-4af8-b0ba-7d1eeb34f199","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the renin-angiotensin\r system, concomitant use of potassium-sparing diuretics, potassium supplements,\r salt substitutes containing potassium or other medicinal products that may\r increase serum potassium levels (e.g. heparin) may lead to increases in\r serum potassium and is, therefore, not recommended (see section 4.4).<\/span><\/p>","ID":"39a2e9f2-158a-4196-942d-9fe0bd166863","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Potassium supplements and\r potassium-sparing diuretics:based on\r experience with the use of other medicinal products that affect the renin-angiotensin\r system, concomitant use of potassium-sparing diuretics, potassium supplements,\r salt substitutes containing potassium or other medicinal products that may\r increase serum potassium levels (e.g. heparin) may lead to increases in\r serum potassium and is, therefore, not recommended (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8351e79a-79b5-4370-b1da-1c36b340a87b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p>","ID":"f3c141c8-01ce-4b73-8abb-9da0de94f814","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin\r converting enzyme inhibitors. Similar effects have been very rarely reported\r with irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9ad1f387-6d1b-4f0a-9b63-37e5d14fd043","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p>","ID":"d1346421-3093-4277-8cf3-62fab1d45c47","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (> 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE inhibitors,\r concomitant use of angiotensin II antagonists and NSAIDs may lead to an\r increased risk of worsening of renal function, including possible acute renal\r failure, and an increase in serum potassium, especially in patients with poor\r pre-existing renal function. The combination should be administered with\r caution, especially in the elderly. Patients should be adequately hydrated and\r consideration should be given to monitoring renal function after initiation of\r concomitant therapy, and periodically thereafter.<\/span><\/p>","ID":"7001024f-12d3-4f37-b1d7-12846fc5e7d9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As with ACE inhibitors,\r concomitant use of angiotensin II antagonists and NSAIDs may lead to an\r increased risk of worsening of renal function, including possible acute renal\r failure, and an increase in serum potassium, especially in patients with poor\r pre-existing renal function. The combination should be administered with\r caution, especially in the elderly. Patients should be adequately hydrated and\r consideration should be given to monitoring renal function after initiation of\r concomitant therapy, and periodically thereafter.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8f9852dc-a771-4b62-9833-43a03beb1c2a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p>","ID":"72443ce5-fbf5-435f-bad6-f095b3e5b7e4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Repaglinide: irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the Cmax\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b03befa6-f3cc-436e-bf81-590abb3852a2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p>","ID":"ea4203c7-233e-46f8-a10c-32f8e3cf343a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Additional information on irbesartan\r interactions: in clinical\r studies, the pharmacokinetic of irbesartan is not affected by\r hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser\r extent by glucuronidation. No significant pharmacokinetic or pharmacodynamic\r interactions were observed when irbesartan was coadministered with warfarin, a\r medicinal product metabolised by CYP2C9. The effects of CYP2C9 inducers such as\r rifampicin on the pharmacokinetic of irbesartan have not been evaluated. The\r pharmacokinetic of digoxin was not altered by coadministration of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"72da9e9f-334d-4c77-9c4a-dcee32dc418b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and lactation<\/span><\/p>","ID":"9ebdcb82-dc9b-4781-b069-f02906389e83","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and lactation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"1b4e90d4-6e97-4431-a0db-650e99a2245a","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"fe5e7187-907a-4f15-b77d-5aed9f77b905","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"caade6a0-6317-4963-ba43-34d44dcbafed","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p> <\/div>","ID":"693bfdc8-82e1-439f-91e1-3e6f23af81f7","Styles":"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":true,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"  ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).<\/span><\/p>","ID":"e340966f-3f23-48b6-a9ae-666fd3e648fd","Styles":"border:none;padding:0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see\r section 4.4). The use of AIIRAs is contraindicated during the second and\r third trimesters of pregnancy (see sections 4.3 and 4.4).","ParentId":"693bfdc8-82e1-439f-91e1-3e6f23af81f7"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d68ecd56-952a-4e86-8624-005da723cfa3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p>","ID":"4fecedb6-ed5f-4b5b-b7dd-31e226ec87d0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in\r risk cannot be excluded. Whilst there is no controlled epidemiological data on\r the risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks\r may exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f5d45007-3d8f-4e09-9f04-ad4abdf61cee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p>","ID":"6c42ab78-8c26-42ba-95a6-eb6b087deb79","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p>","ID":"0aa93158-3323-42d2-a9a7-22231295d07a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).<\/span><\/p>","ID":"a03cd9b8-cab9-4afa-aa43-1835ff9682a7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3\r and 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"89a7e4c7-27ae-44fe-a228-61e0fac1a8da","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"c89f8c0e-9e20-4969-afb9-65b6cde2622f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"1d76ade6-7da5-45dd-a9fe-a7f4526d7f5a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p>","ID":"0351c4cb-9604-422d-95c8-6c953b4fa97c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"835e8e7f-7d7e-4c25-87e5-dbd9674637a6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether irbesartan or its\r metabolites are excreted in human milk. <\/span><\/p>","ID":"c3db6ee3-64a4-4413-9e9d-0cba8f7c6bc0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether irbesartan or its\r metabolites are excreted in human milk. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).<\/span><\/p>","ID":"b930b1b6-a8b8-405f-9ef4-a77b1ccd03e0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"ba3dc8e4-ad3c-4052-850d-5a5ed7f557a3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"1b98f9e2-986e-41c7-b111-adc9201585f4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"314d287d-8573-4a60-a60b-3fc18e6e39ba","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). <\/p>","ID":"a7c40208-1449-4e94-a337-a7d95351e620","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4c7af3c4-4792-43e2-957f-a080e275acaa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p>","ID":"9a097434-dc84-4cb8-9793-0d06b3bf175e","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and\r use machines","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"00b41a00-3e5e-4969-bc3b-893230118888","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Based on its\r pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive\r and use machines. When driving vehicles or operating machines, it should be\r taken into account that dizziness or weariness may occur during treatment.<\/span><\/p>","ID":"14940bc1-f81f-4fbd-899b-356dc6270635","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Based on its\r pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive\r and use machines. When driving vehicles or operating machines, it should be\r taken into account that dizziness or weariness may occur during treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c6f06af3-bb24-4137-8df0-f4396ae683aa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p>","ID":"cdb0c5b8-1b41-4767-af57-a1e8754c02fa","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"1fe8f73e-02f7-48dd-9a4a-de0938b1cd90","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for\r irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).\r The incidence of adverse events was not related to dose (in the recommended\r dose range), gender, age, race, or duration of treatment.<\/span><\/p>","ID":"9eef448e-deae-49c8-8b92-6035cc4301a6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for\r irbesartan-treated patients (3.3%) than for placebo-treated patients (4.5%).\r The incidence of adverse events was not related to dose (in the recommended\r dose range), gender, age, race, or duration of treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"99f15952-40eb-429a-a5e6-8c6d929b2d2c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and orthostatic\r hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess\r of placebo.<\/span><\/p>","ID":"ce1a4702-310a-4779-9890-99dc5ee89e40","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and orthostatic\r hypotension were reported in 0.5% of the patients (i.e., uncommon) but in excess\r of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5badcf34-7b52-48b9-a3d0-4bd15e485450","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.<\/span><\/p>","ID":"44024c02-35d2-425a-b9ee-bfd1189b0da7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in > 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt\r proteinuria and in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"80343748-c377-46a4-9a7f-ae8e4491e916","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p>","ID":"484a6b68-7297-46f0-aefd-d83fc8ce2655","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The frequency of adverse reactions\r listed below is defined using the following convention:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p>","ID":"0ad19c16-1d00-4e18-9950-eaef34e2cc44","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"very common (\u2265 1\/10); common\r (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to\r < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare\r (< 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"50301d4a-2d95-4f6b-b442-47d38ed476c2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.<\/span><\/p>","ID":"aa9147fc-fd67-4b6c-9f62-6fd05fec6e65","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are\r derived from spontaneous reports.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"5b5b4d2a-f14c-42fc-a345-c6055f65df40","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p>","ID":"c7efcb4e-2997-47c8-99bb-12aab494f9e5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Blood\r and lymphatic system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p>","ID":"d0dcdfdd-f9e5-4d6f-94d0-249bef94ab21","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       anaemia, thrombocytopenia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"0317cda9-1a78-43ef-9eb1-6853d890c608","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p>","ID":"9106b879-087c-4c54-b0a2-6550bd8d940c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Immune\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p>","ID":"6352d068-c986-4676-bde3-d48cf7a1116c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"363b90a0-6a4a-4338-950b-be1725f4886e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p>","ID":"b802060a-8ba0-4bbd-9612-90025a9fda7c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Metabolism\r and nutrition disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p>","ID":"70dea414-bb59-4e49-8ac9-2d2580ac5708","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hyperkalaemia, hypoglycaemia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3f6a241a-ac97-4332-b0ae-5cca9ff8e0ec","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p>","ID":"b34246cd-57bc-4b91-bd82-8f6eeaa7f740","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Nervous\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p>","ID":"6bb9f9a4-c4bd-4127-9a91-6955081944c5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         dizziness, orthostatic\r dizziness*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p>","ID":"739fce11-7486-4407-8237-b5ddbea252a3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       vertigo, headache","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"2f9e22f7-d47e-40cd-b19f-90485c41b7ad","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear and\r labyrinth disorder<\/span><\/u><\/p>","ID":"c77ee6d6-1f3d-4368-a93f-69bb7842bea5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ear and\r labyrinth disorder","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p>","ID":"8f0a8780-599f-45ec-ba8a-64b9362fa28f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       tinnitus","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"8bde8b44-199d-4d76-9a30-fb2e172ee081","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p>","ID":"a27ee1a9-615a-4667-8fba-efde9b5c3df3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Cardiac\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p>","ID":"246c98cd-29fe-4892-bb32-21464269bccf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      tachycardia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"79d653b8-20bb-4565-b9c3-ea66025fa8be","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p>","ID":"ffcf4962-8329-439f-b8a2-788b0b08097f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Vascular\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p>","ID":"205a6226-b81b-49fb-8b4c-dc6d76fd9c37","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         orthostatic\r hypotension*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p>","ID":"bd53147c-6d2a-419f-8e22-bd1439d89c04","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      flushing","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"59430a80-d6b9-4cf3-a598-3ec7b8f163ad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p>","ID":"1033b487-e989-4298-8092-28555511a671","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Respiratory,\r thoracic and mediastinal disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p>","ID":"9048b034-4db0-457b-a1c3-b230b15ca552","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      cough","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2526fbc9-51c8-40bd-b1a0-1ceeafa60a69","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p>","ID":"22fc7d7e-9a65-4e3d-8000-8dca1d864179","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Gastrointestinal\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p>","ID":"cffe06b7-a6fb-4604-8efd-eb5fc5fb882a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         nausea\/vomiting","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p>","ID":"231c1fd1-bd59-48b5-8c59-7a8a945439c6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      diarrhoea,\r dyspepsia\/heartburn","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p>","ID":"8d286df6-6bee-499a-afd5-a6a9a78496e5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       dysgeusia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0f7ea497-028d-486d-8b61-b4adc7e191f0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p>","ID":"65047497-86cc-4499-bac0-0ec947d01429","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatobiliary\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p>","ID":"f5eee98a-5496-40d0-8d9a-ffb02ed8c26a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      jaundice","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p>","ID":"8e18bd9f-a90e-4407-9f4b-d8d886eda5bb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hepatitis, abnormal liver function","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"f2a17063-a7fc-4b6f-a10e-25c53a933edb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p>","ID":"7ad08d3f-214b-458f-b9da-a2108034fa91","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Skin\r and subcutaneous tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p>","ID":"9196579f-3de4-46c7-85f7-d827ff031e1a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       leukocytoclastic vasculitis","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"b104d35f-9d58-4b26-a26d-d59039b1424c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders <\/span><\/u><\/p>","ID":"bcf96f91-13bb-4704-8c2a-61f20d4caff3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Musculoskeletal\r and connective tissue disorders ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p>","ID":"8ce6284d-024e-4827-b5cb-6b181d06da6e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         musculoskeletal pain*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p>","ID":"54576d56-ac63-4887-a7ca-6a04417a27a2","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2cc8fcc9-aabc-425b-a186-840bedd73e92","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p>","ID":"6d4fc941-7a0a-4cf3-90d6-09e734b6ec6a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal\r and urinary disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:       impaired renal function including cases\r of renal failure in patients at risk (see section 4.4)<\/span><\/p>","ID":"d470a66d-1e5e-4cc7-b5c3-4ae432b4a399","Styles":"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r\navoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       impaired renal function including cases\r of renal failure in patients at risk (see section 4.4)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"85ebf9a4-44db-427a-9e0f-10698123ad5a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/u><\/p>","ID":"933b3ba3-92bf-4f07-a19a-f53ddae803ea","Styles":"text-align:justify;page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reproductive system and breast disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      sexual dysfunction<\/span><\/p>","ID":"0d897656-dc87-4dff-b232-a754f201b074","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      sexual dysfunction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><\/p>","ID":"4ab42886-a23e-4dc1-92b2-8562dec6c34e","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p>","ID":"a77b1bc8-af36-4a63-af6c-d55504ed4195","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General\r disorders and administration site conditions","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p>","ID":"6ecbd0ff-9cf6-44fa-b7e7-e34a06601bb7","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         fatigue","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p>","ID":"a6e4afd7-b9a0-425e-b662-83fd5df61663","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      chest\r pain","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"36145475-bc9f-4568-acab-7d7a062b5547","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p>","ID":"037323e6-1e97-4af0-9633-c029af660eb9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Investigations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p>","ID":"fff9bc96-623e-4498-a20a-cb0f367143a7","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p>","ID":"1313b357-59b3-4a99-aec1-f48ebed95f60","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"2d6832c9-0d5f-43f5-a42f-7596265020de","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"79406c74-6ff0-456b-8516-f7b907f8d4f3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d1ddb886-09b9-40c8-a529-cf03c401796f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">I<\/span><span lang=\"EN-GB\">n a randomised\r trial of 318 hypertensive children and adolescents aged 6 to\r 16 years, the following adverse reactions occurred in the 3-week\r double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),\r cough (0.9%). In the 26-week open-label period of this trial the most frequent\r laboratory abnormalities observed were creatinine increases (6.5%) and elevated\r CK values in 2% of child recipients.<\/span><\/p>","ID":"5bac6ed4-9264-4fab-8db0-c9b03fa58f3c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In a randomised\r trial of 318 hypertensive children and adolescents aged 6 to\r 16 years, the following adverse reactions occurred in the 3-week\r double-blind phase: headache (7.9%), hypotension (2.2%), dizziness (1.9%),\r cough (0.9%). In the 26-week open-label period of this trial the most frequent\r laboratory abnormalities observed were creatinine increases (6.5%) and elevated\r CK values in 2% of child recipients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"552c76cd-ec62-4f24-968a-7ef9d5a024d1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p>","ID":"25f3f567-85d4-41f3-8934-e80a02682887","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse\r reactions ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"ad59a719-76cf-4509-a81a-d38843afd559","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p>","ID":"70485365-dea8-4d04-924f-4f020ab3ec0b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bc4fefa4-54ea-47f3-b314-3b69def0b05f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p>","ID":"dea0c180-0669-4bed-93e0-84c7f3eb0671","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"764607b9-5c9f-43bf-a251-2f765e3bca49","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be\r hypotension and tachycardia; bradycardia might also occur from overdose. No\r specific information is available on the treatment of overdose with Karvea. The\r patient should be closely monitored, and the treatment should be symptomatic\r and supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan\r is not removed by haemodialysis.<\/span><\/p>","ID":"f47e94b6-923b-49fa-aec4-a198e402badb","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be\r hypotension and tachycardia; bradycardia might also occur from overdose. No\r specific information is available on the treatment of overdose with Karvea. The\r patient should be closely monitored, and the treatment should be symptomatic\r and supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose. Irbesartan\r is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5605a297-e7f0-43dc-83bd-c8a03c0c4e2f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2b9566a1-e88c-451b-95d0-88397f0c1f83","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p>","ID":"ae4608a1-7dc7-4f69-8f99-5b337b9ae1be","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"3212513c-8883-42b9-ac17-0da4d506fa0c","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p>","ID":"7f771807-e2c4-4cab-8e9b-02fcf3d979f2","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"fabdf75e-5dc2-4b14-86e9-87cfc101b849","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.<\/span><\/p>","ID":"a56aa31c-0866-42fc-a92f-2597908d2fb0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ATC code: C09C A04.<\/span><\/p>","ID":"cbc0f49e-6690-4299-ab81-fccaf07ddebc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ATC code: C09C A04.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"aaec9e19-6e88-499a-9411-c27f9e6e67c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"a82726ce-562e-4548-b217-d5b99313c04c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d4ca555f-bb6a-4c16-b93e-cdaab42b2245","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.<\/span><\/p>","ID":"d26cd6fc-b2a9-4b87-b569-d6ccd97bfe6a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT1) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT1\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT1) receptors results in\r increases in plasma renin levels and angiotensin-II levels, and a decrease in\r plasma aldosterone concentration. Serum potassium levels are not significantly\r affected by irbesartan alone at the recommended doses. Irbesartan does not\r inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also\r degrades bradykinin into inactive metabolites. Irbesartan does not require\r metabolic activation for its activity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"dc03a02a-b78e-4aec-96ce-8526de1d05d0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p>","ID":"6c78bd6d-1a12-4589-8e05-ce55b4b0a018","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clinical\r efficacy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"52697d62-7bb0-4094-bde3-57e4e953aa44","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p>","ID":"bbae573a-cee2-4192-816b-9c5cc471e8c3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of 8-13\/5-8 mm Hg\r (systolic\/diastolic) greater than those associated with placebo.<\/span><\/p>","ID":"5efeb267-e4f2-40b6-9438-c83f10d24e1a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan lowers blood pressure with minimal\r change in heart rate. The decrease in blood pressure is dose-related for once a\r day doses with a tendency towards plateau at doses above 300 mg. Doses of\r 150-300 mg once daily lower supine or seated blood pressures at trough\r (i.e. 24 hours after dosing) by an average of 8-13\/5-8 mm Hg\r (systolic\/diastolic) greater than those associated with placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p>","ID":"916856e8-dcba-4a5c-9e52-4f77017b3bb7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.<\/span><\/p>","ID":"56f0cffe-2102-4bd2-b85e-9ef66004f95e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by\r 4-6 weeks after start of therapy. The antihypertensive effects are\r maintained during long term therapy. After withdrawal of therapy, blood pressure\r gradually returns toward baseline. Rebound hypertension has not been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide\r (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood\r pressure reduction at trough of 7-10\/3-6 mm Hg (systolic\/diastolic).<\/span><\/p>","ID":"e3659b98-e66a-41bb-8ba9-5e01407554ec","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide\r (12.5 mg) to irbesartan once daily results in a further placebo-adjusted blood\r pressure reduction at trough of 7-10\/3-6 mm Hg (systolic\/diastolic).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.<\/span><\/p>","ID":"762a40dc-3f80-4893-8968-e55f5a9a0393","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less\r response to irbesartan monotherapy. When irbesartan is administered\r concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg\r daily), the antihypertensive response in black patients approaches that of\r white patients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p>","ID":"23fc8f4a-b003-47ca-b01a-a276382b8abe","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f1f53934-7dd6-43fe-8eb0-e7ab84676302","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"c9f82cae-7f64-4286-a01d-c36f860fe93c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"7e097750-e9d7-4bf1-a904-2f3470538702","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk\r (diabetic, family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean reduction\r from baseline in the primary efficacy variable, trough seated systolic blood\r pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose),\r 13.2 mmHg (high dose). No significant difference was apparent between\r these doses. Adjusted mean change of trough seated diastolic blood pressure\r (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose),\r 5.6 mmHg (high dose). Over a subsequent two week period where patients\r were re-randomized to either active medicinal product or placebo, patients on\r placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to\r +0.1 and -0.3 mmHg changes respectively in those on all doses of\r irbesartan (see section 4.2).<\/span><\/p>","ID":"df89c9f6-2821-4fce-85f8-aa70a4c9f41c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk\r (diabetic, family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean reduction\r from baseline in the primary efficacy variable, trough seated systolic blood\r pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium dose),\r 13.2 mmHg (high dose). No significant difference was apparent between\r these doses. Adjusted mean change of trough seated diastolic blood pressure\r (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium dose),\r 5.6 mmHg (high dose). Over a subsequent two week period where patients\r were re-randomized to either active medicinal product or placebo, patients on\r placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP compared to\r +0.1 and -0.3 mmHg changes respectively in those on all doses of\r irbesartan (see section 4.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2fbd1035-c99d-4895-8952-274edeabdc63","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p>","ID":"47c7518b-a380-4593-9495-5be0f34f56ad","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension\r and type 2 diabetes with renal disease","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes,\r proteinuria \u2265 900 mg\/day and serum creatinine ranging from\r 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately\r 33% of patients in the irbesartan group reached the primary renal composite\r endpoint compared to 39% and 41% in the placebo and amlodipine groups [20%\r relative risk reduction versus placebo (p = 0.024) and 23% relative\r risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p>","ID":"672523d3-5804-4058-9cb9-c615bfa3824c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2 diabetes,\r proteinuria \u2265 900 mg\/day and serum creatinine ranging from\r 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined.\r Patients were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg\r amlodipine, or placebo as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r > 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality. Approximately\r 33% of patients in the irbesartan group reached the primary renal composite\r endpoint compared to 39% and 41% in the placebo and amlodipine groups [20%\r relative risk reduction versus placebo (p = 0.024) and 23% relative\r risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0d3eb6d0-2be4-443c-a56f-e1d41723e81c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p>","ID":"33e5e415-844e-49e6-ba4b-d2eaea214f4d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c2a4f217-a88a-4410-b12c-eade78f39ebc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (&lt; 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the placebo\r group (21%).<\/span><\/p>","ID":"df6e4e45-5751-4ca1-82c1-e7713bbdf15c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with\r type 2 diabetes, microalbuminuria (30-300 mg\/day) and normal renal\r function (serum creatinine \u2264 1.5 mg\/dl in males and\r < 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) > 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and\r dihydropyridine calcium blockers) were added as needed to help achieve the\r blood pressure goal. While similar blood pressure was achieved in all treatment\r groups, fewer subjects in the irbesartan 300 mg group (5.2%) than in the\r placebo (14.9%) or in the irbesartan 150 mg group (9.7%) reached the\r endpoint of overt proteinuria, demonstrating a 70% relative risk reduction\r versus placebo (p = 0.0004) for the higher dose. An accompanying\r improvement in the glomerular filtration rate (GFR) was not observed during the\r first three months of treatment. The slowing in the progression to clinical\r proteinuria was evident as early as three months and continued over the\r 2 year period. Regression to normoalbuminuria (< 30 mg\/day)\r was more frequent in the Karvea 300 mg group (34%) than in the placebo\r group (21%).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1feb8f17-0456-4b38-88ad-9426f71ea97c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p>","ID":"80136b3d-fc25-4171-b0a1-ae54c8d28fef","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p>","ID":"15393c00-b9e8-4bb2-bfb8-24398fa51f73","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.<\/span><\/p>","ID":"cebe4352-4a72-4737-9791-8ae16dd01e72","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and\r angiotensin II receptor blockers.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p>","ID":"2fdde3f9-b937-4ba6-b516-b22dc954cbf1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p>","ID":"122d9c02-bf12-4f0b-aa64-f3addbcd96d4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c707c96f-0db8-4e90-9c28-16995a8d55dd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p>","ID":"7b881592-902a-43ea-9913-294f91218407","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"32ae6539-a959-4259-b1c6-b91b46d43b1b","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"f887053b-bbdd-491f-acb6-9d65222aa99a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Absorption","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"3b050e68-8cc9-41b3-beb0-7ff2509b52a3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p>","ID":"3bd10560-ea3f-443c-8f41-a8d15bcccaa8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"a8265dc4-e971-4600-9d54-db158b928de8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"0efd5c69-e14c-4440-a3c7-4b218cf2a0a1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Distribution","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"fe0e026f-d7a7-450b-a750-79cbf268d49b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. <\/span><\/p>","ID":"542c7d03-ffb5-449e-bb35-6e399d042030","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"581caf83-040a-4fa5-855d-0d472f5af15f","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"e5f908c6-5a61-4ff2-ab05-9cca3a2a67c9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Biotransformation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"a334bdaa-6b5c-41e3-93be-7505d75217fd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p>","ID":"4ce06045-d34b-46a2-84c7-5de46c428c5d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following\r oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5cfb77b3-2cfe-44dd-bd8c-3125d6549e06","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linearity \/ non-linearity<\/span><\/u><\/p>","ID":"66ff21eb-e8d1-4edc-94c3-b8a55f259c6b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Linearity \/ non-linearity","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"50aa610f-58a5-4649-a454-259dee820e12","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.<\/span><\/p>","ID":"49904dda-5d78-4757-9722-2e9188d16520","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (< 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a4f7447c-012e-49e6-91ff-33d4d7284045","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"05f26be3-4e57-4133-a308-39d66488171b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elimination","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b0f09278-5ca4-477d-aa40-3e51f3d2d9a2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are eliminated\r by both biliary and renal pathways. After either oral or IV administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C irbesartan, about 20% of\r the radioactivity is recovered in the urine, and the remainder in the faeces.\r Less than 2% of the dose is excreted in the urine as unchanged irbesartan.<\/span><\/p>","ID":"f7f6659a-f692-4d62-bb04-011cbb650886","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan and its metabolites are eliminated\r by both biliary and renal pathways. After either oral or IV administration of 14C irbesartan, about 20% of\r the radioactivity is recovered in the urine, and the remainder in the faeces.\r Less than 2% of the dose is excreted in the urine as unchanged irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bd80ab0b-718c-4bee-a8ef-486a7b392069","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"add51e4c-7f94-4033-b0d9-ebbc4dfdc03e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"84c1ce96-d056-4682-9e68-80f48f285126","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p>","ID":"facf334f-09a4-4afc-9953-6c6c19e5d2db","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6b8ae5e1-6ff8-4c6e-9430-57609c6db8e2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"5301d46a-5ac5-49c2-ae0c-171717d1eb39","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b7f80758-4f29-4a66-9a93-106095220da5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"e76295f4-9164-4712-8fb4-3465b1fdf7f4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a6e21555-972b-488d-a8f9-eab6ffb2c22f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p>","ID":"d191ba9e-fe40-4e54-a27e-4a8bfbf00ec3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"63ea49ac-72c4-4e66-8713-57b3271fd92e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. <\/span><\/p>","ID":"6bba3e17-d77a-4604-ad0a-0f2a365c22d3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p>","ID":"47458d8a-48a6-481d-9566-52f160409bf9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Studies have not been performed in\r patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a690369b-9c2f-4536-bf5c-124c82ddf038","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p>","ID":"6aaad5f6-74a7-4576-a483-14ec0075a9e7","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3Preclinical safety data","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"4d8d5311-7823-4a53-b206-294a9b4f880d","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.<\/span><\/p>","ID":"765577be-408d-4ad4-aa47-0e1de068f206","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at\r \u2265 90 mg\/kg\/day, in macaques at \u2265 10 mg\/kg\/day).\r All of these changes were considered to be caused by the pharmacological action\r of irbesartan. For therapeutic doses of irbesartan in humans, the hyperplasia\/\r hypertrophy of the renal juxtaglomerular cells does not appear to have any\r relevance.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a510a4fa-cfd7-4f0b-be14-0054d5fc81e9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p>","ID":"df7d3fbc-459d-44a8-a328-2e182c81c9d3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"58115983-c4d6-4056-93c7-08116823141f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p>","ID":"1e52779f-56cd-4351-969a-44b387232f5f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bcea51a4-9984-4225-9179-ab56609d42bc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p>","ID":"398adc49-8982-4d63-b1bc-94476bc52804","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"78d6d680-4ba4-4b21-9bcc-00dfeb56a85f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"be70faab-40ae-4406-b2bb-9eea5c05c8c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p>","ID":"dcf068da-0060-4db3-869e-b112fe0e4059","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"c5fbb690-075b-4712-8032-060f2841de1d","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p>","ID":"f6752d76-14d4-423f-b770-794bc8c02f76","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"58d21139-f259-4415-a8b3-46527cedcf14","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet\r core:<\/span><\/p>","ID":"a386873d-2bbd-407c-a5f9-c5c5b5cad9b8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet\r core:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p>","ID":"9142d258-c7bc-4bcf-a4ed-868dde85d8f7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Microcrystalline cellulose<\/span><\/p>","ID":"36d3c356-3d6f-4a37-b57c-352d779cee35","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Microcrystalline cellulose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p>","ID":"bc348c00-2b9c-42c4-be1a-8551984cabfb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p>","ID":"66f1857f-5524-4e01-a71c-4e49bd961111","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Silicon dioxide<\/span><\/p>","ID":"c32bf793-063f-499f-8f5f-1cbd9a6ceeda","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Silicon dioxide","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Magnesium stearate.<\/span><\/p>","ID":"fe04845c-d669-4e71-98fb-96c52b65c610","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d31fbda9-8d8d-408c-bd71-d156e20e515f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Film-coating:<\/span><\/p>","ID":"a612bcd8-61b9-44d1-8a75-82121fb140d1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coating:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p>","ID":"1795353a-662c-4c4d-84f3-84acf126ee44","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p>","ID":"f5cbee2d-7f19-40ab-9a77-ba5503d32ee1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Titanium dioxide<\/span><\/p>","ID":"4971a40d-5214-4966-81ba-cabe1f498536","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Titanium dioxide","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Macrogol 3000<\/span><\/p>","ID":"b6a30cfd-7af5-4ffd-8804-718122145213","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Macrogol 3000","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Carnauba wax.<\/span><\/p>","ID":"f6b43e93-3ea0-4353-b6cd-02596f25512c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Carnauba wax.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f859e4eb-90eb-45aa-ace5-9cf687dec0f2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p>","ID":"61bd8a72-b89c-4012-835e-84e72716315b","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"9d832933-56dd-4a42-a731-2fc55e9c9862","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p>","ID":"c7ed66b6-2645-429a-a066-4518bf74c2f4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not applicable.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fca0c775-eb92-4cff-8756-c120255df023","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p>","ID":"e66edd5f-f0f0-4af2-93b0-dc0bb882c695","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"e118c010-a512-4146-bb62-7d5063bff84f","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"28b17bfe-c209-49de-a620-7506e293baaf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"11c9dfd3-efc1-4df9-99b3-c58aa8997275","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p>","ID":"8eb7bc33-dac0-47a7-8819-0e49a87c85e7","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"336249de-157d-40f3-aa9c-6429de189f6f","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p>","ID":"e925aa48-0fae-45db-b47e-e0b145ed7b1f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not store above 30\u00b0C.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"849b5ecd-0fd2-40e9-b903-0a4895789525","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p>","ID":"ccacd604-a686-47fe-9e03-eb7a2dd17527","Styles":"margin-left:0in;text-indent:0in","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature\r and contents of container","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"afff1552-4c00-474b-a490-778076b3db48","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"72be509a-0e2d-425e-8f56-3c3936ab0da8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 30<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"213691a9-3bbb-4afb-ba41-8c7c3beabad6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 30\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"77b02083-143f-4806-bc69-c241e5cc803d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 90<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"ea6b0d64-11e1-4653-8778-c090c00d358e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 90\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.<\/span><\/p>","ID":"3c11e559-fd2c-4499-b1a5-f6818393ae38","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"be774e44-e4a6-4cad-8525-8d9c362b3423","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"f2fe37db-47c6-4f53-a224-575309b1831f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ecfbcc62-4df8-4bca-903b-dbd9704d6295","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p>","ID":"a52fade3-1b0f-4de7-a326-3fa52d198fcc","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"56b99183-f23a-4347-af0d-03a434aab3d9","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.<\/span><\/p>","ID":"54b92694-791e-4d40-9ec2-f9ab9cfbb06f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"47b3dd1f-03ea-4a5a-9ad6-1217497ef753","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"36b6f6c8-10ca-4536-93a4-c3e52b993ca8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p>","ID":"e350065f-cbde-4c0b-96ae-e085f202590d","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"7ed7e686-b044-425c-904b-f9190c0e07f5","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p>","ID":"d2185982-faa4-422e-aff6-bbe04216d60c","Styles":"None","Classes":"['EMEAAddress']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"sanofi-aventis groupe\r 54, rue La Bo\u00e9tie\r F-75008 Paris - France","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8d5a95e0-269a-4f8f-878e-cfc7cafc47a6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"35178dd8-6a16-4230-85f5-e301ff602082","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p>","ID":"9e9c7e60-f18d-49d1-a3a4-1c9b79ba9a03","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBERS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"16db77ce-5bb0-45d5-a79d-7c26c6b16650","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"SL\">EU\/1\/97\/049\/021-025<br\/>\r EU\/1\/97\/049\/032<br\/>\r EU\/1\/97\/049\/035<br\/>\r EU\/1\/97\/049\/038<\/span><\/p>","ID":"29dd9b55-bdbd-49fa-9b2a-ef5076b9198f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/97\/049\/021-025\r EU\/1\/97\/049\/032\r EU\/1\/97\/049\/035\r EU\/1\/97\/049\/038","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e5748080-3ce2-4690-8575-57b622d3e049","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fd05fe44-28bd-4e93-89dc-4aecd9161a44","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p>","ID":"49148200-f802-4057-95cd-1dcaa056f5f0","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"5ba1c0b6-5152-4462-82a8-c073872e1862","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p>","ID":"738c40dc-337e-447f-8b60-188dd77d706e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 27 August\r 1997\r Date of latest renewal: 27 August 2007","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"98d2042a-f9b7-4533-87f9-76fe6328ecad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6d42bfa2-f7a5-491c-bc17-bc034b4bfaa6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p>","ID":"a9baed8a-5c05-46be-958a-97183fc2089b","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"48549062-ec8d-4220-86ec-be110810dc41","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p>","ID":"d654032c-c0ab-4697-9f92-fa55947a5297","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<b><span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span><\/b>","ID":"c436f1c4-c1e8-48a8-a83f-1c20e465220e","Styles":"None","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif;\r text-transform:uppercase'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"38b30e80-c858-444c-9fa5-ee72a213385a","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif;\r\ntext-transform:uppercase","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"c436f1c4-c1e8-48a8-a83f-1c20e465220e"},{"Element":"<br clear=\"all\" style=\"page-break-before:always\"\/>","ID":"6f4990b0-d321-412d-b054-f492e25854e8","Styles":"page-break-before:always","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"38b30e80-c858-444c-9fa5-ee72a213385a"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">1.       NAME OF THE MEDICINAL PRODUCT<\/span><\/p>","ID":"ab70df97-eaf4-4d5d-b4da-d291d5819b74","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"1.       NAME OF THE MEDICINAL PRODUCT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"88b24401-d30b-48fc-b58a-aa8337c1fd62","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated\r tablets.<\/span><\/p>","ID":"795f0b98-2242-4b9b-bc19-cb16ead89eb3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 300 mg film-coated\r tablets.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1cdae717-c603-4c95-b039-a7ec93902d29","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"53faa3f4-372d-4c78-93c0-f317e21feb74","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION<\/span><\/p>","ID":"a467ccb4-0e9e-480f-8e25-a0ff00b1be9f","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"2.       QUALITATIVE AND QUANTITATIVE\r COMPOSITION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"26cf4f72-61a4-4a99-88f5-00c15a0637e9","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Each film-coated tablet contains 300 mg\r of irbesartan.<\/span><\/p>","ID":"1438251a-8b8d-4c04-ac5a-2cc684a118d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Each film-coated tablet contains 300 mg\r of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"41306529-c6ad-4b69-8713-c65434551cad","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Excipient with known effect<\/span><\/u><span lang=\"EN-GB\">: 102.00 mg of lactose monohydrate per film-coated tablet.<\/span><\/p>","ID":"bfa5cc61-2c9e-4384-84d5-4fa8352b5b36","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipient with known effect: 102.00 mg of lactose monohydrate per film-coated tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5ba9c9fa-e3dc-464d-80d0-ea90bcc9a4cf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For the full list of excipients, see\r section 6.1.<\/span><\/p>","ID":"3ac650de-2fa7-4f31-9c09-bfd5b7c90df0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For the full list of excipients, see\r section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3e6d87be-15a9-4260-8cfa-7915fd8a8751","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"09c95833-fb64-4ded-957f-03354078d379","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">3.       PHARMACEUTICAL FORM<\/span><\/p>","ID":"9b56c22d-65c2-4704-922f-ad55d3de8c49","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"3.       PHARMACEUTICAL FORM","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"9ec1079d-df30-4626-9d18-660537265a52","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Film-coated\r tablet.<\/span><\/p>","ID":"6cf27af3-74a9-4d4c-a834-b1ed89cedea6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coated\r tablet.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2873 engraved\r on the other side.<\/span><\/p>","ID":"8e1986ff-b919-4edc-bf01-818fa25a145a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"White to off-white, biconvex, and\r oval-shaped with a heart debossed on one side and the number 2873 engraved\r on the other side.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d7ffb6f9-737b-47f2-9060-d30b7d01db6c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"09f97136-fb13-4ff6-b968-39ea51b35486","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">4.       CLINICAL PARTICULARS<\/span><\/p>","ID":"476c50fa-d7ce-41bc-851a-a8a0e5171659","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"4.       CLINICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"5b8fe803-66dd-4b5c-9ac1-a767c13c4a97","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.1     Therapeutic indications<\/span><\/p>","ID":"f39d7926-36e3-4289-9ddc-f6706a8d1abe","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.1     Therapeutic indications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8686042b-7710-42d2-9c05-736aab5e2687","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Karvea is\r indicated in adults for the treatment of essential hypertension.<\/span><\/p>","ID":"19f9271d-19ad-4584-b3dc-53411382ec97","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea is\r indicated in adults for the treatment of essential hypertension.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"8dbee276-2395-4f02-830a-e168e74c8c95","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is also indicated for the treatment\r of renal disease in adult patients with hypertension and type 2 diabetes\r mellitus as part of an antihypertensive medicinal product regimen (see sections\r 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"57a65bff-9cf9-4c6e-8a6f-1788d42f413c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.2     Posology and method of\r administration<\/span><\/p>","ID":"5f0f7fa6-6159-4fdd-8bc6-9e59fcd09d18","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.2     Posology and method of\r administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"de5ecb8f-213a-4086-b654-e2474ae2d986","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Posology<\/span><\/u><\/p>","ID":"2c947dee-c7a6-44ed-a2cf-de51caca7df3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Posology","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"90ac15d9-8167-41a0-8348-1f22573b00da","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.<\/span><\/p>","ID":"d0f1f2f2-ece2-44d8-a140-e8085f084315","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The usual\r recommended initial and maintenance dose is 150 mg once daily, with or\r without food. Karvea at a dose of 150 mg once daily generally provides a\r better 24 hour blood pressure control than 75 mg. However, initiation\r of therapy with 75 mg could be considered, particularly in haemodialysed\r patients and in the elderly over 75 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e7c9adb2-786b-40ca-8433-b342aac2aa9f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).<\/span><\/p>","ID":"6d53b741-6189-41bf-bf62-15502918ac66","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients insufficiently controlled\r with 150 mg once daily, the dose of Karvea can be increased to\r 300 mg, or other antihypertensive agents can be added (see sections 4.3,\r 4.4, 4.5 and 5.1). In particular, the addition of a diuretic such as\r hydrochlorothiazide has been shown to have an additive effect with Karvea (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c2c3571b-9db8-4a86-ad37-9121d7618afa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.<\/span><\/p>","ID":"6ddf6c68-7ede-4285-86dc-bb9fd0d0ac42","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In hypertensive type 2 diabetic\r patients, therapy should be initiated at 150 mg irbesartan once daily and\r titrated up to 300 mg once daily as the preferred maintenance dose for\r treatment of renal disease.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).<\/span><\/p>","ID":"084a90b9-9189-4077-bae0-135a1cb4e423","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The demonstration of renal benefit of Karvea\r in hypertensive type 2 diabetic patients is based on studies where\r irbesartan was used in addition to other antihypertensive agents, as needed, to\r reach target blood pressure (see sections 4.3, 4.4, 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"28d508df-7bf7-4296-9992-882576d29f51","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Special Populations<\/span><\/u><\/p>","ID":"a73a1701-5d08-495c-85dd-a89052c596b1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Special Populations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"157ed76d-1ec7-48b3-aa6d-0908bf5431ab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Renal impairment<\/span><\/i><\/p>","ID":"59001600-d838-44a8-b0a0-e00b4cff093b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ec1b2b94-69f4-4d39-b926-65074df01fea","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).<\/span><\/p>","ID":"21cd1210-0643-42ac-8a59-f2ef406eb89e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with impaired renal function. A lower starting dose (75 mg)\r should be considered for patients undergoing haemodialysis (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c6448a4b-0775-435e-bb7e-024e7c18c007","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Hepatic impairment<\/span><\/i><\/p>","ID":"6b9456f9-2721-4158-b00b-acfaf3588828","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1fd6deec-4b85-4727-a179-156606cf13ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.<\/span><\/p>","ID":"6e84d1db-0dbe-4ca2-b5fd-577771995269","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"No dosage adjustment is necessary in\r patients with mild to moderate hepatic impairment. There is no clinical\r experience in patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"938e4b21-3022-4068-886e-b63c913c987d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Older people<\/span><\/i><\/p>","ID":"ef458952-096c-4200-b026-9793cb0cb5da","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Older people","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"92187351-57f7-4d95-bcde-1baa17cbe130","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary forolder people.<\/span><\/p>","ID":"6b7db8aa-38d0-4b8e-9e9f-2e0dff341852","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Although consideration should be given\r to initiating therapy with 75 mg in patients over 75 years of age,\r dosage adjustment is not usually necessary forolder people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"53026a4b-e9f3-475c-b9d3-605ef74d64f8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Paediatric population<\/span><\/i><\/p>","ID":"342575f1-1eaf-48cd-9d33-06e8097c32b3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b8492806-1a45-472f-9750-431ad7a76186","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can\r be made.<\/span><\/p>","ID":"ae056a86-7d9f-4066-9049-9baf4654c39d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The safety and efficacy of Karvea in\r children aged 0 to 18 has not been established. Currently available data are\r described in section 4.8, 5.1 and 5.2 but no recommendation on a posology can\r be made.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"aaa65c77-63bc-42a2-8436-a8994e161a21","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Method of Administration<\/span><\/u><\/p>","ID":"d389093d-266e-41cb-97e1-ee57abe0e4ce","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Method of Administration","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4cef2570-3c9a-47fb-9be1-094df922d5aa","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">For oral use.<\/span><\/p>","ID":"17ed4b00-1c8e-4d37-aabd-43c457ab8f36","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"For oral use.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8f77df46-bfe8-4331-8fd9-3e941493a3b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.3     Contraindications<\/span><\/p>","ID":"f328dc93-21b6-44e2-a740-48d6f3980ded","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.3     Contraindications","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"7276d361-cad9-4ca2-9d36-d26a7d1657e7","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.<\/span><\/p>","ID":"63c8310a-1440-4c60-9d53-48177a001fa2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypersensitivity\r to the active substance or to any of the excipients listed in section 6.1.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).<\/span><\/p>","ID":"9422d841-448d-4613-99cf-5377a163c3b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Second and third trimesters of pregnancy\r (see sections 4.4 and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c05bb321-17c9-4141-883c-b4e80200edd1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) &lt;60\r ml\/min\/1.73m<sup>2<\/sup>) (see sections 4.5 and 5.1).<\/span><\/p>","ID":"e7707cfd-7adc-42ba-9d57-b8801890b076","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The concomitant use of Karvea with\r aliskiren-containing products is contraindicated in patients with diabetes\r mellitus or renal impairment (glomerular filtration rate (GFR) <60\r ml\/min\/1.73m2) (see sections 4.5 and 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"071a7ba2-a111-463b-83f5-0cbb3a43213d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.4     Special warnings and precautions\r for use<\/span><\/p>","ID":"73e9f41f-19fc-45df-922c-a519e94fba5e","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.4     Special warnings and precautions\r for use","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"9aba2868-0dd8-4ada-a48f-8b497cc2a635","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Intravascular\r volume depletion<\/span><\/u><span lang=\"EN-GB\">: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.<\/span><\/p>","ID":"c74d651d-0ef9-4ec5-8c87-895a82035dda","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Intravascular\r volume depletion: symptomatic hypotension,\r especially after the first dose, may occur in patients who are volume and\/or\r sodium depleted by vigorous diuretic therapy, dietary salt restriction,\r diarrhoea or vomiting. Such conditions should be corrected before the\r administration of Karvea.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4046d70d-5a3b-44f2-90e0-645145e543e1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renovascular hypertension<\/span><\/u><span lang=\"EN-GB\">: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with angiotensin-II\r receptor antagonists.<\/span><\/p>","ID":"ec211715-4267-47db-bbd4-3fc67cef8395","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renovascular hypertension: there is an increased risk of severe hypotension and renal\r insufficiency when patients with bilateral renal artery stenosis or stenosis of\r the artery to a single functioning kidney are treated with medicinal products\r that affect the renin-angiotensin-aldosterone system. While this is not\r documented with Karvea, a similar effect should be anticipated with angiotensin-II\r receptor antagonists.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e317d5f0-0a0d-47a4-a578-e8b6c52a24af","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment and kidney\r transplantation<\/span><\/u><span lang=\"EN-GB\">: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the administration\r of Karvea in patients with a recent kidney transplantation.<\/span><\/p>","ID":"f276f59d-6f4c-4fdb-ac31-963c15b7d502","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Renal impairment and kidney\r transplantation: when Karvea is used in patients\r with impaired renal function, a periodic monitoring of potassium and creatinine\r serum levels is recommended. There is no experience regarding the administration\r of Karvea in patients with a recent kidney transplantation.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"da8e2a45-457c-4dc6-b691-4668ddd87f2f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypertensive patients with\r type 2 diabetes and renal disease<\/span><\/u><span lang=\"EN-GB\">:<\/span><span lang=\"EN-GB\" style=\"layout-grid-mode:line\"> the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).<\/span><\/p>","ID":"1b52c5ee-06ee-4cf8-9144-807a983d3ef2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypertensive patients with\r type 2 diabetes and renal disease: the effects of irbesartan both on\r renal and cardiovascular events were not uniform across all subgroups, in an\r analysis carried out in the study with patients with advanced renal disease. In\r particular, they appeared less favourable in women and non-white subjects (see\r section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b30fc486-dbd6-4a59-a9ee-1ff4fd0e62dd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS<\/span><\/u><span lang=\"EN-GB\">): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.<\/span><\/p>","ID":"6dccbc30-b653-4623-af24-74c99628afba","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS): there\r is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor\r blockers or aliskiren increases the risk of hypotension, hyperkalaemia and\r decreased renal function (including acute renal failure). Dual blockade of RAAS\r through the combined use of ACE-inhibitors, angiotensin II receptor blockers or\r aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual\r blockade therapy is considered absolutely necessary, this should only occur\r under specialist supervision and subject to frequent close monitoring of renal\r function, electrolytes and blood pressure. ACE-inhibitors and angiotensin II\r receptor blockers should not be used concomitantly in patients with diabetic\r nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"df102017-1e8c-4d7d-b079-38ad7a5c8013","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hyperkalaemia<\/span><\/u><span lang=\"EN-GB\">: as with other medicinal products that affect the renin-angiotensin-aldosterone\r system, hyperkalaemia may occur during the treatment with Karvea, especially in\r the presence of renal impairment, overt proteinuria due to diabetic renal\r disease, and\/or heart failure. Close monitoring of serum potassium in patients\r at risk is recommended (see section 4.5).<\/span><\/p>","ID":"7c772d3c-2569-4449-a782-60f705e619b0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone\r system, hyperkalaemia may occur during the treatment with Karvea, especially in\r the presence of renal impairment, overt proteinuria due to diabetic renal\r disease, and\/or heart failure. Close monitoring of serum potassium in patients\r at risk is recommended (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"53b114e3-b279-4911-9d75-eac416ea7ccf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hypoglycaemia<\/span><\/u><span lang=\"EN-GB\">: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).<\/span><\/p>","ID":"3e83a479-f47f-4433-b0e6-88d9127ee31d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients.\r In patients treated with insulin or antidiabetics an appropriate blood glucose\r monitoring should be considered; a dose adjustment of insulin or antidiabetics may\r be required when indicated (see section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a79e2e9f-84e8-4117-b142-a33413da3170","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).<\/span><\/p>","ID":"87730a07-dfcb-4a64-b7c0-9f0f123c026f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:\r the combination of lithium and Karvea is not recommended (see\r section 4.5).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2bba021e-656d-4231-b5aa-6e3ee1b4958c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy<\/span><\/u><span lang=\"EN-GB\">: as with\r other vasodilators, special caution is indicated in patients suffering from aortic\r or mitral stenosis, or obstructive hypertrophic cardiomyopathy.<\/span><\/p>","ID":"fcc79c30-2a0a-4d07-9140-0dc964b843a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aortic and mitral valve stenosis,\r obstructive hypertrophic cardiomyopathy: as with\r other vasodilators, special caution is indicated in patients suffering from aortic\r or mitral stenosis, or obstructive hypertrophic cardiomyopathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"317a5aed-5be4-4d71-898e-a251d9082dcd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Primary aldosteronism<\/span><\/u><span lang=\"EN-GB\">: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.<\/span><\/p>","ID":"a41949ab-8bf9-4601-a3aa-67f92a4733fd","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Primary aldosteronism: patients with primary aldosteronism generally will not respond to\r antihypertensive medicinal products acting through inhibition of the\r renin-angiotensin system. Therefore, the use of Karvea is not recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"57806f97-9a5a-408f-8b54-6955efce3003","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">General<\/span><\/u><span lang=\"EN-GB\">:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.<\/span><\/p>","ID":"8b07f555-9d65-4ccb-9868-50824daa8d27","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"General:\r in patients whose vascular tone and renal function depend predominantly on the\r activity of the renin-angiotensin-aldosterone system (e.g. patients with\r severe congestive heart failure or underlying renal disease, including renal\r artery stenosis), treatment with angiotensinconverting enzyme\r inhibitors or angiotensin-II receptor antagonists that affect this system has\r been associated with acute hypotension, azotaemia, oliguria, or rarely acute\r renal failure (see section 4.5). As with any antihypertensive agent, excessive\r blood pressure decrease in patients with ischaemic cardiopathy or ischaemic\r cardiovascular disease could result in a myocardial infarction or stroke.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).<\/span><\/p>","ID":"31804dad-121b-4043-b672-6befc7952f92","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As observed for angiotensin converting\r enzyme inhibitors, irbesartan and the other angiotensin antagonists are\r apparently less effective in lowering blood pressure in black people than in\r non-blacks, possibly because of higher prevalence of low-renin states in the\r black hypertensive population (see section 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4db3da2a-82bc-4880-afb8-e5c450e30de9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Pregnancy:<\/span><\/u><span lang=\"EN-GB\"> angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. <\/span><span lang=\"EN-GB\">Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with <\/span><span lang=\"EN-GB\">AIIRAs<\/span><span lang=\"EN-GB\"> should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).<\/span><\/p>","ID":"7b6edef8-6f7a-4af8-aa22-e937615e6ac8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be\r initiated during pregnancy. Unless continued AIIRA\r therapy is considered essential, patients planning pregnancy should be changed\r to alternative antihypertensive treatments which have an established safety\r profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and,\r if appropriate, alternative therapy should be started (see sections 4.3\r and 4.6).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"60e30985-9d53-4ac6-a6da-9423743d4cbb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"e97c8483-f23e-4719-846a-b957d2831885","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><span lang=\"EN-GB\">: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).<\/span><\/p>","ID":"9d928cc6-1c95-4064-b077-09c281870200","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Paediatric population: irbesartan has been studied in paediatric populations aged 6 to 16\r years old but the current data are insufficient to support an extension of the\r use in children until further data become available (see sections 4.8, 5.1\r and 5.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c60145bd-6840-4501-85ae-3ec50f3180eb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"MsoNormal\"><u><span lang=\"EN-GB\">Excipients<\/span><\/u><span lang=\"FR\">:<\/span><\/p>","ID":"0af062c3-54a3-4c55-ad04-9f3abd939f72","Styles":"None","Classes":"['MsoNormal']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Excipients:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.<\/span><\/p>","ID":"d62d9406-7f29-43c7-9e95-5358a747c148","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 300 mg film-coated tablet contains\r lactose. Patients with rare hereditary problems of galactose intolerance, total\r lactase deficiency or glucose-galactose malabsorption should not take this\r medicine.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"87d5e7d4-5109-498a-8c29-19a883047545","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Karvea 300 mg film-coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.<\/span><\/p>","ID":"ec71a37f-ad8d-4e22-98fb-92e8900ea020","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Karvea 300 mg film-coated tablet contains\r sodium. This medicine contains less than 1 mmol sodium (23 mg) per tablet, that\r is to say essentially \u2018sodium-free\u2019.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"11ff947c-7377-4d8d-8095-5bdc3b586d68","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.5     Interaction with other medicinal\r products and other forms of interaction<\/span><\/p>","ID":"73e1f725-e8a2-483c-833d-a4084390d1b0","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.5     Interaction with other medicinal\r products and other forms of interaction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"318a99ee-6927-4aab-aacf-3b81248ef11f","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Diuretics and other antihypertensive\r agents<\/span><\/u><span lang=\"EN-GB\">: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).<\/span><\/p>","ID":"0e64dc85-1322-46f3-9d26-7e9bc5855fe3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Diuretics and other antihypertensive\r agents: other antihypertensive agents may increase\r the hypotensive effects of irbesartan; however Karvea has been safely\r administered with other antihypertensive agents, such as beta-blockers,\r long-acting calcium channel blockers, and thiazide diuretics. Prior treatment\r with high dose diuretics may result in volume depletion and a risk of\r hypotension when initiating therapy with Karvea (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4d9ae938-9a36-4241-a896-f94f8e94773b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Aliskiren-containing products or\r ACE-inhibitors<\/span><\/u><span lang=\"EN-GB\">: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).<\/span><\/p>","ID":"337daf06-8124-4e7a-b84a-6bd04a70a76a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Aliskiren-containing products or\r ACE-inhibitors: clinical trial data has shown that\r dual blockade of the renin-angiotensin-aldosterone system (RAAS) through the\r combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren\r is associated with a higher frequency of adverse events such as hypotension,\r hyperkalaemia and decreased renal function (including acute renal failure)\r compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and\r 5.1).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7029a9b7-26dc-4ed0-a2b1-132be819f159","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Potassium supplements and\r potassium-sparing diuretics<\/span><\/u><span lang=\"EN-GB\">:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see\r section 4.4).<\/span><\/p>","ID":"87cff41b-b473-48f3-8ec6-285611783c2a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Potassium supplements and\r potassium-sparing diuretics:based on\r experience with the use of other medicinal products that affect the\r renin-angiotensin system, concomitant use of potassium-sparing diuretics,\r potassium supplements, salt substitutes containing potassium or other medicinal\r products that may increase serum potassium levels (e.g. heparin) may lead\r to increases in serum potassium and is, therefore, not recommended (see\r section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"254ee6d4-dbce-4fc2-9bf8-ce2734d821c6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Lithium<\/span><\/u><span lang=\"EN-GB\">:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin converting\r enzyme inhibitors. Similar effects have been very rarely reported with\r irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.<\/span><\/p>","ID":"d3a63ada-85fa-4e03-942d-32e613105917","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lithium:reversible increases in serum lithium concentrations and toxicity have been\r reported during concomitant administration of lithium with angiotensin converting\r enzyme inhibitors. Similar effects have been very rarely reported with\r irbesartan so far. Therefore, this combination is not recommended (see\r section 4.4). If the combination proves necessary, careful monitoring of\r serum lithium levels is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b8ae3612-edd9-483f-8865-2c8fd73b3358","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Non-steroidal anti-inflammatory drugs<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<\/span><\/span><\/p>","ID":"0d6541d4-bcae-442b-92ae-ff64ae400234","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are\r administered simultaneously with non-steroidal anti-inflammatory drugs (i.e.\r selective COX-2 inhibitors, acetylsalicylic acid (> 3 g\/day) and\r non-selective NSAIDs), attenuation of the antihypertensive effect may occur.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"be6016b5-e3df-4a04-969f-65bebea76f7d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"color:black\">As with ACE inhibitors,\r concomitant use of angiotensin II antagonists and NSAIDs may lead to an\r increased risk of worsening of renal function, including possible acute renal\r failure, and an increase in serum potassium, especially in patients with poor\r pre-existing renal function. The combination should be administered with\r caution, especially in the elderly. Patients should be adequately hydrated and\r consideration should be given to monitoring renal function after initiation of\r concomitant therapy, and periodically thereafter.<\/span><\/p>","ID":"458abbc7-014b-444b-af24-87ee434dc363","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"As with ACE inhibitors,\r concomitant use of angiotensin II antagonists and NSAIDs may lead to an\r increased risk of worsening of renal function, including possible acute renal\r failure, and an increase in serum potassium, especially in patients with poor\r pre-existing renal function. The combination should be administered with\r caution, especially in the elderly. Patients should be adequately hydrated and\r consideration should be given to monitoring renal function after initiation of\r concomitant therapy, and periodically thereafter.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1974373e-ce0a-4cef-85dd-d2d273ba9f2e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Repaglinide:<\/span><\/u><span lang=\"EN-GB\" style=\"color:black\"> irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the C<sub>max<\/sub>\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).<\/span><\/p>","ID":"5d2a51b5-271d-4e8b-91ff-a01e273d80f9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Repaglinide: irbesartan has the potential to inhibit OATP1B1.\r In a clinical study, it was reported that irbesartan increased the Cmax\r and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and 1.3\u2011fold,\r respectively, when administered 1 hour before repaglinide. In another study, no\r relevant pharmacokinetic interaction was reported, when the two drugs were\r co-administered. Therefore, dose adjustment of antidiabetic treatment such as\r repaglinide may be required (see section 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a31a9843-744b-4497-8fe9-681123d44fdb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Additional information on irbesartan\r interactions<\/span><\/u><span lang=\"EN-GB\">: <span style=\"color:black\">in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.\r No significant pharmacokinetic or pharmacodynamic interactions were observed when\r irbesartan was coadministered with warfarin, a medicinal product metabolised by\r CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the\r pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of\r digoxin was not altered by coadministration of irbesartan.<\/span><\/span><\/p>","ID":"dfbf1ac4-8c08-475c-8d1a-41cb408d8296","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Additional information on irbesartan\r interactions: in clinical\r studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.\r Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent by glucuronidation.\r No significant pharmacokinetic or pharmacodynamic interactions were observed when\r irbesartan was coadministered with warfarin, a medicinal product metabolised by\r CYP2C9. The effects of CYP2C9 inducers such as rifampicin on the\r pharmacokinetic of irbesartan have not been evaluated. The pharmacokinetic of\r digoxin was not altered by coadministration of irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a05e3267-6717-47fb-acff-7687731d5926","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.6     Fertility, pregnancy and\r lactation<\/span><\/p>","ID":"dea7ed4f-4990-48b3-830b-a92eba5e9f47","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.6     Fertility, pregnancy and\r lactation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"5e70c06b-5263-455e-a6ab-7152d476e7db","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Pregnancy<\/span><\/u><\/p>","ID":"48a945f2-c4e6-48d4-877e-1d30a784f7d2","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Pregnancy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"b5762b79-b02b-4ecf-bd9f-87a533590dbf","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<div style=\"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt\"> <p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy\r (see sections 4.3 and 4.4).<\/span><\/p> <\/div>","ID":"f3a787cf-94ba-4df9-b4cb-83518c58d556","Styles":"border:solid windowtext 1.0pt;padding:1.0pt 4.0pt 1.0pt 4.0pt","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":true,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"  ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"border:none;padding:0in\"><span lang=\"EN-GB\">The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy\r (see sections 4.3 and 4.4).<\/span><\/p>","ID":"c0b9fe81-91b6-41fa-88c8-c6b99e368fe3","Styles":"border:none;padding:0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The use\r of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4).\r The use of AIIRAs is contraindicated during the second and third trimesters of pregnancy\r (see sections 4.3 and 4.4).","ParentId":"f3a787cf-94ba-4df9-b4cb-83518c58d556"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f46c2b69-b211-4225-a3df-477f27aaf16b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in risk\r cannot be excluded. Whilst there is no controlled epidemiological data on the\r risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may\r exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.<\/span><\/p>","ID":"938688ef-9019-4e48-8b07-c416fda07ba4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Epidemiological evidence regarding the\r risk of teratogenicity following exposure to ACE inhibitors during the first\r trimester of pregnancy has not been conclusive; however a small increase in risk\r cannot be excluded. Whilst there is no controlled epidemiological data on the\r risk with Angiotensin II Receptor Antagonists (AIIRAs), similar risks may\r exist for this class of drugs. Unless continued AIIRA therapy is considered\r essential, patients planning pregnancy should be changed to alternative\r antihypertensive treatments which have an established safety profile for use in\r pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped\r immediately, and, if appropriate, alternative therapy should be started.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9a8cf46e-33f0-42dd-830f-a796357da449","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).<\/span><\/p>","ID":"245fdc5a-daac-4d1d-8229-e571f7ccdf11","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Exposure to AIIRA therapy during the\r second and third trimesters is known to induce human foetotoxicity (decreased\r renal function, oligohydramnios, skull ossification retardation) and neonatal\r toxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.<\/span><\/p>","ID":"f7dd68db-9052-4036-9de6-417c4e45a63c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Should exposure to AIIRAs have occurred\r from the second trimester of pregnancy, ultrasound check of renal function and\r skull is recommended.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3 and 4.4).<\/span><\/p>","ID":"f1ca266a-5031-49de-bbdf-330adc08e70d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Infants whose mothers have taken AIIRAs\r should be closely observed for hypotension (see sections 4.3 and 4.4).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"cbc370e6-f390-4928-a854-62a9b2ff8525","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Breast-feeding<\/span><\/u><\/p>","ID":"9296cf4a-b816-4b72-ac2d-b5ae3d122ffc","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Breast-feeding","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"f9efd5d5-53a5-4f5b-98f8-75204a35f29c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.<\/span><\/p>","ID":"ea39a8c3-6e7b-42a2-ad77-6d6fa0acf4a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Because no information is available\r regarding the use of Karvea during breast-feeding, Karvea is not recommended\r and alternative treatments with better established safety profiles during breast-feeding\r are preferable, especially while nursing a newborn or preterm infant.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d9cd93f9-0a20-4cc4-80a4-49a280dc89ac","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">It is unknown whether irbesartan or its\r metabolites are excreted in human milk. <\/span><\/p>","ID":"48136424-e5e7-4ea1-a0e5-9512db7ef50a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"It is unknown whether irbesartan or its\r metabolites are excreted in human milk. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).<\/span><\/p>","ID":"2588e670-98b9-46c5-b80b-6cee8a270dee","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Available pharmacodynamic\/toxicological\r data in rats have shown excretion of irbesartan or its metabolites in milk (for\r details see 5.3).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"> <\/p>","ID":"0b42689c-c16c-4b6e-ad51-159c066a8ad2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Fertility<\/span><\/u><\/p>","ID":"5fdaabc2-3048-4666-a874-bc5472d54ce9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Fertility","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"06c25722-91e9-4fe2-a4cb-7bac27b743e4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\">Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). <\/p>","ID":"1ac82351-4e95-4bcf-ad01-671c9be36f6d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan had no effect upon fertility of treated rats\r and their offspring up to the dose levels inducing the first signs of parental\r toxicity (see section 5.3). ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"5b592ac7-c1b5-44db-af2a-0868f11b1933","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.7     Effects on ability to drive and\r use machines<\/span><\/p>","ID":"3d6c038b-b1d8-451a-9c8f-da9cbdfe4e43","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.7     Effects on ability to drive and\r use machines","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"bc3fc749-c2c9-4446-9c1e-84782f19b11b","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Based on\r its pharmacodynamic properties, irbesartan is unlikely to affect the ability to\r drive and use machines. When driving vehicles or operating machines, it should\r be taken into account that dizziness or weariness may occur during treatment.<\/span><\/p>","ID":"10ab5851-4635-406d-8618-cd145b748b5b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Based on\r its pharmacodynamic properties, irbesartan is unlikely to affect the ability to\r drive and use machines. When driving vehicles or operating machines, it should\r be taken into account that dizziness or weariness may occur during treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8adab7d1-9e4b-4faf-8f82-2575b201acfb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.8     Undesirable effects<\/span><\/p>","ID":"09449fab-0a3f-487f-8081-944334f3bc67","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.8     Undesirable effects","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"0a3915e7-e5a8-4fe0-bfea-3e0615421bff","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for irbesartan-treated\r patients (3.3%) than for placebo-treated patients (4.5%). The incidence of\r adverse events was not related to dose (in the recommended dose range), gender,\r age, race, or duration of treatment.<\/span><\/p>","ID":"4014fbb9-696e-46c2-a500-94d574f14a1f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In placebo-controlled trials in patients\r with hypertension, the overall incidence of adverse events did not differ\r between the irbesartan (56.2%) and the placebo groups (56.5%). Discontinuation\r due to any clinical or laboratory adverse event was less frequent for irbesartan-treated\r patients (3.3%) than for placebo-treated patients (4.5%). The incidence of\r adverse events was not related to dose (in the recommended dose range), gender,\r age, race, or duration of treatment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"c17f61d7-902f-4b9d-8248-6c9e3ec8a8a0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon)\r but in excess of placebo.<\/span><\/p>","ID":"e7a63b31-7ca2-40ac-8a7c-cff448722770","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In diabetic hypertensive patients with\r microalbuminuria and normal renal function, orthostatic dizziness and\r orthostatic hypotension were reported in 0.5% of the patients (i.e., uncommon)\r but in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"964b5170-b117-46cb-a952-8ae3f81977f1","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in &gt; 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria\r and in excess of placebo.<\/span><\/p>","ID":"1a19f930-3ed9-4ddf-a283-5d121be65c0c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The following table presents the adverse\r drug reactions that were reported in placebo-controlled trials in which\r 1,965 hypertensive patients received irbesartan. Terms marked with a star\r (*) refer to the adverse reactions that were additionally reported in > 2%\r of diabetic hypertensive patients with chronic renal insufficiency and overt proteinuria\r and in excess of placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f0d6a96a-ecf7-405b-9311-6200226b5d30","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The frequency of adverse reactions\r listed below is defined using the following convention:<\/span><\/p>","ID":"ef78096d-e438-43bc-aff9-9f9cd989072b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The frequency of adverse reactions\r listed below is defined using the following convention:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">very common (\u2265 1\/10); common\r (\u2265 1\/100 to &lt; 1\/10); uncommon (\u2265 1\/1,000 to\r &lt; 1\/100); rare (\u2265 1\/10,000 to &lt; 1\/1,000); very rare\r (&lt; 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.<\/span><\/p>","ID":"edf2c908-47a7-4d22-9495-44986782d2fc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"very common (\u2265 1\/10); common\r (\u2265 1\/100 to < 1\/10); uncommon (\u2265 1\/1,000 to\r < 1\/100); rare (\u2265 1\/10,000 to < 1\/1,000); very rare\r (< 1\/10,000). Within each frequency grouping, undesirable effects are\r presented in order of decreasing seriousness.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"40a86dd9-353b-4c52-9b8f-607b62ed1b85","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are derived\r from spontaneous reports.<\/span><\/p>","ID":"da4d7762-2bf9-456e-9cff-ffea7f402a97","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Adverse reactions additionally reported\r from post\u2013marketing experience are also listed. These adverse reactions are derived\r from spontaneous reports.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><b><\/b><\/p>","ID":"4a58e86c-d5be-4ff0-b0e5-2b09dd611ebc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Blood\r and lymphatic system disorders<\/span><\/u><\/p>","ID":"c5df7b34-1a12-41ff-aa96-c7359d33c4b3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Blood\r and lymphatic system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       anaemia, thrombocytopenia<\/span><\/p>","ID":"039f09f1-f7c0-49a7-a51d-a51cbb6d5659","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       anaemia, thrombocytopenia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a9870da6-b8c2-45fd-8d9c-a6a16d0b70f5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Immune\r system disorders<\/span><\/u><\/p>","ID":"79340f12-a6d3-4561-80d0-7fa7aa2e7aa9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Immune\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock<\/span><\/p>","ID":"e9a38c2c-e5bd-438d-8c8f-d9974b17d3ac","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hypersensitivity reactions such as angioedema, rash, urticaria,\r anaphylactic reaction, anaphylactic shock","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"5d32ed49-9087-4488-95e1-a048ea23ff5e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Metabolism\r and nutrition disorders<\/span><\/u><\/p>","ID":"fb977e6a-3b12-447f-ad9b-04b1dbe81383","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Metabolism\r and nutrition disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hyperkalaemia, hypoglycaemia<\/span><\/p>","ID":"6a67db42-91be-4ed9-912e-4bf6f1b3d1df","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hyperkalaemia, hypoglycaemia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"345d8ede-3b9f-4613-88ef-de0af76aa491","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Nervous\r system disorders<\/span><\/u><\/p>","ID":"385dea2a-d495-4fdc-a0a9-d545f4ed1441","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Nervous\r system disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         dizziness, orthostatic\r dizziness*<\/span><\/p>","ID":"86bef333-c849-4213-ba44-a9c258d391bf","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         dizziness, orthostatic\r dizziness*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       vertigo, headache<\/span><\/p>","ID":"a6ea5767-8a88-409b-a07b-298b250d9e23","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       vertigo, headache","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"9940ea66-6da9-4176-86b8-a1c376708e7a","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Ear\r and labyrinth disorder<\/span><\/u><\/p>","ID":"eccf1047-175b-41a5-ae01-285f8e3c84d0","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Ear\r and labyrinth disorder","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       tinnitus<\/span><\/p>","ID":"5c0c7ffa-452c-4549-8066-7de4ea44105b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       tinnitus","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"ae68b81d-4250-4060-b44e-e06db85a7c29","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Cardiac\r disorders<\/span><\/u><\/p>","ID":"6c89732f-4e3e-4ea3-ac33-9cb0aa784c58","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Cardiac\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      tachycardia<\/span><\/p>","ID":"1872ced2-ca4a-4989-89b4-9daf4ee6d2be","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      tachycardia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"a79fc9e2-bf9e-4963-8fbe-3beec196b6e3","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Vascular\r disorders<\/span><\/u><\/p>","ID":"a97d9dd3-352f-4bda-a7ce-8a446d82f01e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Vascular\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         orthostatic\r hypotension*<\/span><\/p>","ID":"878b27a6-6454-43e9-b2fa-a1ec72f0c858","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         orthostatic\r hypotension*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      flushing<\/span><\/p>","ID":"09201724-fcc2-457c-88d8-05b7bcad960d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      flushing","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"556918c2-843c-4607-928f-491c1f8dc417","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Respiratory,\r thoracic and mediastinal disorders<\/span><\/u><\/p>","ID":"7f5e227e-bdae-4989-879b-0a38be8ecfd5","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Respiratory,\r thoracic and mediastinal disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      cough<\/span><\/p>","ID":"9cf99dbc-7b57-409e-85ec-6ff6f54461e7","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      cough","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3b01dd62-739a-4d03-8bfe-0aca02d9d8b4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Gastrointestinal\r disorders<\/span><\/u><\/p>","ID":"9fe88a98-b9e3-47a7-b55d-dbd1adacffa6","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Gastrointestinal\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         nausea\/vomiting<\/span><\/p>","ID":"013eac92-eeff-465e-8fdc-a9b7a7fe6265","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         nausea\/vomiting","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      diarrhoea,\r dyspepsia\/heartburn<\/span><\/p>","ID":"df482c4a-8326-40aa-99d0-906a68df8126","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      diarrhoea,\r dyspepsia\/heartburn","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not known:       dysgeusia<\/span><\/p>","ID":"6fe52538-3aa5-4dc0-9b91-953acf62c3e6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       dysgeusia","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b430b9c6-803a-4b12-afbf-86a7a9ae9bc2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Hepatobiliary\r disorders<\/span><\/u><\/p>","ID":"e3aa7e85-d670-4585-84a7-e16af698ab0b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatobiliary\r disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      jaundice<\/span><\/p>","ID":"fd8236ac-1bb0-4bb8-acc4-1cbc8b53e5f4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      jaundice","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       hepatitis, abnormal liver function<\/span><\/p>","ID":"860defec-74fe-46f4-ba32-8a3128c4af57","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       hepatitis, abnormal liver function","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"e863a37c-4ec0-4acc-a6a3-1d8bb1d14a5e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Skin\r and subcutaneous tissue disorders<\/span><\/u><\/p>","ID":"ffed4b12-0c72-403c-902f-5d30ad3fa86e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Skin\r and subcutaneous tissue disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Not\r known:       leukocytoclastic vasculitis<\/span><\/p>","ID":"550bcdca-76d4-4025-bcec-bc5c16cd429b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not\r known:       leukocytoclastic vasculitis","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"f872f84c-d846-4717-b029-596ff2658468","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Musculoskeletal\r and connective tissue disorders <\/span><\/u><\/p>","ID":"630f04ab-581e-4a93-ab08-97a32c435a2e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Musculoskeletal\r and connective tissue disorders ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Common:         musculoskeletal pain*<\/span><\/p>","ID":"85c5ea12-52d9-4765-8418-eb676785c356","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         musculoskeletal pain*","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps<\/span><\/p>","ID":"167b5909-b43b-4d85-8573-58ac4cdc5114","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:       arthralgia, myalgia (in some cases associated with\r increased plasma creatine kinase levels), muscle cramps","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d9a8ddd1-8155-4033-9a0c-634895ed27d5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Renal\r and urinary disorders<\/span><\/u><\/p>","ID":"203231e7-c9de-4fe1-8eea-eae5f6e16fa8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal\r and urinary disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r avoid\"><span lang=\"EN-GB\">Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)<\/span><\/p>","ID":"e5dae85a-8864-4bf0-acbb-62ab2a3e9add","Styles":"margin-left:1.0in;text-indent:-1.0in;page-break-after:\r\navoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not known:        impaired renal function including\r cases of renal failure in patients at risk (see section 4.4)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"8404bb0d-9adc-4441-8b53-5a7ab07c531d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify;page-break-after:avoid\"><u><span lang=\"EN-GB\">Reproductive system and breast disorders<\/span><\/u><\/p>","ID":"f0b52225-8243-45c7-9379-9fbb71e6e02f","Styles":"text-align:justify;page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reproductive system and breast disorders","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Uncommon:      sexual dysfunction<\/span><\/p>","ID":"bb955b8b-0d5a-41db-9e6b-5d23f8776588","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      sexual dysfunction","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"text-align:justify\"><\/p>","ID":"84f812ed-2389-40ec-9e53-d10195d6f251","Styles":"text-align:justify","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">General\r disorders and administration site conditions<\/span><\/u><\/p>","ID":"cd487865-124f-4b41-91ab-612a9177a485","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"General\r disorders and administration site conditions","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Common:         fatigue<\/span><\/p>","ID":"6a2dceb5-b45f-45fe-a85c-4c2765ca4f7c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         fatigue","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Uncommon:      chest\r pain<\/span><\/p>","ID":"30cf588a-0c43-49f8-991d-cbcd3d264208","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Uncommon:      chest\r pain","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"c55298e2-648f-452b-b6b1-232b0399dbee","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Investigations<\/span><\/u><\/p>","ID":"084fd60b-986b-4eda-808c-634abc4278ba","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Investigations","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.<\/span><\/p>","ID":"2f61bf57-85fe-4e20-8a7c-1a46e7b98b69","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Very common:  Hyperkalaemia* occurred more often in diabetic\r patients treated with irbesartan than with placebo. In diabetic hypertensive\r patients with microalbuminuria and normal renal function, hyperkalaemia\r (\u2265 5.5 mEq\/L) occurred in 29.4% of the patients in the irbesartan\r 300 mg group and 22% of the patients in the placebo group. In diabetic\r hypertensive patients with chronic renal insufficiency and overt proteinuria,\r hyperkalaemia (\u2265 5.5 mEq\/L) occurred in 46.3% of the patients\r in the irbesartan group and 26.3% of the patients in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"margin-left:1.0in;text-indent:-1.0in\"><span lang=\"EN-GB\">Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.<br\/>\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.<\/span><\/p>","ID":"cafd4bf3-6f44-4541-ab11-97b2700fa6d8","Styles":"margin-left:1.0in;text-indent:-1.0in","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Common:         significant increases in plasma creatine kinase were\r commonly observed (1.7%) in irbesartan treated subjects. None of these\r increases were associated with identifiable clinical musculoskeletal events.\r In 1.7% of hypertensive patients with advanced diabetic renal disease treated\r with irbesartan, a decrease in haemoglobin*, which was not clinically\r significant, has been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><u><span lang=\"EN-GB\"><\/span><\/u><\/i><\/p>","ID":"1efc12d5-d09f-4b53-aaf5-99928faeb0fb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Paediatric population<\/span><\/u><\/p>","ID":"20d3ef16-a2d9-4acc-9299-eab65327d902","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"bfb6b460-bad1-4aff-8e5d-1aa08a949ed2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">I<\/span><span lang=\"EN-GB\">n a randomised\r trial of 318 hypertensive children and adolescents aged 6 to 16 years,\r the following adverse reactions occurred in the 3-week double-blind phase:\r headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the\r 26-week open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.<\/span><\/p>","ID":"7b2121ed-0689-4a27-95da-45e81570d979","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In a randomised\r trial of 318 hypertensive children and adolescents aged 6 to 16 years,\r the following adverse reactions occurred in the 3-week double-blind phase:\r headache (7.9%), hypotension (2.2%), dizziness (1.9%), cough (0.9%). In the\r 26-week open-label period of this trial the most frequent laboratory abnormalities\r observed were creatinine increases (6.5%) and elevated CK values in 2% of child\r recipients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"eb4a85a7-5aa9-4153-85c6-0b7b262a43ba","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Reporting of suspected adverse\r reactions <\/span><\/u><\/p>","ID":"a7124d51-55cd-40e1-873f-5575fa3a4e50","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Reporting of suspected adverse\r reactions ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"811d1e35-0f92-4fc8-ba4d-93087865d2b3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via <span style=\"background:silver\">the national reporting system listed in Appendix V.<\/span> <\/span><\/p>","ID":"ca94d95b-a6fb-447c-8526-aa9ebc708940","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reporting suspected adverse reactions\r after authorisation of the medicinal product is important. It allows continued\r monitoring of the benefit\/risk balance of the medicinal product. Healthcare\r professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"53cea6f9-c679-4503-bbb0-ab60da344530","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">4.9     Overdose<\/span><\/p>","ID":"1edb2c9f-36e3-42d3-8e2e-b4ac9c3f07ba","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"4.9     Overdose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8fb89ef6-c751-41ad-91ae-3e49a332663e","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be hypotension\r and tachycardia; bradycardia might also occur from overdose. No specific\r information is available on the treatment of overdose with Karvea. The patient\r should be closely monitored, and the treatment should be symptomatic and\r supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose.\r Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"beb18172-880c-4e91-811c-885aaad85593","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Experience\r in adults exposed to doses of up to 900 mg\/day for 8 weeks revealed\r no toxicity. The most likely manifestations of overdose are expected to be hypotension\r and tachycardia; bradycardia might also occur from overdose. No specific\r information is available on the treatment of overdose with Karvea. The patient\r should be closely monitored, and the treatment should be symptomatic and\r supportive. Suggested measures include induction of emesis and\/or gastric\r lavage. Activated charcoal may be useful in the treatment of overdose.\r Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"d7de41ac-426e-4a37-a5f4-8bd281c9c425","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2743f9ca-a407-4fe2-b782-76ccdb36adfb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">5.       PHARMACOLOGICAL PROPERTIES<\/span><\/p>","ID":"2968cb05-607e-4bcf-9ac1-34b05dad1985","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"5.       PHARMACOLOGICAL PROPERTIES","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"272211d5-c19d-4b88-9b36-a4f6781fd33f","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.1     Pharmacodynamic properties<\/span><\/p>","ID":"052bf017-9b83-4f35-9c49-fdfe20b1811c","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.1     Pharmacodynamic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"2ab19b49-7880-4ca7-b7e4-14c4655f0271","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.<\/span><\/p>","ID":"1fa1d75d-c589-41a5-826f-2abade3fc065","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Pharmacotherapeutic group:\r Angiotensin-II antagonists, plain.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ATC code: C09C A04.<\/span><\/p>","ID":"7218d6e6-7cc1-4514-bcde-1e35faf5cf86","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ATC code: C09C A04.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9c82151d-d0b6-4398-b285-77b4a37d3dc5","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Mechanism of action<\/span><\/u><\/p>","ID":"50e3955e-f17c-4f0b-9103-27233ac7fc1e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Mechanism of action","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"135bd8b1-6bed-438a-8906-8755e5300e07","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT<sub>1<\/sub>) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT<sub>1<\/sub>\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT<sub>1<\/sub>) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.<\/span><\/p>","ID":"914dcc84-6b9f-4700-aacf-4de734f2cf76","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan is a potent, orally active,\r selective angiotensin-II receptor (type AT1) antagonist. It is\r expected to block all actions of angiotensin-II mediated by the AT1\r receptor, regardless of the source or route of synthesis of angiotensin-II. The\r selective antagonism of the angiotensin-II (AT1) receptors results\r in increases in plasma renin levels and angiotensin-II levels, and a decrease\r in plasma aldosterone concentration. Serum potassium levels are not\r significantly affected by irbesartan alone at the recommended doses. Irbesartan\r does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II\r and also degrades bradykinin into inactive metabolites. Irbesartan does not\r require metabolic activation for its activity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b26304f5-c5f8-4437-9368-dc36344217af","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><u><span lang=\"EN-GB\" style=\"font-weight:normal\">Clinical\r efficacy<\/span><\/u><\/p>","ID":"445ced46-47d1-4856-84cf-a04e5d4704fe","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Clinical\r efficacy","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"7f8a64ab-e5ad-4097-b31b-2b4bad641491","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension<\/span><\/i><\/p>","ID":"32542049-b1f0-4290-8f67-58411e1e273c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan lowers blood pressure with\r minimal change in heart rate. The decrease in blood pressure is dose-related\r for once a day doses with a tendency towards plateau at doses above\r 300 mg. Doses of 150-300 mg once daily lower supine or seated blood\r pressures at trough (i.e. 24 hours after dosing) by an average of 8-13\/5-8 mm Hg\r (systolic\/diastolic) greater than those associated with placebo.<\/span><\/p>","ID":"dc21f74a-97a9-4225-9f48-f4d97425c2d4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan lowers blood pressure with\r minimal change in heart rate. The decrease in blood pressure is dose-related\r for once a day doses with a tendency towards plateau at doses above\r 300 mg. Doses of 150-300 mg once daily lower supine or seated blood\r pressures at trough (i.e. 24 hours after dosing) by an average of 8-13\/5-8 mm Hg\r (systolic\/diastolic) greater than those associated with placebo.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.<\/span><\/p>","ID":"cc1db4ae-591a-440b-9703-bbff24305ef9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Peak reduction of blood pressure is\r achieved within 3-6 hours after administration and the blood pressure\r lowering effect is maintained for at least 24 hours. At 24 hours the\r reduction of blood pressure was 60-70% of the corresponding peak diastolic and\r systolic responses at the recommended doses. Once daily dosing with 150 mg\r produced trough and mean 24 hour responses similar to twice daily dosing\r on the same total dose.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks\r after start of therapy. The antihypertensive effects are maintained during long\r term therapy. After withdrawal of therapy, blood pressure gradually returns toward\r baseline. Rebound hypertension has not been observed.<\/span><\/p>","ID":"9c5fdafc-32db-4c95-ae2e-f0c97c0e3d79","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effect of Karvea\r is evident within 1-2 weeks, with the maximal effect occurring by 4-6 weeks\r after start of therapy. The antihypertensive effects are maintained during long\r term therapy. After withdrawal of therapy, blood pressure gradually returns toward\r baseline. Rebound hypertension has not been observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide\r (12.5 mg) to irbesartan once daily results in a further placebo-adjusted\r blood pressure reduction at trough of 7-10\/3-6 mm Hg\r (systolic\/diastolic).<\/span><\/p>","ID":"09fb1aec-4927-47b9-bc99-7cccb6990acc","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The blood pressure lowering effects of\r irbesartan and thiazide-type diuretics are additive. In patients not adequately\r controlled by irbesartan alone, the addition of a low dose of hydrochlorothiazide\r (12.5 mg) to irbesartan once daily results in a further placebo-adjusted\r blood pressure reduction at trough of 7-10\/3-6 mm Hg\r (systolic\/diastolic).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less response\r to irbesartan monotherapy. When irbesartan is administered concomitantly with a\r low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive\r response in black patients approaches that of white patients.<\/span><\/p>","ID":"f3b7ea7a-c274-48c2-923c-806ae7047e25","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The efficacy of Karvea is not influenced\r by age or gender. As is the case with other medicinal products that affect the\r renin-angiotensin system, black hypertensive patients have notably less response\r to irbesartan monotherapy. When irbesartan is administered concomitantly with a\r low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive\r response in black patients approaches that of white patients.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.<\/span><\/p>","ID":"e95d8dfe-5cf2-45d1-b8df-88b9e4edbd02","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There is no clinically important effect\r on serum uric acid or urinary uric acid secretion.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ac9b97c-025a-489d-88d0-790008ad8e0c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"7013c9cd-01f6-4d11-9b12-25a8cce1c713","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"f2bf8a39-3a55-413b-b122-c5a89a01d6d4","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic,\r family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean\r reduction from baseline in the primary efficacy variable, trough seated systolic\r blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium\r dose), 13.2 mmHg (high dose). No significant difference was apparent\r between these doses. Adjusted mean change of trough seated diastolic blood\r pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium\r dose), 5.6 mmHg (high dose). Over a subsequent two week period where\r patients were re-randomized to either active medicinal product or placebo,\r patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP\r compared to +0.1 and -0.3 mmHg changes respectively in those on all doses\r of irbesartan (see section 4.2).<\/span><\/p>","ID":"92a5b985-6a44-4803-8ebd-421a0f63f28d","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Reduction of blood pressure with\r 0.5 mg\/kg (low), 1.5 mg\/kg (medium) and 4.5 mg\/kg (high) target\r titrated doses of irbesartan was evaluated in 318 hypertensive or at risk (diabetic,\r family history of hypertension) children and adolescents aged 6 to\r 16 years over a three week period. At the end of the three weeks the mean\r reduction from baseline in the primary efficacy variable, trough seated systolic\r blood pressure (SeSBP) was 11.7 mmHg (low dose), 9.3 mmHg (medium\r dose), 13.2 mmHg (high dose). No significant difference was apparent\r between these doses. Adjusted mean change of trough seated diastolic blood\r pressure (SeDBP) was as follows: 3.8 mmHg (low dose), 3.2 mmHg (medium\r dose), 5.6 mmHg (high dose). Over a subsequent two week period where\r patients were re-randomized to either active medicinal product or placebo,\r patients on placebo had increases of 2.4 and 2.0 mmHg in SeSBP and SeDBP\r compared to +0.1 and -0.3 mmHg changes respectively in those on all doses\r of irbesartan (see section 4.2).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ca6af1e-da2e-4e4d-a1b5-c44f786d0d0f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><i><span lang=\"EN-GB\">Hypertension\r and type 2 diabetes with renal disease<\/span><\/i><\/p>","ID":"8a1b03e5-8147-4f77-9669-f9ef71c03690","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Hypertension\r and type 2 diabetes with renal disease","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined. Patients\r were titrated from 75 mg to a maintenance dose of 300 mg Karvea<\/span><span lang=\"EN-GB\" style='font-family:\"Times\",serif'>, from 2.5 mg to 10 mg\r amlodipine, or placebo<\/span><span lang=\"EN-GB\"> as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r &gt; 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.<\/span><\/p>","ID":"df4afaaa-44df-4bb3-a3de-d4ac3103bf23","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The \u201cIrbesartan Diabetic Nephropathy\r Trial (IDNT)\u201d shows that irbesartan decreases the progression of renal disease\r in patients with chronic renal insufficiency and overt proteinuria. IDNT was a\r double blind, controlled, morbidity and mortality trial comparing Karvea,\r amlodipine and placebo. In 1,715 hypertensive patients with type 2\r diabetes, proteinuria \u2265 900 mg\/day and serum creatinine ranging\r from 1.0-3.0 mg\/dl, the long-term effects (mean 2.6 years) of Karvea\r on the progression of renal disease and all-cause mortality were examined. Patients\r were titrated from 75 mg to a maintenance dose of 300 mg Karvea, from 2.5 mg to 10 mg\r amlodipine, or placebo as tolerated. Patients in all\r treatment groups typically received between 2 and 4 antihypertensive\r agents (e.g., diuretics, beta blockers, alpha blockers) to reach a\r predefined blood pressure goal of \u2264 135\/85 mmHg or a\r 10 mmHg reduction in systolic pressure if baseline was\r > 160 mmHg. Sixty per cent (60%) of patients in the placebo group\r reached this target blood pressure whereas this figure was 76% and 78% in the\r irbesartan and amlodipine groups respectively. Irbesartan significantly reduced\r the relative risk in the primary combined endpoint of doubling serum\r creatinine, end-stage renal disease (ESRD) or all-cause mortality.\r Approximately 33% of patients in the irbesartan group reached the primary renal\r composite endpoint compared to 39% and 41% in the placebo and amlodipine groups\r [20% relative risk reduction versus placebo (p = 0.024) and 23%\r relative risk reduction compared to amlodipine (p = 0.006)]. When the\r individual components of the primary endpoint were analysed, no effect in all\r cause mortality was observed, while a positive trend in the reduction in ESRD\r and a significant reduction in doubling of serum creatinine were observed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"85c78318-093d-4d06-9830-92e6b1a23628","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\" style=\"layout-grid-mode:line\">Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, <\/span>although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.<\/p>","ID":"081084fd-807f-43de-a3ed-c795dd2be430","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Subgroups\r consisting of gender, race, age, duration of diabetes, baseline blood pressure,\r serum creatinine, and albumin excretion rate were assessed for treatment\r effect. In the female and black subgroups which represented 32% and 26% of the\r overall study population respectively, a renal benefit was not evident, although\r the confidence intervals do not exclude it. As for the secondary endpoint of\r fatal and non-fatal cardiovascular events, there was no difference among the\r three groups in the overall population, although an increased incidence of\r non-fatal MI was seen for women and a decreased incidence of non-fatal MI was\r seen in males in the irbesartan group versus the placebo-based regimen. An\r increased incidence of non-fatal MI and stroke was seen in females in the\r irbesartan-based regimen versus the amlodipine-based regimen, while\r hospitalization due to heart failure was reduced in the overall population.\r However, no proper explanation for these findings in women has been identified.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"a55c8f13-831b-41b2-90e8-863734728b7a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r &lt; 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) &gt; 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine\r calcium blockers) were added as needed to help achieve the blood pressure goal.\r While similar blood pressure was achieved in all treatment groups, fewer\r subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%)\r or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt\r proteinuria, demonstrating a 70% relative risk reduction versus placebo\r (p = 0.0004) for the higher dose. An accompanying improvement in the\r glomerular filtration rate (GFR) was not observed during the first three months\r of treatment. The slowing in the progression to clinical proteinuria was\r evident as early as three months and continued over the 2 year period.\r Regression to normoalbuminuria (&lt; 30 mg\/day) was more frequent in\r the Karvea 300 mg group (34%) than in the placebo group (21%).<\/span><\/p>","ID":"9527af51-498f-4b63-bedb-9c45e3ffa419","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The study of the \u201cEffects of Irbesartan\r on Microalbuminuria in Hypertensive Patients with type 2 Diabetes Mellitus\r (IRMA 2)\u201d shows that irbesartan 300 mg delays progression to overt\r proteinuria in patients with microalbuminuria. IRMA 2 was a\r placebo-controlled double blind morbidity study in 590 patients with type 2\r diabetes, microalbuminuria (30-300 mg\/day) and normal renal function\r (serum creatinine \u2264 1.5 mg\/dl in males and\r < 1.1 mg\/dl in females). The study examined the long-term effects\r (2 years) of Karvea on the progression to clinical (overt) proteinuria\r (urinary albumin excretion rate (UAER) > 300 mg\/day, and an\r increase in UAER of at least 30% from baseline). The predefined blood pressure\r goal was \u2264 135\/85 mmHg. Additional antihypertensive agents\r (excluding ACE inhibitors, angiotensin II receptor antagonists and dihydropyridine\r calcium blockers) were added as needed to help achieve the blood pressure goal.\r While similar blood pressure was achieved in all treatment groups, fewer\r subjects in the irbesartan 300 mg group (5.2%) than in the placebo (14.9%)\r or in the irbesartan 150 mg group (9.7%) reached the endpoint of overt\r proteinuria, demonstrating a 70% relative risk reduction versus placebo\r (p = 0.0004) for the higher dose. An accompanying improvement in the\r glomerular filtration rate (GFR) was not observed during the first three months\r of treatment. The slowing in the progression to clinical proteinuria was\r evident as early as three months and continued over the 2 year period.\r Regression to normoalbuminuria (< 30 mg\/day) was more frequent in\r the Karvea 300 mg group (34%) than in the placebo group (21%).","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0c5f2cbf-a10c-4c51-b26d-56e559f5061f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><i><span lang=\"EN-GB\">Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)<\/span><\/i><\/p>","ID":"9b1f70d1-3ddf-439f-a422-2ef08042ea6e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":true,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L4","IsULTag":null,"Text":"Dual blockade of the\r renin-angiotensin-aldosterone system (RAAS)","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.<\/span><\/p>","ID":"9ae606f6-536c-41f6-b2eb-303b6aa62409","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Two large randomised, controlled trials\r (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global\r Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes))\r have examined the use of the combination of an ACE-inhibitor with an\r angiotensin II receptor blocker. ONTARGET was a study conducted in patients\r with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes\r mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study\r in patients with type 2 diabetes mellitus and diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and angiotensin\r II receptor blockers.<\/span><\/p>","ID":"15a09f6c-e997-47ef-bc7e-6623c8693376","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"These studies have shown no significant\r beneficial effect on renal and\/or cardiovascular outcomes and mortality, while\r an increased risk of hyperkalaemia, acute kidney injury and\/or hypotension as\r compared to monotherapy was observed. Given their similar pharmacodynamic\r properties, these results are also relevant for other ACE-inhibitors and angiotensin\r II receptor blockers.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.<\/span><\/p>","ID":"20966987-3326-4a15-84ad-85657630339e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ACE-inhibitors and angiotensin II\r receptor blockers should therefore not be used concomitantly in patients with\r diabetic nephropathy.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.<\/span><\/p>","ID":"ffed714f-f723-40df-94b0-d5638eeb65f8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"ALTITUDE (Aliskiren Trial in Type 2\r Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed\r to test the benefit of adding aliskiren to a standard therapy of an\r ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2\r diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.\r The study was terminated early because of an increased risk of adverse\r outcomes. Cardiovascular death and stroke were both numerically more frequent\r in the aliskiren group than in the placebo group and adverse events and serious\r adverse events of interest (hyperkalaemia, hypotension and renal dysfunction)\r were more frequently reported in the aliskiren group than in the placebo group.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"467a8ad6-73b0-4468-b990-f68d2096d733","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.2     Pharmacokinetic properties<\/span><\/p>","ID":"f67ec0fa-0dfb-42f8-87d7-58b532a58766","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.2     Pharmacokinetic properties","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"28ad3bb9-3675-43c0-9309-4ef86eac3647","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Absorption<\/span><\/u><\/p>","ID":"56eb3da8-36ba-441e-8f2a-ed3659943862","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Absorption","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"e93eae95-dbc9-42d3-91b2-a057c274642c","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. <\/span><\/p>","ID":"3738b6c8-6889-48d6-91a0-c2a3d13d523e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"After\r oral administration, irbesartan is well absorbed: studies of absolute\r bioavailability gave values of approximately 60-80%. Concomitant food intake\r does not significantly influence the bioavailability of irbesartan. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"7177c559-3969-4777-a50d-10cde863f01d","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Distribution<\/span><\/u><\/p>","ID":"dbecaf6a-a828-4951-87f7-4b03a797ff92","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Distribution","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"9d22c898-49f6-4a67-943e-e0736944b45b","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. <\/span><\/p>","ID":"42213494-3139-44f9-a07c-cec4bf3427c0","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Plasma\r protein binding is approximately 96%, with negligible binding to cellular blood\r components. The volume of distribution is 53 - 93 litres. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"74a439c5-a5b3-4fe9-8eeb-9a7e3cbeb4f8","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Biotransformation<\/span><\/u><\/p>","ID":"94f58dc6-daf4-4d4d-99b5-6479a4148591","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Biotransformation","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><\/p>","ID":"d7d24cc0-4cf2-45cc-b465-bfa92c00710e","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Following\r oral or intravenous administration of <sup><span style=\"position:relative;\r top:-1.0pt\">14<\/span><\/sup>C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). <i>In vitro<\/i>\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.<\/span><\/p>","ID":"56d0c291-4bf5-43a0-9d2c-bc55ca0bc623","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Following\r oral or intravenous administration of 14C irbesartan, 80-85% of the circulating plasma\r radioactivity is attributable to unchanged irbesartan. Irbesartan is\r metabolised by the liver via glucuronide conjugation and oxidation. The major\r circulating metabolite is irbesartan glucuronide (approximately 6%). In vitro\r studies indicate that irbesartan is primarily oxidised by the\r cytochrome P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"1bed1c2d-f41e-4289-86b5-f917b0be5402","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Linarity \/ non-linearity<\/span><\/u><\/p>","ID":"b1fa241e-f7f9-4baa-9b5b-ff90b0b4e40f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Linarity \/ non-linearity","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b65f501b-2f97-4e64-9836-a81c3bd3dd28","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (&lt; 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and C<span class=\"EMEASubscript\">max<\/span> values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.<\/span><\/p>","ID":"3a39cae9-d524-4083-bb43-d1e27c2efbcb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan exhibits linear and dose\r proportional pharmacokinetics over the dose range of 10 to 600 mg. A\r less than proportional increase in oral absorption at doses beyond 600 mg\r (twice the maximal recommended dose) was observed; the mechanism for this is\r unknown. Peak plasma concentrations are attained at\r 1.5 - 2 hours after oral administration. The total body and\r renal clearance are 157 - 176 and 3 - 3.5 ml\/min,\r respectively. The terminal elimination half-life of irbesartan is\r 11 - 15 hours. Steady-state plasma concentrations are attained\r within 3 days after initiation of a once-daily dosing regimen. Limited\r accumulation of irbesartan (< 20%) is observed in plasma upon repeated\r once-daily dosing. In a study, somewhat higher plasma concentrations of\r irbesartan were observed in female hypertensive patients. However, there was no\r difference in the half-life and accumulation of irbesartan. No dosage\r adjustment is necessary in female patients. Irbesartan AUC and Cmax values were also somewhat greater in older subjects\r (\u2265 65 years) than those of young subjects\r (18 - 40 years). However the terminal half-life was not\r significantly altered. No dosage adjustment is necessary in older people.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0e67df68-3d09-4dc6-bc83-820df875a500","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Elimination<\/span><\/u><\/p>","ID":"b71c6ae1-9952-4f45-ac16-f070ceb0eb24","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Elimination","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"aeca6506-ba82-49fb-a2b2-c6e325085c55","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of <sup><span style=\"position:relative;top:-1.0pt\">14<\/span><\/sup>C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.<\/span><\/p>","ID":"95843c10-e1c9-4059-ae0e-e61f111d49da","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Irbesartan and its metabolites are\r eliminated by both biliary and renal pathways. After either oral or IV\r administration of 14C\r irbesartan, about 20% of the radioactivity is recovered in the urine, and the\r remainder in the faeces. Less than 2% of the dose is excreted in the urine as\r unchanged irbesartan.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6966b7be-02ab-441d-87a4-2106ee115315","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\">Paediatric\r population<\/span><\/u><\/p>","ID":"9d189283-c3fd-4204-b7cc-de866437bda9","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Paediatric\r population","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><u><span lang=\"EN-GB\"><\/span><\/u><\/p>","ID":"dee3f0a3-426a-4615-aae9-c858d403c2fd","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that C<span class=\"EMEASubscript\">max<\/span>, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.<\/span><\/p>","ID":"504563ed-ebf8-44b7-a296-0730b61e144c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"The pharmacokinetics of irbesartan were\r evaluated in 23 hypertensive children after the administration of single\r and multiple daily doses of irbesartan (2 mg\/kg) up to a maximum daily\r dose of 150 mg for four weeks. Of those 23 children, 21 were evaluable for\r comparison of pharmacokinetics with adults (twelve children over 12 years,\r nine children between 6 and 12 years). Results showed that Cmax, AUC and clearance rates were comparable to\r those observed in adult patients receiving 150 mg irbesartan daily. A\r limited accumulation of irbesartan (18%) in plasma was observed upon repeated\r once daily dosing.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0559662e-4931-4f88-a3b0-f6b34ffb7af9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Renal impairment<\/span><\/u><\/p>","ID":"b6e463d6-3afc-4d04-a323-2e9fb8209626","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Renal impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"0e4ed4d1-869a-49b8-92ee-a60e24425ff2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.<\/span><\/p>","ID":"31a549dc-c2c3-42e0-bd90-97b1a246f758","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with renal impairment or\r those undergoing haemodialysis, the pharmacokinetic parameters of irbesartan\r are not significantly altered. Irbesartan is not removed by haemodialysis.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"35e44c31-f683-47e1-a580-99dcc5f26d12","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><u><span lang=\"EN-GB\">Hepatic impairment<\/span><\/u><\/p>","ID":"00e4789e-a652-4aee-a1f0-a9b0e0743643","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":true,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L3","IsULTag":null,"Text":"Hepatic impairment","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3ac2c2dc-e7ab-46b0-8efe-fc050a85f7f3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. <\/span><\/p>","ID":"12bd8c79-b5a6-43e7-850d-c7ae6387e5c3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"In patients with mild to moderate\r cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly\r altered. ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Studies have not been performed in\r patients with severe hepatic impairment.<\/span><\/p>","ID":"2d28f111-cfec-46ed-a655-4fd52bc16f96","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Studies have not been performed in\r patients with severe hepatic impairment.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7d85a384-93d1-4239-97aa-f0fe5db44698","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">5.3Preclinical safety data<\/span><\/p>","ID":"eed9969e-2c05-4fbf-a666-5d48c5f31758","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"5.3Preclinical safety data","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"0f2cc96a-e1c2-4615-9da6-694378b6b384","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at \u2265 90 mg\/kg\/day,\r in macaques at \u2265 10 mg\/kg\/day). All of these changes were\r considered to be caused by the pharmacological action of irbesartan. For\r therapeutic doses of irbesartan in humans, the hyperplasia\/ hypertrophy of the\r renal juxtaglomerular cells does not appear to have any relevance.<\/span><\/p>","ID":"6375aae9-7a19-463e-aa67-f5e78ff1afb1","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was\r no evidence of abnormal systemic or target organ toxicity at clinically\r relevant doses. In non-clinical safety studies, high doses of irbesartan\r (\u2265 250 mg\/kg\/day in rats and \u2265 100 mg\/kg\/day in\r macaques) caused a reduction of red blood cell parameters (erythrocytes,\r haemoglobin, haematocrit). At very high doses (\u2265 500 mg\/kg\/day)\r degenerative changes in the kidney (such as interstitial nephritis, tubular\r distension, basophilic tubules, increased plasma concentrations of urea and\r creatinine) were induced by irbesartan in the rat and the macaque and are\r considered secondary to the hypotensive effects of the medicinal product which\r led to decreased renal perfusion. Furthermore, irbesartan induced\r hyperplasia\/hypertrophy of the juxtaglomerular cells (in rats at \u2265 90 mg\/kg\/day,\r in macaques at \u2265 10 mg\/kg\/day). All of these changes were\r considered to be caused by the pharmacological action of irbesartan. For\r therapeutic doses of irbesartan in humans, the hyperplasia\/ hypertrophy of the\r renal juxtaglomerular cells does not appear to have any relevance.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9778ffa8-f918-4377-acb6-e2d2a3d81697","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.<\/span><\/p>","ID":"ae9fddd5-e22e-48cd-a66e-2fe62d3ed24a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"There was no evidence of mutagenicity,\r clastogenicity or carcinogenicity.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fc62b076-7d1a-4f6e-b75f-f576458b920f","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.<\/span><\/p>","ID":"0d632907-bb21-45fb-97a7-230ddc20f2b3","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Fertility and reproductive performance\r were not affected in studies of male and female rats even at oral doses of\r irbesartan causing some parental toxicity (from 50 to 650 mg\/kg\/day), including\r mortality at the highest dose. No significant effects on the number of corpora\r lutea, implants, or live foetuses were observed. Irbesartan did not affect\r survival, development, or reproduction of offspring. Studies in animals\r indicate that the radiolabelled irbesartan is detected in rat and rabbit foetuses.\r Irbesartan is excreted in the milk of lactating rats.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"f0b51d56-5711-4082-b69d-627a84ff94b6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.<\/span><\/p>","ID":"6bed9ae9-ccea-48cb-896a-c13739e14b0a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Animal studies with irbesartan showed\r transient toxic effects (increased renal pelvic cavitation, hydroureter or\r subcutaneous oedema) in rat foetuses, which were resolved after birth. In\r rabbits, abortion or early resorption were noted at doses causing significant\r maternal toxicity, including mortality. No teratogenic effects were observed in\r the rat or rabbit.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fab8388c-83cc-4bb8-a9dc-937fc66182ab","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"6f8c0899-b505-440f-a232-542ae0a2a440","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">6.       PHARMACEUTICAL PARTICULARS<\/span><\/p>","ID":"62b12146-7dee-4f3e-8513-dfae877bad36","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"6.       PHARMACEUTICAL PARTICULARS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"fe652f13-5a0b-49ff-b3f8-840284a70992","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.1     List of excipients<\/span><\/p>","ID":"84225b67-c35a-4d0c-8b91-18b771f29ea3","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.1     List of excipients","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"e2680bc1-285e-481e-bada-cbddf020013d","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\" style=\"page-break-after:avoid\"><span lang=\"EN-GB\">Tablet\r core:<\/span><\/p>","ID":"d1dc8ffa-1e20-4b61-931d-639e73c33bca","Styles":"page-break-after:avoid","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Tablet\r core:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p>","ID":"57bab5d9-7c56-47b3-b278-7c8a1f2e0644","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Microcrystalline cellulose<\/span><\/p>","ID":"130b22c4-765c-46ef-8a15-22bfbee59f3c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Microcrystalline cellulose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Croscarmellose sodium<\/span><\/p>","ID":"50ff5144-1b0f-4c9d-b43a-27f03340c898","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Croscarmellose sodium","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p>","ID":"6d00be09-587a-41df-a9d1-447bd1de4435","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Silicon dioxide<\/span><\/p>","ID":"00e1ee0f-67aa-4b7f-b4e7-33d014b912de","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Silicon dioxide","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Magnesium stearate.<\/span><\/p>","ID":"adabfabd-9b29-438a-9482-80dd5147c01e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Magnesium stearate.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4a795944-0366-45fb-a628-5ccbbe8383fb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Film-coating:<\/span><\/p>","ID":"0fea3e7f-ee55-4565-91f2-b55de5a2c7eb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Film-coating:","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Lactose monohydrate<\/span><\/p>","ID":"efba8df0-e4eb-48e0-a4c8-5a96c9068628","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Lactose monohydrate","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Hypromellose<\/span><\/p>","ID":"8e71ed8a-2f44-48a6-ac50-3e81c9b852bb","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Hypromellose","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Titanium dioxide<\/span><\/p>","ID":"96bf43e4-51af-45af-b7f9-79dad1d84f3c","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Titanium dioxide","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Macrogol 3000<\/span><\/p>","ID":"cc63a506-179f-4b4c-9f9f-15c3ca07e862","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Macrogol 3000","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"IT\">Carnauba wax.<\/span><\/p>","ID":"74894726-733c-4b1c-bdb2-5ff6d1246369","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Carnauba wax.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"95ba8cad-64a3-4ca3-94ca-08074c9fed3a","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.2     Incompatibilities<\/span><\/p>","ID":"00b23bdd-1720-4c51-af99-43878fe60f6b","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.2     Incompatibilities","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"5f59459c-53a9-41b1-8a64-9a8fce6ca1ed","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not applicable.<\/span><\/p>","ID":"4513c6f9-1635-44ec-8f31-a33b9c09fce2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not applicable.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"297ae08c-d85c-424f-9911-022b47cfa620","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.3     Shelf life<\/span><\/p>","ID":"f6d4ffea-a086-44de-b4a9-52c5aa7a61ac","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.3     Shelf life","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"8f6af02d-c501-49ae-b023-bb246b424986","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">3 years.<\/span><\/p>","ID":"595bd4e7-4002-4b01-ba9a-e5bf3b429e12","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"3 years.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"ce899266-c08b-4260-a89d-e990f6f63731","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.4     Special precautions for storage<\/span><\/p>","ID":"43d38960-682d-4ed1-8b4f-f65885d67e44","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.4     Special precautions for storage","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"dad9272c-a016-409c-be23-2c27ca5e83b1","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Do not store above 30\u00b0C.<\/span><\/p>","ID":"11fa3157-c251-4dd0-9f6e-edb9c0b50a73","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Do not store above 30\u00b0C.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"88a98d2a-203e-4a92-aea9-47e3ae681012","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\" style=\"margin-left:0in;text-indent:0in\"><span lang=\"EN-GB\">6.5     Nature\r and contents of container<\/span><\/p>","ID":"99ce7c15-d9f8-4b79-952f-41355dea8878","Styles":"margin-left:0in;text-indent:0in","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.5     Nature\r and contents of container","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"a8555846-7989-416a-939b-391b48fe626b","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"a9402c61-36e6-406b-b977-614be4e30fa2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 14 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 28 film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 30<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"ec118419-4120-47a6-8fc7-ef3555ef3842","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 30\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"fe43032b-a564-4464-a72f-a620a3f064ff","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 56 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 84 film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 90<\/span><span lang=\"EN-GB\">\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.<\/span><\/p>","ID":"d53f1984-a90c-474d-aba0-344b65631a55","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 90\r film-coated tablets in PVC\/PVDC\/Aluminium blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.<br\/>\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.<\/span><\/p>","ID":"38881107-f687-4e65-838c-7ae186bf18c4","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Cartons of 98 film-coated tablets\r in PVC\/PVDC\/Aluminium blisters.\r Cartons of 56 x 1 film-coated tablet in PVC\/PVDC\/Aluminium\r perforated unit dose blisters.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"4d0f6d02-cd62-4e74-81e8-1aaf4647dc74","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Not all pack sizes may be marketed.<\/span><\/p>","ID":"b83c72de-1abc-4770-982e-0302868f6b34","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Not all pack sizes may be marketed.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"157091e0-306d-472a-9641-3f82642ea067","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><span lang=\"EN-GB\">6.6     Special precautions for disposal<\/span><\/p>","ID":"eb188145-0fb2-4e14-9e48-bac21cc15869","Styles":"None","Classes":"['EMEAHeading2']","Bold":true,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L2","IsULTag":null,"Text":"6.6     Special precautions for disposal","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading2\"><\/p>","ID":"241968cc-fe0f-4536-b815-e29b63077360","Styles":"None","Classes":"['EMEAHeading2']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.<\/span><\/p>","ID":"64131322-58d0-4b18-b3cb-2d4cb97a9ba2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Any unused medicinal product or waste\r material should be disposed of in accordance with local requirements.","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"07d318d6-83f2-45ff-bccb-819aa69a02f0","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"2a45eace-8b74-43f3-92f4-6c33b71bd1c2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">7.       MARKETING AUTHORISATION HOLDER<\/span><\/p>","ID":"d97847aa-cfee-4eed-a00b-295c411fb62b","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"7.       MARKETING AUTHORISATION HOLDER","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"962e75d7-15f0-4bf3-b5fc-fdafa45b953d","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAAddress\"><span lang=\"FR\">sanofi-aventis groupe<br\/>\r 54, rue La Bo\u00e9tie<br\/>\r F-75008 Paris - France<\/span><\/p>","ID":"1ea60648-daf8-4524-9d75-9e17e41cb246","Styles":"None","Classes":"['EMEAAddress']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"sanofi-aventis groupe\r 54, rue La Bo\u00e9tie\r F-75008 Paris - France","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"79dc57b2-9f71-4e9b-8722-ed38a381a1f8","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"7dffe6be-d95c-41c3-9ba9-f112a41f3e8e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"FR\">8.       MARKETING AUTHORISATION NUMBERS<\/span><\/p>","ID":"029c136e-eb96-405a-80bc-7e79cb2c5e6a","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"8.       MARKETING AUTHORISATION NUMBERS","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"2c2896e9-2b84-4d96-bd75-0edbd6708830","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"SL\">EU\/1\/97\/049\/026-030<br\/>\r EU\/1\/97\/049\/033<br\/>\r EU\/1\/97\/049\/036<br\/>\r EU\/1\/97\/049\/039<\/span><\/p>","ID":"34cdaad7-7b5e-437d-807d-b709e0f341d6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"EU\/1\/97\/049\/026-030\r EU\/1\/97\/049\/033\r EU\/1\/97\/049\/036\r EU\/1\/97\/049\/039","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"922d5a1f-1525-4675-9987-53a29b44fce2","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"fca281a4-d84c-4ebf-94a8-995f5a02e5d9","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION<\/span><\/p>","ID":"dafa0113-43c0-4371-8cb0-35502d16f6f7","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"9.       DATE OF FIRST AUTHORISATION \/\r RENEWAL OF THE AUTHORISATION","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><\/p>","ID":"5c3f3f63-23c7-4df5-b8c9-cb6fca7af0b5","Styles":"None","Classes":"['EMEAHeading1']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Date of first authorisation: 27 August\r 1997<br\/>\r Date of latest renewal: 27 August 2007<\/span><\/p>","ID":"32411bdf-7389-4068-baa8-16baf014b2a6","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Date of first authorisation: 27 August\r 1997\r Date of latest renewal: 27 August 2007","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"3012a742-aed7-48e0-806c-2bec7b98076b","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"29a6d8fa-5a39-4678-8f15-be3c43241f56","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEAHeading1\"><span lang=\"EN-GB\">10.     DATE OF REVISION OF THE TEXT<\/span><\/p>","ID":"a2e7bbf2-29b7-484c-8893-366ccd8cbc32","Styles":"None","Classes":"['EMEAHeading1']","Bold":true,"Italics":false,"Uppercased":true,"Underlined":false,"Indexed":true,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":true,"IsHeadingType":"L1","IsULTag":null,"Text":"10.     DATE OF REVISION OF THE TEXT","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"9265f075-4472-4775-87ad-dc6a4b31b143","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><span lang=\"EN-GB\">Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu<\/span><\/p>","ID":"32a98cd4-bb81-4060-ba0a-c69aee80f55e","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"Detailed information on this medicinal\r product is available on the website of the European Medicines Agency\r http:\/\/www.ema.europa.eu","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<p class=\"EMEABodyText\"><\/p>","ID":"b5f8f5bd-ddd8-472a-b86c-b85d053d7085","Styles":"None","Classes":"['EMEABodyText']","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":"","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"},{"Element":"<span lang=\"EN-GB\" style='font-size:11.0pt;font-family:\"Times New Roman\",serif'><br clear=\"all\" style=\"page-break-before:always\"\/> <\/span>","ID":"3476f7a4-fcb9-42e3-bd15-146b920eb5af","Styles":"font-size:11.0pt;font-family:\"Times New Roman\",serif","Classes":"None","Bold":false,"Italics":false,"Uppercased":false,"Underlined":false,"Indexed":false,"IsListItem":false,"HasBorder":false,"IsPossibleHeading":false,"IsHeadingType":null,"IsULTag":null,"Text":" ","ParentId":"002ddf86-bc56-497d-a851-f81a205acd94"}]